However	O
,	O
there	O
are	O
some	O
major	O
shortcomings	O
in	O
the	O
currently	O
available	O
data	O
.	O
	
Determination	O
of	O
the	O
infecting	B-KP
species	I-KP
was	O
based	O
on	O
cultured	O
isolates	O
in	O
many	O
of	O
these	O
studies	O
,	O
but	O
culture	O
of	O
Borrelia	B-KP
spp	I-KP
.	I-KP
is	O
not	O
very	O
sensitive	O
,	O
particularly	O
in	O
CSF	B-KP
samples	I-KP
[104,110,111,397],	O
and	O
even	O
less	O
so	O
in	O
synovial	B-KP
fluid	I-KP
or	O
tissue	B-KP
samples	I-KP
[112,113]	O
.	O
	
PCR-based	B-KP
amplification	I-KP
of	I-KP
DNA	I-KP
isolated	O
directly	O
from	O
tissue	B-KP
specimens	I-KP
generally	O
shows	O
greater	O
sensitivity	O
[	O
114	O
]	O
,	O
but	O
largely	O
depends	O
on	O
the	O
specific	O
PCR	B-KP
target	I-KP
[23,104],	O
still	O
lacks	O
sensitivity	O
,	O
particularly	O
in	O
CSF	B-KP
[104,115,116],	O
and	O
does	O
not	O
necessarily	O
detect	O
Borrelia	B-KP
spp	I-KP
.	I-KP
in	O
all	O
samples	O
that	O
are	O
culture	O
positive	O
[104,108]	O
.	O
	
Furthermore	O
,	O
since	O
patients	O
with	O
EM	B-KP
are	O
now	O
routinely	O
treated	O
with	O
antibiotics	B-KP
,	O
determination	O
of	O
the	O
infecting	O
species	O
of	O
Borrelia	B-KP
in	O
samples	O
from	O
extracutaneous	B-KP
lesions	I-KP
is	O
likely	O
to	O
yield	O
results	O
that	O
are	O
skewed	O
towards	O
those	O
strains	O
that	O
do	O
not	O
also	O
cause	O
easily	O
recognizable	O
EM	B-KP
lesions	I-KP
.	O
	
Fewof	O
these	O
studies	O
examined	O
what	O
is	O
likely	O
to	O
be	O
a	O
major	O
determinant	O
of	O
the	O
probability	O
of	O
acquiring	O
an	O
infection	O
with	O
a	O
particular	O
species	O
of	O
Borrelia	B-KP
,	O
namely	O
its	O
prevalence	O
in	O
regional	O
ticks	O
[20,24,111,386,391,398]	O
.	O
	
The	O
results	O
are	O
somewhat	O
conflicting	O
,	O
most	O
likely	O
because	O
of	O
the	O
small	O
number	O
of	O
ticks	O
and	O
/	O
or	O
human	O
samples	O
examined	O
in	O
some	O
of	O
these	O
investigations	O
.	O
	
In	O
addition	O
,	O
tick	O
and	O
human	O
samples	O
were	O
collected	O
during	O
different	O
time	O
periods	O
and	O
in	O
different	O
locations	O
,	O
thereby	O
not	O
taking	O
into	O
consideration	O
that	O
there	O
may	O
be	O
considerable	O
temporal	O
and	O
regional	O
variation	O
in	O
the	O
number	O
of	O
infected	O
ticks	O
and	O
the	O
distribution	O
of	O
Borrelia	B-KP
spp	I-KP
.	I-KP
in	O
ticks	O
[20,71,399,400]	O
.	O
	
Overall	O
,	O
the	O
results	O
suggest	O
that	O
B	B-KP
.	I-KP
garinii	I-KP
may	O
be	O
underrepresented	O
in	O
skin	O
rather	O
than	O
overrepresented	O
in	O
CSF	B-KP
[20,24,386,391]	O
.	O
	
Note	O
,	O
however	O
,	O
that	O
B	B-KP
.	I-KP
afzelii	I-KP
infection	I-KP
of	O
the	O
nervous	B-KP
system	I-KP
may	O
simply	O
be	O
underrecognized	O
because	O
it	O
does	O
not	O
cause	O
the	O
typical	O
clinical	O
picture	O
of	O
European	O
LNB	B-KP
associated	O
with	O
B	B-KP
.	I-KP
garinii	I-KP
infection	I-KP
,	O
namely	O
radiculoneuritis	B-KP
and	O
/	O
or	O
peripheral	B-KP
facial	I-KP
palsy	I-KP
[	O
110	O
]	O
.	O
	
Instead	O
,	O
detection	O
of	O
B	B-KP
.	I-KP
afzelii	I-KP
in	O
CSF	B-KP
was	O
associated	O
with	O
mostly	O
nonspecific	O
symptoms	O
,	O
and	O
most	O
of	O
the	O
patients	O
from	O
whose	O
CSF	B-KP
B	I-KP
.	I-KP
afzelii	I-KP
could	O
be	O
cultured	O
did	O
not	O
fulfill	O
the	O
European	O
diagnostic	O
criteria	O
for	O
LNB	B-KP
.	O
	
﻿Histopathology	B-KP
of	O
peripheral	B-KP
nerve	I-KP
biopsy	I-KP
specimens	I-KP
from	O
patients	O
with	O
neurological	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
shows	O
a	O
perivascular	O
infiltrate	O
of	O
lymphocytes	B-KP
,	O
plasma	B-KP
cells	I-KP
and	O
histiocytes	B-KP
in	O
association	O
with	O
patchy	B-KP
multifocal	I-KP
axonal	I-KP
degeneration	I-KP
[179,484-486]	O
.	O
	
A	O
lymphocytic	B-KP
infiltrate	I-KP
has	O
also	O
been	O
observed	O
in	O
the	O
meninges	B-KP
[	O
365	O
]	O
,	O
extending	O
into	O
the	O
white	B-KP
and	I-KP
gray	I-KP
matter	I-KP
in	O
an	O
advanced	O
case	O
,	O
along	O
with	O
infiltration	O
of	O
dorsal	B-KP
root	I-KP
ganglia	I-KP
and	O
nerve	B-KP
roots	I-KP
[484,487]	O
.	O
	
It	O
is	O
likely	O
that	O
these	O
infiltrating	O
immune	B-KP
cells	I-KP
also	O
contribute	O
to	O
the	O
production	O
of	O
inflammatory	B-KP
and	I-KP
neurotoxic	I-KP
substances	I-KP
.	O
	
T-cell	B-KP
lines	I-KP
and	O
clones	O
isolated	O
from	O
the	O
CSF	B-KP
of	O
patients	O
with	O
LNB	B-KP
show	O
a	O
strong	O
polarization	O
towards	O
a	O
type	B-KP
1	I-KP
cytokine	I-KP
pattern	I-KP
(	O
high	O
production	O
of	O
IFNg	B-KP
and	O
mostly	O
undetectable	O
levels	O
of	O
IL-4	B-KP
)	O
[488,489]	O
.	O
	
When	O
CSF	B-KP
mononuclear	I-KP
cells	I-KP
(	O
MNC	B-KP
)	O
from	O
adult	O
patients	O
with	O
LNB	B-KP
are	O
stimulated	O
with	O
borrelial	B-KP
antigens	I-KP
in	O
vitro	O
,	O
there	O
is	O
a	O
marked	O
upregulation	O
of	O
the	O
number	O
of	O
IFNgsecreting	B-KP
cells	I-KP
[	O
490-494	O
]	O
,	O
and	O
this	O
upregulation	O
is	O
significantly	O
greater	O
compared	O
to	O
peripheral	B-KP
blood	I-KP
,	O
suggesting	O
a	O
strong	O
compartmentalization	O
of	O
the	O
Borrelia-specific	O
IFNg	O
response	O
[490,494]	O
.	O
	
However	O
,	O
the	O
number	O
of	O
responder	B-KP
cells	I-KP
shows	O
pronounced	O
variation	O
between	O
patients	O
[	O
490-494	O
]	O
,	O
as	O
do	O
the	O
concentrations	O
of	O
IFNg	B-KP
and	O
essentially	O
all	O
other	O
cytokines	B-KP
and	O
chemokines	B-KP
that	O
have	O
been	O
measured	O
in	O
CSF	B-KP
of	O
patients	O
with	O
LNB	B-KP
[	O
495-497	O
]	O
.	O
	
The	O
actual	O
concentrations	O
of	O
IFNg	B-KP
in	O
CSF	B-KP
are	O
remarkably	O
low	O
[495,497]	O
.	O
	
Not	O
only	O
have	O
CD8þ	B-KP
T	I-KP
cells	I-KP
been	O
detected	O
in	O
nerve	B-KP
biopsy	I-KP
samples	I-KP
from	O
patients	O
with	O
ACA-associated	B-KP
polyneuropathy	I-KP
[	O
216	O
]	O
,	O
but	O
clonal	O
expansion	O
of	O
CD8	B-KP
T	I-KP
cells	I-KP
has	O
been	O
demonstrated	O
in	O
the	O
CSF	B-KP
of	O
patients	O
with	O
acute	B-KP
LNB	I-KP
[	O
498	O
]	O
.	O
	
The	O
expanded	O
clones	O
produced	O
TNFa	B-KP
and	O
some	O
IFNg	B-KP
in	O
response	O
to	O
stimulation	O
with	O
Borrelia	B-KP
antigens	I-KP
.	O
	
While	O
the	O
role	O
of	O
these	O
Borrelia-specific	B-KP
CD8þ	I-KP
T	I-KP
cells	I-KP
in	O
LNB	B-KP
remains	O
to	O
be	O
established	O
,	O
their	O
detection	O
in	O
tissues	O
that	O
are	O
targeted	O
soon	O
after	O
Borrelia	B-KP
infection	I-KP
suggests	O
a	O
role	O
in	O
early	O
host	O
defense	O
.	O
	
On	O
the	O
other	O
hand	O
,	O
peripheral	B-KP
CD8þ	I-KP
and	O
gd	B-KP
T	I-KP
cells	I-KP
were	O
identified	O
as	O
the	O
predominant	O
sources	O
of	O
Borrelia-specific	B-KP
IFNg	I-KP
production	O
in	O
patients	O
with	O
chronic	B-KP
Lyme	I-KP
borreliosis	I-KP
(	O
mostly	O
LNB	O
)	O
[	O
499	O
]	O
.	O
	
In	O
view	O
of	O
the	O
strong	O
CSF	B-KP
compartmentalization	O
of	O
the	O
immune	B-KP
response	I-KP
,	O
the	O
relevance	O
of	O
these	O
findings	O
is	O
unclear	O
and	O
the	O
precise	O
role	O
of	O
this	O
T	B-KP
cell	I-KP
subset	O
remains	O
to	O
be	O
elucidated	O
.	O
	
﻿Early	O
disseminated	O
infection	B-KP
typically	O
occurs	O
within	O
a	O
few	O
days	O
to	O
weeks	O
after	O
contact	O
with	O
the	O
infected	O
tick	O
.	O
	
Signs	O
include	O
multiple	O
(	O
secondary	O
)	O
erythema	B-KP
migrans	I-KP
lesions	I-KP
.	O
	
Additionally	O
,	O
musculoskeletal	B-KP
,	O
neurologic	B-KP
,	O
or	O
cardiovascular	B-KP
symptoms	I-KP
can	O
occur	O
.	O
	
Musculoskeletal	B-KP
symptoms	I-KP
(	O
present	O
in	O
60	O
%	O
of	O
those	O
infected	O
)	O
include	O
migratory	B-KP
joint	I-KP
or	O
muscle	B-KP
pain	I-KP
,	O
with	O
or	O
without	O
joint	B-KP
swelling	I-KP
.	O
	
Neurologic	B-KP
manifestations	I-KP
(	O
present	O
in	O
15	O
%	O
of	O
cases	O
)	O
may	O
include	O
meningitis	B-KP
,	O
paralysis	O
of	O
the	O
facial	B-KP
cranial	I-KP
nerve	I-KP
,	O
and	O
radicular	B-KP
neuropathies	I-KP
.	O
	
Cardiovascular	B-KP
symptoms	I-KP
are	O
less	O
common	O
(	O
present	O
in	O
8	O
%	O
of	O
those	O
infected	O
)	O
but	O
may	O
include	O
temporary	B-KP
atrioventricular	I-KP
blocks	I-KP
of	O
varying	O
degree	O
.	O
	
Although	O
temporary	O
pacing	O
may	O
be	O
necessary	O
in	O
more	O
than	O
30	O
%	O
of	O
patients	O
with	O
cardiac	B-KP
involvement	I-KP
,	O
complete	O
heart	B-KP
block	I-KP
rarely	O
develops	O
.	O
[	O
15	O
]	O
Untreated	O
or	O
inadequately	O
treated	O
Lyme	B-KP
disease	I-KP
may	O
progress	O
to	O
late	O
disseminated	O
disease	O
within	O
weeks	O
to	O
months	O
after	O
initial	O
infection	O
.	O
	
﻿In	O
many	O
areas	O
of	O
the	O
United	O
States	O
,	O
tick	O
bites	O
are	O
extremely	O
common	O
.	O
	
B	B-KP
burgdorferi	I-KP
is	O
endemic	B-KP
in	O
New	O
England	O
,	O
the	O
mid-Atlantic	O
states	O
,	O
Minnesota	O
,	O
and	O
Wisconsin	O
.	O
	
In	O
these	O
areas	O
,	O
the	O
risk	O
of	O
infection	O
after	O
a	O
prolonged	O
bite	O
can	O
be	O
high	O
(10%-25%).	O
	
[23,24]	O
Risk	O
of	O
infection	O
is	O
much	O
lower	O
in	O
the	O
southern	O
and	O
western	O
United	O
States	O
.	O
	
Furthermore	O
,	O
there	O
is	O
no	O
risk	O
of	O
transmission	O
of	O
B	B-KP
burgdorferi	I-KP
from	O
an	O
unengorged	O
tick	O
because	O
the	O
spirochetes	B-KP
require	O
up	O
to	O
36	O
hours	O
after	O
a	O
bite	O
to	O
migrate	O
from	O
the	O
tick	O
gut	O
to	O
the	O
salivary	B-KP
glands	I-KP
.	O
[	O
25-27	O
]	O
Because	O
of	O
these	O
factors	O
,	O
routine	O
antibiotic	B-KP
prophylaxis	I-KP
is	O
not	O
recommended	O
.	O
	
However	O
,	O
if	O
an	O
engorged	O
Ixodes	B-KP
tick	I-KP
has	O
been	O
removed	O
from	O
a	O
patient	O
in	O
an	O
endemic	B-KP
area	I-KP
(	O
local	O
rate	O
of	O
infection	O
of	O
ticks	O
with	O
B	B-KP
burgdorferi	I-KP
≥	O
20	O
%	O
)	O
,	O
or	O
if	O
the	O
tick	O
has	O
been	O
attached	O
for	O
at	O
least	O
36	O
hours	O
,	O
a	O
single	O
200-mg	O
oral	O
dose	O
of	O
doxycycline	B-KP
can	O
be	O
administered	O
within	O
72	O
hours	O
after	O
removal	O
of	O
the	O
tick	O
for	O
prophylaxis	B-KP
against	O
Lyme	B-KP
disease	I-KP
.	O
[2,24]	O
Prophylaxis	B-KP
is	O
generally	O
unnecessary	O
after	O
an	O
I	B-KP
pacificus	I-KP
bite	O
unless	O
the	O
local	O
rate	O
of	O
infection	O
with	O
B	B-KP
burgdorferi	I-KP
is	O
20	O
%	O
or	O
greater	O
.	O
[	O
2	O
]	O
﻿Avoidance	O
of	O
tick	O
bites	O
is	O
the	O
most	O
obvious	O
means	O
to	O
prevent	O
B	B-KP
burgdorferi	I-KP
infection	I-KP
.	O
	
If	O
people	O
must	O
be	O
outside	O
in	O
areas	O
where	O
Ixodes	B-KP
ticks	I-KP
are	O
found	O
,	O
they	O
are	O
advised	O
to	O
wear	O
protective	O
clothing	O
and	O
tick	O
repellent	O
containing	O
N,N-di-ethyl-m-toluamide	B-KP
(	O
DEET	B-KP
)	O
.	O
	
Frequent	O
skin	B-KP
inspection	O
and	O
prompt	O
removal	O
of	O
ticks	O
should	O
also	O
decrease	O
the	O
risk	O
of	O
infection	O
.	O
	
However	O
,	O
data	O
regarding	O
the	O
efficacy	O
of	O
these	O
measures	O
are	O
limited	O
.	O
	
Other	O
measures	O
,	O
including	O
burning	O
or	O
removal	O
of	O
vegetation	O
in	O
tick-harboring	O
areas	O
,	O
use	O
of	O
acaricides	B-KP
,	O
and	O
control	O
of	O
the	O
deer	O
population	O
,	O
result	O
in	O
up	O
to	O
a	O
94	O
%	O
decrease	O
in	O
the	O
population	O
of	O
I	B-KP
scapularis	I-KP
ticks	I-KP
.	O
	
Studies	O
show	O
that	O
,	O
despite	O
warnings	O
,	O
only	O
40	O
%	O
to	O
50	O
%	O
of	O
adults	O
take	O
precautions	O
against	O
tick	O
bites	O
even	O
when	O
they	O
are	O
aware	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
Immediate	O
removal	O
of	O
attached	O
ticks	O
can	O
help	O
prevent	O
Lyme	B-KP
disease	I-KP
infection	O
.	O
	
Therefore	O
,	O
complete	O
inspection	O
of	O
the	O
skin	B-KP
and	O
scalp	B-KP
,	O
particularly	O
for	O
children	O
,	O
is	O
recommended	O
after	O
spending	O
time	O
outside	O
in	O
endemic	B-KP
areas	I-KP
.	O
	
﻿Lyme	B-KP
disease	I-KP
,	O
also	O
referred	O
to	O
as	O
Lyme	B-KP
borreliosis	I-KP
,	O
was	O
first	O
clinically	O
described	O
in	O
1977	O
by	O
Dr	O
.	O
	
Allen	O
Steere	O
,	O
a	O
rheumatologist	B-KP
who	O
led	O
an	O
investigation	O
of	O
an	O
outbreak	O
of	O
arthritis	B-KP
,	O
initially	O
believed	O
to	O
be	O
juvenile	B-KP
rheumatoid	I-KP
arthritis	I-KP
,	O
in	O
39	O
children	O
and	O
12	O
adults	O
clustered	O
in	O
the	O
small	O
town	O
of	O
Lyme	O
,	O
Connecticut	O
.	O
[	O
1	O
]	O
First	O
called	O
“	O
Lyme	B-KP
Arthritis	I-KP
”	O
,	O
he	O
suspected	O
this	O
condition	O
was	O
caused	O
by	O
an	O
arthropod-born	O
infection	O
,	O
as	O
most	O
patients	O
suffered	O
from	O
asymmetric	O
swelling	O
of	O
large	O
joints	O
,	O
many	O
of	O
whom	O
also	O
presented	O
with	O
an	O
erythematous	B-KP
annular	I-KP
rash	I-KP
similar	O
to	O
that	O
described	O
decades	O
earlier	O
in	O
Europe	O
associated	O
with	O
the	O
bite	O
of	O
the	O
Ixodes	O
ricinus	O
tick	O
.	O
[	O
2	O
]	O
Although	O
the	O
causative	O
agent	O
was	O
unknown	O
,	O
the	O
etiology	B-KP
was	O
believed	O
to	O
be	O
a	O
bacterial	B-KP
pathogen	I-KP
in	O
that	O
the	O
rash	B-KP
seemed	O
to	O
respond	O
to	O
treatment	O
with	O
penicillin	B-KP
.	O
	
During	O
this	O
time	O
,	O
the	O
entity	O
was	O
given	O
several	O
names	O
including	O
erythema	B-KP
chronicum	I-KP
migrans	I-KP
,	O
Bannwarth’s	B-KP
syndrome	I-KP
,	O
and	O
acrodermatitis	B-KP
chronica	I-KP
atrophicans	I-KP
.	O
[	O
3	O
]	O
It	O
was	O
not	O
until	O
1982	O
that	O
Dr	O
.	O
	
Willy	O
Burgdorfer	O
,	O
a	O
microbiologist	O
studying	O
the	O
microbiology	O
of	O
the	O
hindgut	O
of	O
ticks	O
,	O
successfully	O
isolated	O
the	O
pathogen	B-KP
,	O
named	O
in	O
his	O
honor	O
Borrelia	B-KP
burgdorferfi	I-KP
,	O
from	O
I	B-KP
.	I-KP
damimini	I-KP
(	O
I	B-KP
.	I-KP
scapularis	I-KP
)	O
ticks	O
found	O
on	O
Shelter	O
Island	O
,	O
New	O
York	O
.	O
[4,5]	O
Subsequently	O
,	O
this	O
causative	O
spirochete	B-KP
bacterium	I-KP
has	O
been	O
isolated	O
from	O
the	O
typical	O
skin	B-KP
lesions	I-KP
,	O
as	O
well	O
as	O
blood	O
and	O
cerebrospinal	B-KP
fluid	I-KP
of	O
infected	O
individuals	O
.	O
	
Since	O
its	O
early	O
discovery	O
,	O
Lyme	B-KP
disease	I-KP
has	O
geographically	O
spread	O
to	O
an	O
extent	O
that	O
this	O
zoonotic	B-KP
infection	I-KP
is	O
currently	O
the	O
most	O
prevalent	O
vector-borne	O
disease	O
in	O
both	O
North	O
America	O
and	O
Europe	O
.	O
	
﻿B	B-KP
.	I-KP
burgdorferi	I-KP
sensu	O
lato	O
are	O
obligate	B-KP
parasites	I-KP
heavily	O
dependent	O
upon	O
their	O
hosts	O
for	O
nutritional	O
support	O
.	O
	
Proliferation	O
of	O
each	O
B	B-KP
.	I-KP
burgdorferi	I-KP
species	I-KP
is	O
contingent	O
upon	O
its	O
transmission	O
to	O
other	O
reservoir	B-KP
animals	I-KP
.	O
	
This	O
is	O
accomplished	O
via	O
each	O
species	O
'	O
preferred	O
Ixodes	O
tick	O
,	O
which	O
acquires	O
the	O
spirochetes	B-KP
during	O
its	O
larval	O
stage	O
blood	O
feed	O
and	O
passes	O
them	O
on	O
to	O
other	O
reservoir	B-KP
hosts	I-KP
after	O
molting	O
into	O
its	O
nymphal	B-KP
stage	I-KP
.	O
	
Essential	O
to	O
the	O
propagation	O
and	O
survival	O
of	O
these	O
Borrelia	B-KP
species	I-KP
is	O
their	O
plasmid-encoded	O
production	O
of	O
lipoproteins	B-KP
.	O
	
The	O
most	O
important	O
and	O
well	O
researched	O
are	O
outer-surface	B-KP
proteins	I-KP
(	O
Osp	B-KP
)	O
A-F	B-KP
and	O
VIsE	B-KP
.	O
[	O
16	O
]	O
These	O
components	O
along	O
with	O
other	O
surface	B-KP
lipoproteins	I-KP
allow	O
the	O
spirochete	B-KP
to	O
attach	O
to	O
and	O
survive	O
in	O
a	O
variety	O
of	O
small	O
mammals	O
,	O
birds	O
,	O
and	O
tick	O
arthropods	O
.	O
	
Throughout	O
most	O
the	O
year	O
life	O
cycle	O
,	O
the	O
spirochetes	O
remain	O
dormant	O
within	O
the	O
gut	O
of	O
the	O
nymphal	O
tick	O
.	O
	
During	O
this	O
period	O
,	O
the	O
dominant	O
protein	O
expressed	O
on	O
the	O
outer-surface	O
of	O
the	O
bacteria	O
is	O
protein	B-KP
OspA	I-KP
.	O
In	O
late	O
spring	O
and	O
summer	O
,	O
when	O
the	O
nymphal	O
tick	O
engages	O
in	O
another	O
feed	O
,	O
constituents	O
present	O
in	O
the	O
ingested	O
mammalian	O
blood	O
stimulates	O
the	O
spirochete’s	O
production	O
of	O
OspC	B-KP
,	O
which	O
enables	O
the	O
organism	O
to	O
spread	O
in	O
the	O
tick	O
eventually	O
reaching	O
the	O
tick’s	O
salivary	O
gland	O
,	O
where	O
it	O
becomes	O
coated	O
by	O
a	O
protective	O
tick	O
protein	B-KP
,	O
known	O
as	O
VIsE	B-KP
.	O
[	O
17	O
]	O
Once	O
the	O
tick	O
bites	O
the	O
reservoir	O
host	O
,	O
OspC	B-KP
affords	O
the	O
bacteria	O
protection	O
from	O
the	O
animal's	O
innate	O
immune	B-KP
system	I-KP
.	O
	
The	O
VIsE	B-KP
protein	B-KP
is	O
involved	O
in	O
resistance	O
to	O
acquired	O
immunity	O
.	O
[18,19]	O
The	O
reservoir	O
hosts	O
,	O
chiefly	O
rodents	O
and	O
birds	O
,	O
provide	O
a	O
favorable	O
environment	O
supporting	O
bacterial	O
growth	O
,	O
but	O
they	O
do	O
not	O
themselves	O
develop	O
disease	O
.	O
	
Because	O
B	B-KP
.	I-KP
burgdorferi	I-KP
do	O
not	O
possess	O
other	O
virulence	O
factors	O
or	O
have	O
the	O
ability	O
to	O
produce	O
toxins	B-KP
,	O
disease	O
in	O
humans	O
is	O
the	O
consequence	O
of	O
the	O
immunopathologic	B-KP
response	I-KP
to	O
the	O
invading	O
organism	O
and	O
to	O
the	O
bacterial	O
products	O
it	O
produces	O
.	O
	
In-vitro	O
laboratory	O
growth	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
requires	O
incubation	O
in	O
a	O
special	O
medium	O
named	O
Barbour–Stoenner–Kelly	B-KP
medium	I-KP
,	O
preferably	O
at	O
33°C.	O
﻿Microbiologic	O
isolation	O
of	O
a	O
pathogen	O
remains	O
the	O
‘	O
gold	O
standard	O
’	O
in	O
infectious	O
diseases	O
diagnosis	O
.	O
	
However	O
,	O
some	O
etiologic	B-KP
agents	I-KP
,	O
for	O
example	O
Treponema	B-KP
pallidum	I-KP
(	O
the	O
causative	O
agent	O
of	O
syphilis	B-KP
)	O
,	O
cannot	O
be	O
cultivated	O
on	O
artificial	O
medium	O
leaving	O
diagnosis	O
to	O
rely	O
on	O
the	O
direct	O
detection	O
of	O
the	O
pathogen	O
in	O
patient	O
specimens	O
and	O
/	O
or	O
reactivity	O
in	O
serologic	B-KP
tests	I-KP
.	O
	
Advances	O
in	O
molecular	O
medicine	O
,	O
particularly	O
PCR	B-KP
assays	I-KP
designed	O
to	O
detect	O
even	O
minute	O
quantities	O
of	O
organism-specific	B-KP
nucleic	I-KP
acid	I-KP
,	O
have	O
greatly	O
enhanced	O
the	O
laboratory’s	O
ability	O
to	O
make	O
a	O
specific	O
diagnosis	O
of	O
an	O
infectious	O
disease	O
.	O
	
B	B-KP
.	I-KP
burgdorferi	I-KP
can	O
be	O
isolated	O
in-vitro	O
from	O
EM	B-KP
skin	I-KP
tissue	I-KP
,	O
blood	B-KP
samples	O
,	O
and	O
on	O
occasions	O
from	O
cerebrospinal	B-KP
(	O
meningitis	B-KP
cases	O
)	O
and	O
joint	B-KP
fluids	I-KP
.	O
	
However	O
,	O
this	O
requires	O
incubation	O
on	O
specialized	O
Barbour–Stoenner–Kelly	B-KP
(	O
BSK	B-KP
)	O
medium	O
,	O
has	O
a	O
low	O
yield	O
,	O
and	O
generally	O
is	O
not	O
performed	O
in	O
most	O
clinical	O
microbiology	O
laboratories	O
.	O
[	O
65	O
]	O
Moreover	O
,	O
routine	O
hematologic	B-KP
,	O
metabolic	B-KP
,	O
and	O
liver	B-KP
profile	O
tests	O
are	O
usually	O
unremarkable	O
and	O
offer	O
limited	O
diagnostic	O
utility	O
in	O
confirming	O
Lyme	B-KP
disease	I-KP
.	O
	
﻿Lyme	B-KP
borreliosis	I-KP
’	O
natural	O
propensity	O
to	O
evolve	O
from	O
one	O
stage	O
into	O
another	O
,	O
which	O
at	O
times	O
overlap	O
but	O
typically	O
present	O
with	O
their	O
own	O
set	O
of	O
signs	O
,	O
symptoms	O
,	O
and	O
objective	O
measures	O
,	O
is	O
a	O
unique	O
feature	O
of	O
this	O
disease	O
and	O
important	O
factor	O
when	O
creating	O
a	O
differential	O
diagnosis	O
inclusive	O
of	O
both	O
infectious	B-KP
and	I-KP
non-infectious	I-KP
entities	I-KP
potentially	O
accounting	O
for	O
a	O
patient’s	O
condition	O
.	O
	
Furthermore	O
,	O
for	O
some	O
stages	O
of	O
Lyme	B-KP
disease	I-KP
,	O
the	O
time	O
of	O
year	O
of	O
onset	O
coupled	O
with	O
the	O
geographic	O
area	O
where	O
the	O
patient	O
lives	O
or	O
may	O
have	O
traveled	O
to	O
are	O
important	O
epidemiologic	O
pieces	O
of	O
information	O
when	O
considering	O
infection	O
with	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
Local	B-KP
red	I-KP
skin	I-KP
lesions	I-KP
are	O
not	O
uncommon	O
following	O
the	O
bite	O
of	O
other	O
non-infectious	O
disease	O
transmissible	O
arthropods	O
.	O
	
Features	O
that	O
help	O
to	O
distinguish	O
this	O
hypersensitivity	O
event	O
from	O
a	O
tick	O
bite	O
from	O
those	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
EM	I-KP
lesions	I-KP
are	O
that	O
the	O
former	O
appears	O
almost	O
immediately	O
,	O
rapidly	O
expands	O
in	O
size	O
,	O
is	O
associated	O
with	O
local	O
pruritus	O
,	O
is	O
relative	O
small	O
in	O
size	O
,	O
and	O
tends	O
to	O
resolve	O
promptly	O
.	O
	
Localized	B-KP
soft	I-KP
tissue	I-KP
infections	I-KP
with	O
Staphylococcal	B-KP
aureus	I-KP
(	O
especially	O
methicillin-resistant	B-KP
strains	I-KP
)	O
frequently	O
and	O
incorrectly	O
attributed	O
to	O
unwitnessed	O
spider	O
bites	O
,	O
along	O
with	O
other	O
pyogenic	B-KP
infections	I-KP
,	O
generally	O
evolve	O
into	O
a	O
cellulitic	O
process	O
fairly	O
distinct	O
from	O
EM	B-KP
.	O
The	O
rare	O
vesicular	B-KP
EM	I-KP
may	O
at	O
times	O
be	O
confused	O
with	O
Herpes	B-KP
simplex	I-KP
and	O
Varicella	B-KP
zoster	I-KP
infections	I-KP
,	O
the	O
later	O
of	O
which	O
can	O
be	O
easily	O
excluded	O
by	O
its	O
dermatomal	O
distribution	O
.	O
	
In	O
the	O
absence	O
of	O
EM	B-KP
,	O
the	O
nonspecific	O
manifestations	O
of	O
early	O
Lyme	B-KP
disease	I-KP
such	O
as	O
fever	B-KP
,	O
malaise	B-KP
,	O
headache	B-KP
,	O
myalgias	B-KP
,	O
pain	B-KP
on	I-KP
neck	I-KP
flexion	I-KP
,	O
regional	B-KP
and	I-KP
localized	I-KP
lymphadenopathy	I-KP
,	O
invariably	O
are	O
attributed	O
to	O
an	O
unconfirmed	O
‘	O
viral	B-KP
illness	I-KP
’	O
.	O
	
Altered	O
cranial	B-KP
nerve	I-KP
function	I-KP
associated	O
with	O
Lyme	B-KP
disease	I-KP
,	O
either	O
single	O
,	O
most	O
commonly	O
the	O
7th	O
nerve	O
,	O
or	O
multiple	O
,	O
may	O
also	O
be	O
a	O
manifestation	O
of	O
reactivated	O
H	B-KP
.	I-KP
simplex	I-KP
and	O
V	B-KP
.	I-KP
zoster	I-KP
(Ramsey–Hunt)	O
infection	O
,	O
respectively	O
.	O
	
Lyme	B-KP
arthritis	I-KP
differs	O
from	O
other	O
‘	O
septic	B-KP
joint	I-KP
’	O
infections	O
by	O
its	O
insidious	O
onset	O
and	O
lack	O
of	O
pathogen	B-KP
isolation	O
from	O
synovial	B-KP
fluid	I-KP
that	O
would	O
be	O
expected	O
with	O
pyogenic	B-KP
infections	I-KP
such	O
as	O
S	B-KP
.	I-KP
aureus	I-KP
,	O
etc	O
.	O
	
However	O
,	O
in	O
adults	O
,	O
reactive	B-KP
arthritis	I-KP
following	O
some	O
gastrointestinal	B-KP
and	I-KP
sexually	I-KP
transmitted	I-KP
infections	I-KP
as	O
well	O
as	O
non-infection	B-KP
inflammatory	I-KP
arthritic	I-KP
processes	I-KP
may	O
take	O
on	O
similar	O
presentations	O
.	O
	
Children	O
with	O
Lyme	B-KP
arthritis	I-KP
often	O
are	O
first	O
thought	O
to	O
possibly	O
have	O
juvenile	B-KP
rheumatoid	I-KP
arthritis	I-KP
,	O
as	O
was	O
the	O
circumstance	O
surrounding	O
the	O
early	O
recognition	O
of	O
Lyme	B-KP
disease	I-KP
in	O
Connecticut	O
in	O
the	O
1970s	O
.	O
	
﻿The	O
I	B-KP
.	I-KP
scapularis	I-KP
tick	I-KP
is	O
capable	O
of	O
transmitting	O
seven	O
known	O
human	B-KP
pathogens	I-KP
.	O
	
In	O
order	O
of	O
decreasing	O
frequency	O
of	O
reported	O
cases	O
,	O
three	O
of	O
them	O
,	O
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
Anaplasma	B-KP
phagocytophilium	I-KP
,	O
and	O
Babesia	B-KP
microti	I-KP
have	O
accounted	O
for	O
the	O
majority	O
of	O
related	O
infections	O
in	O
recent	O
years	O
.	O
[	O
68	O
]	O
An	O
accurate	O
determination	O
of	O
the	O
rate	O
of	O
Lyme	B-KP
disease	I-KP
coinfection	O
with	O
either	O
of	O
these	O
has	O
proven	O
inconclusive	O
but	O
appears	O
to	O
be	O
an	O
uncommon	O
event	O
.	O
	
Human	B-KP
granulocytic	I-KP
anaplasmosis	I-KP
(	O
formerly	O
ehrlichosis	B-KP
)	O
caused	O
by	O
A	B-KP
.	I-KP
phagocytophilium	I-KP
typically	O
produces	O
leukopenia	B-KP
,	O
thrombocytopenia	B-KP
,	O
and	O
mild	O
elevation	O
of	O
hepatic	B-KP
amino-transaminases	I-KP
,	O
which	O
when	O
encountered	O
in	O
Lyme	B-KP
disease	I-KP
should	O
prompt	O
the	O
consideration	O
of	O
coinfection	O
with	O
this	O
rickettsial	B-KP
organism	I-KP
.	O
[	O
85	O
]	O
The	O
parasitic	O
protozoa	B-KP
B	I-KP
.	I-KP
microti	I-KP
is	O
also	O
carried	O
by	O
I	B-KP
.	I-KP
scapularis	I-KP
in	O
the	O
Northeast	O
and	O
upper	O
Midwest	O
sections	O
of	O
the	O
United	O
States	O
.	O
	
Infection	O
may	O
also	O
be	O
transmitted	O
by	O
transfusion	O
of	O
infected	B-KP
blood	I-KP
or	O
from	O
an	O
infected	O
mother	O
to	O
her	O
fetus	O
in	O
a	O
vertical	O
fashion	O
.	O
[	O
86	O
]	O
Important	O
clues	O
that	O
should	O
raise	O
the	O
possibility	O
of	O
coinfection	O
with	O
this	O
red	B-KP
blood	I-KP
cell	I-KP
pathogen	I-KP
are	O
a	O
more	O
severe	O
presentation	O
of	O
disease	O
,	O
hemolytic	B-KP
anemia	I-KP
and	O
low	O
platelet	O
counts	O
,	O
and	O
the	O
observance	O
of	O
the	O
classic	O
"	O
maltese	B-KP
cross	I-KP
"	O
arrangement	O
of	O
organisms	O
within	O
infected	O
erythrocytes	B-KP
.	O
	
Patients	O
with	O
functional	B-KP
or	I-KP
anatomic	I-KP
asplenia	I-KP
are	O
known	O
to	O
suffer	O
the	O
harshest	O
infections	O
.	O
[	O
87	O
]	O
﻿Assuming	O
the	O
diagnosis	O
of	O
Lyme	B-KP
disease	I-KP
is	O
accurate	O
,	O
90	O
%	O
or	O
more	O
of	O
individuals	O
treated	O
with	O
proven	O
and	O
recommended	O
antimicrobial	B-KP
therapy	I-KP
(	O
Table	O
2	O
)	O
have	O
successful	O
outcomes	O
.	O
[	O
22	O
]	O
Conversely	O
,	O
long-term	O
outcome	O
studies	O
of	O
untreated	O
patients	O
followed	O
prospectively	O
have	O
found	O
many	O
of	O
these	O
individuals	O
to	O
have	O
developed	O
any	O
one	O
of	O
a	O
variety	O
of	O
clinical	O
manifestations	O
contributed	O
to	O
Lyme	B-KP
borreliosis	I-KP
at	O
some	O
point	O
in	O
time	O
after	O
the	O
spontaneous	O
resolution	O
of	O
their	O
EM	B-KP
lesion	I-KP
.	O
[	O
49	O
]	O
First	O
line	O
agents	O
consist	O
of	O
orally	O
given	O
doxycycline	B-KP
,	O
amoxicillin	B-KP
,	O
and	O
cefuroxime	B-KP
axetil	I-KP
.	O
	
Doxycycline	B-KP
has	O
an	O
added	O
advantage	O
of	O
possessing	O
antimicrobial	O
activity	O
against	O
A	B-KP
.	I-KP
phagocytophilium	I-KP
in	O
the	O
event	O
that	O
coinfection	O
has	O
occurred	O
.	O
	
Macrolide	B-KP
antibiotics	I-KP
are	O
considered	O
to	O
be	O
second-line	O
choices	O
in	O
those	O
with	O
intolerance	O
or	O
contraindications	O
to	O
beta-lactam	B-KP
medications	I-KP
and	O
doxycycline	B-KP
,	O
but	O
require	O
cautious	O
clinical	O
follow-up	O
since	O
they	O
have	O
been	O
found	O
to	O
be	O
less	O
effective	O
.	O
[95,96]	O
Historically	O
,	O
the	O
length	O
of	O
treatment	O
has	O
been	O
14–21	O
days	O
,	O
however	O
,	O
recently	O
available	O
evidence	O
supports	O
shortening	O
the	O
duration	O
of	O
treatment	O
with	O
doxycycline	B-KP
to	O
10	O
days	O
.	O
[	O
97	O
]	O
Retreatment	O
is	O
rarely	O
if	O
at	O
all	O
ever	O
necessary	O
,	O
as	O
individuals	O
with	O
persistent	O
subjective	O
symptoms	O
,	O
but	O
no	O
objective	O
findings	O
of	O
ongoing	O
active	O
infection	O
have	O
not	O
been	O
found	O
to	O
benefit	O
from	O
additional	O
courses	O
of	O
antibiotics	B-KP
.	O
[98,99]	O
The	O
third-generation	O
intravenous	B-KP
(	O
IV	B-KP
)	O
cephalosporin	B-KP
antibiotic	I-KP
,	O
ceftriaxone	B-KP
,	O
has	O
excellent	O
in-vitro	O
antibacterial	O
activity	O
against	O
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
but	O
in	O
almost	O
all	O
clinical	O
circumstances	O
provides	O
little	O
if	O
any	O
clear	O
benefit	O
over	O
the	O
use	O
of	O
oral	B-KP
doxycycline	I-KP
.	O
[100–102]	O
Nonetheless	O
,	O
2–4-week	O
courses	O
of	O
intravenous	B-KP
ceftriaxone	I-KP
is	O
still	O
commonly	O
recommended	O
and	O
given	O
for	O
in	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
and	O
unquestionable	O
objective	O
neurologic	B-KP
abnormalities	I-KP
.	O
[	O
103	O
]	O
Likewise	O
,	O
hospitalized	O
patients	O
with	O
high-degree	O
atrioventricular	B-KP
block	I-KP
are	O
initially	O
treated	O
with	O
intravenous	B-KP
ceftriaxone	I-KP
and	O
with	O
completion	O
of	O
the	O
14–21-day	O
treatment	O
course	O
using	O
an	O
oral	B-KP
agent	I-KP
.	O
[	O
22	O
]	O
Placement	O
of	O
a	O
permanent	O
cardiac	B-KP
pacemaker	I-KP
is	O
rarely	O
,	O
if	O
ever	O
required	O
,	O
although	O
at	O
times	O
,	O
a	O
temporary	O
transvenous	O
or	O
external	O
pacemaker	O
is	O
indicated	O
.	O
	
Lesser	O
degrees	O
of	O
heart	O
block	O
(	O
first-degree	O
AV	B-KP
block	I-KP
,	O
PR	O
interval	O
<	O
300	O
msec	O
)	O
can	O
be	O
managed	O
with	O
oral	B-KP
agents	I-KP
alone	O
.	O
	
﻿Tick-borne	B-KP
diseases	I-KP
(	O
TBD	B-KP
)	O
present	O
a	O
major	O
public	O
health	O
problem	O
in	O
the	O
United	O
States	O
,	O
where	O
74.7%of	O
clinicians	O
in	O
high-incidence	O
states	O
report	O
having	O
treated	O
a	O
patient	O
for	O
TBD	B-KP
in	O
the	O
previous	O
year	O
(	O
Brett	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
	
In	O
the	O
United	O
States	O
,	O
more	O
than	O
a	O
dozen	O
pathogens	B-KP
can	O
be	O
transmitted	O
by	O
five	O
different	O
genera	O
ofticks	O
(	O
Shah	O
and	O
Sood	O
,	O
2013	O
)	O
.	O
	
When	O
a	O
primary	O
care	O
provider	O
sees	O
a	O
patient	O
who	O
has	O
removed	O
and	O
saved	O
an	O
attached	O
tick	O
,	O
it	O
is	O
important	O
to	O
identify	O
the	O
tick	O
genus	O
or	O
common	O
name	O
to	O
determine	O
which	O
pathogens	B-KP
were	O
potentially	O
transmitted	O
and	O
whether	O
antibiotic	B-KP
prophylaxis	I-KP
for	O
Lyme	B-KP
disease	I-KP
is	O
appropriate	O
.	O
	
Some	O
41.1%	O
of	O
providers	O
in	O
states	O
with	O
high	O
Lyme	B-KP
disease	I-KP
incidence	O
recently	O
reported	O
providing	O
tick-bite	B-KP
prophylaxis	I-KP
in	O
the	O
previous	O
year	O
(	O
Brett	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
	
Notably	O
,	O
misidentification	O
of	O
a	O
tick	O
may	O
lead	O
to	O
unnecessary	O
prophylactic	B-KP
antibiotic	I-KP
treatment	I-KP
,	O
unwarranted	O
testing	O
,	O
or	O
potentially	O
a	O
missed	O
diagnosis	O
of	O
TBD	B-KP
.	O
To	O
date	O
,	O
only	O
one	O
study	O
has	O
been	O
published	O
on	O
tick	O
identification	O
by	O
providers	O
in	O
a	O
Lyme	B-KP
disease	I-KP
endemic	B-KP
area	I-KP
(	O
Falco	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O
	
This	O
study	O
examined	O
specimens	O
submitted	O
by	O
physicians	O
or	O
medical	O
groups	O
to	O
the	O
Fordham	O
University	O
Vector	O
Ecology	O
Laboratory	O
in	O
Westchester	O
County	O
,	O
NY	O
between	O
1988	O
and	O
1990	O
for	O
tick	O
identification	O
.	O
	
Among	O
802	O
submitted	O
specimens	O
,	O
74.7%	O
were	O
blacklegged	B-KP
ticks	I-KP
(	O
Ixodes	B-KP
scapularis	I-KP
)	O
.	O
	
It	O
is	O
unclear	O
,	O
however	O
,	O
whether	O
all	O
of	O
these	O
specimens	O
were	O
initially	O
suspected	O
to	O
have	O
been	O
blacklegged	B-KP
ticks	I-KP
and	O
thus	O
whether	O
the	O
remaining	O
25.3%	O
were	O
incorrectly	O
identified	O
.	O
	
Notably	O
,	O
5.9%	O
of	O
specimens	O
submitted	O
for	O
tick	O
identification	O
were	O
non-tick	B-KP
arthropods	I-KP
including	O
beetles	B-KP
,	O
crab	B-KP
lice	I-KP
,	O
and	O
head	B-KP
lice	I-KP
.	O
	
It	O
is	O
also	O
unknown	O
how	O
well	O
this	O
sample	O
represents	O
tick	O
identification	O
by	O
providers	O
during	O
regular	O
clinical	O
practice	O
and	O
not	O
as	O
part	O
of	O
a	O
tick	O
identification	O
service	O
.	O
	
﻿The	O
following	O
day	O
,	O
the	O
patient	O
was	O
evaluated	O
by	O
a	O
neurosurgeon	O
,	O
who	O
noted	O
that	O
the	O
right	O
bicep	O
and	O
brachioradial	O
reflexes	O
were	O
absent	O
which	O
was	O
a	O
variation	O
from	O
the	O
initial	O
presentation	O
in	O
the	O
ED	O
.	O
The	O
neurosurgeon	O
recommended	O
further	O
testing	O
including	O
a	O
myelogram	B-KP
and	O
lumbar	B-KP
puncture	I-KP
to	O
assess	O
the	O
cerebrospinal	B-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
due	O
to	O
the	O
patient’s	O
symptomatology	O
.	O
	
The	O
patient	O
was	O
placed	O
on	O
dexamethasone	B-KP
(	O
Decadron	B-KP
)	O
4	O
mg	O
every	O
6	O
hr	O
intravenously	O
and	O
the	O
outpatient	O
medications	O
were	O
also	O
continued	O
.	O
	
A	O
lumbar	B-KP
puncture	I-KP
(	O
LP	B-KP
)	O
was	O
performed	O
and	O
CSF	B-KP
samples	I-KP
were	O
sent	O
to	O
the	O
lab	O
.	O
	
Results	O
were	O
positive	O
for	O
elevated	O
glucose	B-KP
,	O
white	B-KP
blood	I-KP
cells	I-KP
,	O
and	O
protein	B-KP
levels	I-KP
.	O
	
The	O
CSF	B-KP
was	O
also	O
positive	O
for	O
Lyme	O
(	O
Table	O
2	O
)	O
.	O
	
An	O
infectious	O
disease	O
consult	O
was	O
ordered	O
and	O
the	O
patient	O
was	O
seen	O
that	O
day	O
.	O
	
The	O
infectious	O
disease	O
physician	O
obtained	O
further	O
history	O
of	O
a	O
rash	O
on	O
the	O
right	O
chest	O
wall	O
that	O
developed	O
prior	O
to	O
the	O
patient’s	O
symptoms	O
.	O
	
The	O
patient	O
did	O
not	O
recall	O
seeing	O
a	O
tick	O
at	O
the	O
site	O
of	O
the	O
rash	B-KP
.	O
	
The	O
physician	O
noted	O
a	O
slight	O
left	O
facial	O
droop	O
and	O
an	O
erythematous	B-KP
area	I-KP
to	O
the	O
right	O
chest	O
wall	O
lateral	O
to	O
the	O
breast	B-KP
.	O
	
According	O
to	O
the	O
physician	O
,	O
the	O
lesion	B-KP
was	O
not	O
consistent	O
with	O
erythema	B-KP
migrans	I-KP
at	O
the	O
time	O
of	O
the	O
examination	O
.	O
	
The	O
physician	O
ordered	O
a	O
repeat	O
LP	B-KP
to	O
further	O
evaluate	O
the	O
CSF	B-KP
(	O
Table	O
2	O
)	O
.	O
	
Further	O
Lyme	O
studies	O
were	O
ordered	O
and	O
obtained	O
and	O
the	O
results	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
﻿Three	O
pathogenic	B-KP
Borrelia	I-KP
species	I-KP
are	O
primarily	O
responsible	O
for	O
Lyme	B-KP
disease	I-KP
,	O
the	O
most	O
common	O
tick-transmitted	O
illness	O
of	O
the	O
boreal	O
hemisphere	O
(1,2).	O
	
In	O
Europe	O
,	O
Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
Borrelia	B-KP
burgdorferi	I-KP
,	O
Borrelia	B-KP
afzelii	I-KP
,	O
and	O
Borrelia	B-KP
garinii	I-KP
,	O
whereas	O
in	O
the	O
US	O
,	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
the	O
sole	O
cause	O
(3,4).	O
	
Lyme	B-KP
disease	I-KP
usually	O
begins	O
with	O
a	O
characteristic	O
expanding	O
skin	B-KP
lesion	I-KP
,	O
erythema	B-KP
migrans	I-KP
(	O
5	O
)	O
.	O
	
After	O
several	O
days	O
or	O
weeks	O
,	O
the	O
spirochete	B-KP
may	O
spread	O
to	O
different	O
sites	O
,	O
causing	O
meningitis	B-KP
,	O
cranial	B-KP
or	I-KP
peripheral	I-KP
neuritis	I-KP
,	O
carditis	B-KP
,	O
atrioventricular	B-KP
node	I-KP
block	I-KP
,	O
or	O
migratory	B-KP
musculoskeletal	I-KP
pain	I-KP
.	O
	
Months	O
later	O
,	O
Lyme	B-KP
arthritis	I-KP
may	O
develop	O
in	O
untreated	O
patients	O
with	O
Borrelia	B-KP
infection	I-KP
,	O
with	O
a	O
rapid	O
onset	O
of	O
marked	O
swelling	O
and	O
pain	O
of	O
affected	O
joints	O
,	O
most	O
commonly	O
the	O
knee	O
(	O
6	O
)	O
.	O
	
In	O
these	O
patients	O
,	O
synovial	B-KP
fluid	I-KP
contains	O
polymorphonuclear	B-KP
and	I-KP
mononuclear	I-KP
cells	I-KP
(	O
7	O
)	O
.	O
	
In	O
most	O
patients	O
,	O
Lyme	B-KP
arthritis	I-KP
responds	O
to	O
appropriate	O
oral	B-KP
or	I-KP
intravenous	I-KP
antibiotic	I-KP
therapy	I-KP
.	O
	
However	O
,	O
in	O
rare	O
cases	O
,	O
proliferative	B-KP
synovitis	I-KP
persists	O
after	O
2	O
months	O
of	O
treatment	O
with	O
oral	B-KP
antibiotics	I-KP
or	O
1	O
month	O
of	O
treatment	O
with	O
intravenous	B-KP
antibiotics	I-KP
,	O
or	O
both	O
.	O
	
This	O
condition	O
is	O
called	O
antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
(	O
3	O
)	O
.	O
	
﻿NapA	B-KP
was	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
from	O
Bacillus	B-KP
subtilis	I-KP
.	O
	
The	O
NapA	B-KP
gene	I-KP
was	O
amplified	O
by	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
(	O
PCR	B-KP
)	O
from	O
B	B-KP
burgdorferi	I-KP
strain	I-KP
B31	I-KP
,	O
using	O
standard	O
methods	O
.	O
	
The	O
following	O
primers	O
were	O
used	O
:	O
5-CCCGAGCTCATAAAGGAGATAG-TTATG-3	O
'	O
and	O
5-CCCAAGCTTCTATTTTGCATCACA-CTC-3	O
'	O
(	O
underlining	O
indicates	O
Sac	O
I	O
and	O
Hind	O
III	O
restriction	B-KP
enzyme	I-KP
sites	I-KP
,	O
respectively	O
)	O
.	O
	
The	O
amplified	O
fragment	B-KP
was	O
digested	O
and	O
inserted	O
into	O
the	O
expression	B-KP
vector	I-KP
pSM214G	I-KP
,	O
resulting	O
in	O
plasmid	B-KP
pSM214G-NapA	I-KP
.	O
B	B-KP
subtilis	I-KP
strain	I-KP
SMS	I-KP
118	I-KP
containing	O
the	O
plasmid	B-KP
pSM214G-NapA	I-KP
was	O
grown	O
for	O
15	O
hours	O
in	O
YT	O
medium	O
and	O
15	O
μg	O
/	O
ml	O
of	O
chloramphenicol	B-KP
.	O
	
After	O
centrifugation	O
,	O
cells	O
were	O
resuspended	O
in	O
30	O
mM	O
Tris	O
HCl	O
,	O
pH	O
7.8,	O
and	O
lysed	O
through	O
3	O
French	O
press	O
passages	O
.	O
	
Debris	O
was	O
removed	O
by	O
centrifugation	O
,	O
and	O
ammonium	O
sulfate	O
60	O
%	O
was	O
added	O
to	O
the	O
supernatant	B-KP
.	O
	
﻿Real-time	O
PCR	B-KP
analysis	I-KP
.	O
	
Total	O
RNA	B-KP
was	O
isolated	O
from	O
2	O
x	O
10^6	O
monocytes	O
using	O
TRIzol	O
solution	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer's	O
instructions	O
.	O
	
RNA	B-KP
was	O
reverse-transcribed	O
and	O
amplified	O
with	O
the	O
following	O
primers	B-KP
:	O
for	O
GAPDH	B-KP
,	O
5'-AGCAACAGGGTGGTGGAC-3'	O
and	O
5'-GTGTGGTGGGGGACTGAG-3';	O
for	O
IL-23p19	B-KP
,	O
5'-TCC-ACCAGGGTCTGATTTTT-3'	O
and	O
5'-TTGAAGCGGAGAAGGAGACG-3';	O
for	O
IL-12p40	B-KP
,	O
5'-ACAAAGGAGGCGAGGTTCTAA-3'	O
and	O
5'-CCCTTGGGGGTCAGAAGAG-3';	O
for	O
IL-6	B-KP
,	O
5'-AACCTGAACCTTCCAAAGATGG-3'	O
and	O
5'-TCTGGCTTGTTCCTCACTACT-3';	O
for	O
TGFβ	B-KP
,	O
5'-AGTGGTTGAGCCGTGGAG-3'	O
and	O
5'-CCATGAGAAGCAGGAAAGG-3';	O
and	O
for	O
IL-1	B-KP
,	O
5-CTGTCCTGCGTGTTGAAAGA-3	O
'	O
and	O
5'-TTGGGTAATTTTTGGGATCTACA-3'.	O
	
After	O
the	O
amplification	O
,	O
data	O
analysis	O
was	O
performed	O
using	O
the	O
second	O
derivative	O
method	O
algorithm	O
.	O
	
For	O
each	O
sample	O
,	O
the	O
amount	O
of	O
messenger	B-KP
RNA	I-KP
(	O
mRNA	B-KP
)	O
of	O
the	O
cytokines	B-KP
(	O
IL-23p19	B-KP
,	O
IL-12p40	B-KP
,	O
IL-6	B-KP
,	O
TGFβ	B-KP
,	O
and	O
IL-1β	B-KP
)	O
was	O
expressed	O
as	O
the	O
n-fold	O
of	O
the	O
normalized	O
amount	O
of	O
mRNA	B-KP
in	O
untreated	O
cells	O
(	O
1	O
arbitrary	O
unit	O
cytokine	B-KP
mRNA	I-KP
concentration	O
/	O
GAPDH	B-KP
mRNA	I-KP
concentration	O
[	O
both	O
in	O
fmoles	O
/	O
μl]).	O
	
﻿Bacterial	B-KP
meningitis	I-KP
clinical	O
prediction	O
rules	O
identify	O
children	O
with	O
cerebrospinal	B-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
pleocytosis	B-KP
who	O
are	O
at	O
very	O
low	O
risk	O
of	O
bacterial	B-KP
meningitis	I-KP
.	O
[1–6]	O
However	O
,	O
in	O
Lyme	B-KP
disease–endemic	O
areas	I-KP
,	O
such	O
as	O
the	O
northeastern	O
and	O
mid-Atlantic	O
states	O
,	O
children	O
with	O
CSF	B-KP
pleocytosis	I-KP
who	O
are	O
at	O
low	O
risk	O
of	O
bacterial	B-KP
meningitis	I-KP
may	O
still	O
have	O
Lyme	B-KP
meningitis	I-KP
,	O
which	O
is	O
treated	O
with	O
3	O
to	O
4	O
weeks	O
of	O
parenteral	O
antibiotics	O
.	O
[7,8]	O
Because	O
it	O
takes	O
several	O
days	O
to	O
obtain	O
Borrelia	B-KP
burgdorferi	I-KP
serology	I-KP
results	I-KP
,	O
clinicians	O
must	O
decide	O
whether	O
to	O
hospitalize	O
and	O
to	O
start	O
empirical	O
antibiotics	B-KP
for	O
children	O
being	O
evaluated	O
for	O
Lyme	B-KP
meningitis	I-KP
.	O
	
﻿Early	O
identification	O
of	O
those	O
children	O
at	O
low	O
risk	O
for	O
Lyme	B-KP
meningitis	I-KP
would	O
allow	O
for	O
outpatient	O
management	O
while	O
awaiting	O
Lyme	B-KP
serology	I-KP
results	O
.	O
	
Previous	O
studies	O
identify	O
clinical	O
and	O
laboratory	O
differences	O
between	O
children	O
with	O
Lyme	B-KP
meningitis	I-KP
versus	O
other	O
forms	O
of	O
aseptic	B-KP
meningitis	I-KP
.	O
[9–11]	O
However	O
,	O
these	O
single-center	O
studies	O
were	O
limited	O
by	O
small	O
sample	O
size	O
and	O
lacked	O
validation	O
.	O
	
In	O
a	O
larger	O
retrospective	O
cohort	O
of	O
175	O
children	O
evaluated	O
for	O
Lyme	B-KP
meningitis	I-KP
,	O
Avery	O
et	O
al	O
[	O
12	O
]	O
derived	O
a	O
Lyme	B-KP
meningitis	I-KP
clinical	O
prediction	O
rule	O
based	O
on	O
these	O
3	O
factors	O
:	O
duration	O
of	O
headache	B-KP
,	O
presence	O
of	O
cranial	B-KP
neuritis	I-KP
,	O
and	O
percentage	O
of	O
CSF	B-KP
mononuclear	I-KP
cells	I-KP
.	O
	
In	O
a	O
prospective	O
cohort	O
of	O
50	O
children	O
evaluated	O
for	O
Lyme	B-KP
meningitis	I-KP
,	O
the	O
Avery	O
model	O
performed	O
well	O
.	O
[	O
13	O
]	O
These	O
investigators	O
suggested	O
a	O
simplification	O
of	O
the	O
more	O
complicated	O
Avery	O
regression	O
equation	O
termed	O
the	O
“	O
Rule	O
of	O
79s	O
.	O
”	O
[	O
13	O
]	O
Children	O
who	O
met	O
all	O
of	O
the	O
following	O
3	O
criteria	O
were	O
classified	O
as	O
low	O
risk	O
for	O
Lyme	B-KP
meningitis	I-KP
:	O
<7	O
days	O
of	O
headache	O
,	O
<70%	O
CSF	B-KP
mononuclear	I-KP
cells	I-KP
,	O
and	O
absence	O
of	O
seventh	O
(	O
or	O
other	O
)	O
cranial	B-KP
nerve	I-KP
palsy	I-KP
.	O
	
﻿The	O
constitutional	O
“	O
flu-like	O
”	O
symptoms	O
that	O
frequently	O
accompany	O
early	O
stage	O
LD	B-KP
may	O
also	O
act	O
as	O
a	O
guide	O
to	O
the	O
etiology	O
of	O
FNP	B-KP
.	O
Fever	B-KP
and	O
headache	B-KP
are	O
the	O
most	O
frequent	O
symptoms	O
associated	O
with	O
LD	B-KP
.	O
[13,20]	O
Facial	B-KP
nerve	I-KP
palsy	I-KP
will	O
typically	O
manifest	O
itself	O
early	O
in	O
LD	B-KP
and	O
has	O
been	O
noted	O
to	O
arise	O
during	O
or	O
even	O
after	O
treatment	O
has	O
been	O
initiated	O
.	O
[	O
16	O
]	O
In	O
children	O
,	O
EM	B-KP
frequently	O
occurs	O
on	O
the	O
head	B-KP
and	O
neck	B-KP
region	O
.	O
	
This	O
is	O
in	O
contradistinction	O
to	O
adults	O
who	O
typically	O
develop	O
EM	B-KP
on	O
the	O
lower	O
extremities	O
.	O
	
This	O
likely	O
results	O
from	O
a	O
child’s	O
shorter	O
stature	O
.	O
	
That	O
subsequent	O
FNP	B-KP
arises	O
on	O
the	O
ipsilateral	O
side	O
suggests	O
direct	O
neural	B-KP
invasion	I-KP
,	O
although	O
there	O
is	O
no	O
histopathologic	O
evidence	O
for	O
this	O
.	O
[	O
10	O
]	O
Additionally	O
,	O
FNP	B-KP
is	O
one	O
of	O
the	O
more	O
common	O
neurologic	O
manifestations	O
of	O
LD	B-KP
,	O
especially	O
in	O
children	O
.	O
[10,13,16,17]	O
Children	O
also	O
manifest	O
bilateral	B-KP
FNP	I-KP
more	O
frequently	O
than	O
adults	O
.	O
	
Bilateral	B-KP
FNP	I-KP
is	O
more	O
frequently	O
caused	O
by	O
LD	B-KP
than	O
other	O
causes	O
.	O
	
﻿In	O
general	O
,	O
the	O
duration	O
of	O
FNP	B-KP
with	O
LD	B-KP
is	O
reported	O
to	O
be	O
shorter	O
than	O
with	O
other	O
causes	O
of	O
peripheral	B-KP
FNP	I-KP
.	O
[11,15]	O
Resolution	O
may	O
even	O
begin	O
before	O
beginning	O
treatment	O
,	O
and	O
overall	O
prognosis	O
is	O
typically	O
good	O
.	O
[15,16]	O
We	O
did	O
note	O
several	O
patients	O
who	O
had	O
FNP	B-KP
lasting	O
many	O
months	O
even	O
after	O
intravenous	O
ceftriaxone	O
.	O
	
The	O
laboratory	O
diagnosis	O
of	O
LD	B-KP
can	O
be	O
difficult	O
.	O
	
Erythrocyte	B-KP
sedimentation	I-KP
rates	I-KP
,	O
while	O
elevated	O
,	O
are	O
nonspecific	O
.	O
	
Cerebral	B-KP
spinal	I-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
lymphocytosis	B-KP
and	O
elevated	O
CSF	O
proteins	B-KP
can	O
be	O
seen	O
in	O
viral	B-KP
meningitis	I-KP
as	O
well	O
as	O
LD	B-KP
.	O
Although	O
specific	O
antibody	B-KP
tests	I-KP
may	O
be	O
beneficial	O
,	O
in	O
early	O
LD	B-KP
,	O
the	O
IgM	B-KP
may	O
not	O
be	O
positive	O
for	O
3	O
to	O
4	O
weeks	O
and	O
the	O
IgG	B-KP
may	O
not	O
be	O
positive	O
for	O
6	O
to	O
8	O
weeks	O
.	O
[	O
14	O
]	O
﻿Bilateral	B-KP
lower	I-KP
motor	I-KP
neurone	I-KP
facial	I-KP
weakness	I-KP
and	O
mononeuritis	B-KP
multiplex	I-KP
ring	I-KP
alarm	O
bells	O
for	O
Lyme	B-KP
disease	I-KP
,	O
but	O
unilateral	B-KP
lower	I-KP
motor	I-KP
neurone	I-KP
facial	I-KP
weakness	I-KP
does	O
not	O
necessarily	O
.	O
	
It	O
is	O
important	O
,	O
therefore	O
,	O
to	O
consider	O
the	O
clues	O
to	O
the	O
different	O
diagnoses	O
.	O
	
Bell’s	B-KP
palsy	I-KP
typically	O
presents	O
with	O
an	O
acute	O
onset	O
to	O
a	O
maximum	O
within	O
72	O
hours	O
.	O
[	O
11	O
]	O
About	O
50	O
%	O
of	O
patients	O
have	O
a	O
mild-tomoderate	O
post-auricular	B-KP
pain	I-KP
(	O
25	O
%	O
before	O
the	O
weakness	O
,	O
50	O
%	O
contemporaneous	O
with	O
the	O
weakness	O
,	O
and	O
25	O
%	O
after	O
the	O
weakness	O
)	O
,	O
with	O
altered	O
taste	O
in	O
35%.11	O
In	O
30	O
%	O
a	O
dry	B-KP
eye	I-KP
is	O
noticed	O
,	O
and	O
in	O
20	O
%	O
a	O
dry	O
mouth	O
,	O
due	O
to	O
parasympathetic	O
involvement	O
.	O
[	O
11	O
]	O
Patients	O
with	O
Lyme	B-KP
disease	I-KP
with	O
facial	B-KP
palsy	I-KP
may	O
have	O
noticed	O
a	O
tick	O
bite	O
-	O
a	O
hard-bodied	O
tick	O
attachment	O
with	O
or	O
without	O
engorgement	O
is	O
particularly	O
relevant	O
.	O
[	O
9	O
]	O
And	O
90	O
%	O
will	O
experience	O
a	O
transient	O
rash	O
,	O
erythema	B-KP
migrans	I-KP
,	O
2–40	O
days	O
after	O
exposure	O
.	O
[	O
9	O
]	O
Approximately	O
7	O
%	O
will	O
feel	O
generally	O
unwell	O
,	O
and	O
arthralgia	B-KP
has	O
also	O
been	O
reported	O
.	O
[3,9,12]	O
Although	O
the	O
diagnosis	O
is	O
clinical	O
,	O
serological	B-KP
testing	I-KP
may	O
be	O
useful	O
,	O
particularly	O
paired	O
blood	O
samples	O
taken	O
at	O
a	O
4-week	O
interval	O
,	O
to	O
allow	O
for	O
seroconversion	B-KP
.	O
[	O
9	O
]	O
﻿Cases	O
of	O
Lyme	B-KP
disease	I-KP
have	O
been	O
rising	O
steadily	O
over	O
recent	O
years	O
,	O
as	O
have	O
diagnoses	O
in	O
combination	O
with	O
Bell’s	B-KP
palsy	I-KP
(	O
Table	O
1	O
)	O
.	O
	
This	O
may	O
be	O
due	O
to	O
better	O
surveillance	O
,	O
increased	O
awareness	O
of	O
the	O
disease	O
,	O
or	O
increasing	O
infection	O
rates	O
caused	O
by	O
travel	O
to	O
endemic	B-KP
areas	I-KP
.	O
[	O
1	O
]	O
Classically	O
,	O
Lyme	B-KP
disease	I-KP
is	O
associated	O
with	O
areas	O
of	O
woodland	O
,	O
pasture	O
,	O
and	O
heath	O
,	O
where	O
ticks	O
parasitise	O
small	O
mammals	O
such	O
as	O
field	O
mice	O
and	O
voles	O
,	O
and	O
larger	O
animals	O
such	O
as	O
sheep	O
,	O
deer	O
,	O
and	O
horses	O
.	O
[	O
3	O
]	O
The	O
majority	O
of	O
European	O
cases	O
are	O
within	O
the	O
UK	O
,	O
including	O
forested	O
areas	O
such	O
as	O
the	O
New	O
Forest	O
,	O
Exmoor	O
,	O
the	O
South	O
Downs	O
,	O
Thetford	O
Forest	O
in	O
East	O
Anglia	O
,	O
the	O
Lake	O
District	O
,	O
the	O
Yorkshire	O
Moors	O
,	O
and	O
the	O
Scottish	O
Highlands	O
,	O
although	O
there	O
are	O
also	O
cases	O
in	O
the	O
Dordogne	O
and	O
Eastern	O
Europe	O
.	O
[	O
1	O
]	O
The	O
maps	O
provided	O
in	O
Figures	O
2–4	O
support	O
this	O
finding	O
and	O
add	O
to	O
them	O
(	O
for	O
example	O
,	O
one	O
of	O
the	O
highest	O
areas	O
in	O
England	O
was	O
found	O
in	O
the	O
north	O
west	O
of	O
London	O
in	O
the	O
Chiltern	O
Hills	O
)	O
.	O
	
﻿The	O
primary	O
problem	O
was	O
the	O
right	O
shoulder	O
pain	O
with	O
overhead	O
activity	O
and	O
sleeping	O
on	O
his	O
right	O
side	O
.	O
	
From	O
the	O
patient’s	O
history	O
and	O
systems	O
review	O
,	O
the	O
potential	O
differential	O
diagnoses	O
included	O
right	B-KP
shoulder	I-KP
subacromial	I-KP
impingement	I-KP
due	O
to	O
subacromial	O
bursitis	I-KP
,	O
rotator	B-KP
cuff	I-KP
tendinopathy	I-KP
,	O
or	O
a	O
partial	O
tear	O
of	O
the	O
supraspinatus	B-KP
tendon	I-KP
.	O
[1,2]	O
The	O
radiologist’s	O
interpretation	O
of	O
the	O
radiographs	O
and	O
MRI	B-KP
appeared	O
to	O
support	O
subacromial	B-KP
impingement	I-KP
due	O
to	O
supraspinatus	B-KP
tendinopathy	I-KP
.	O
	
The	O
evaluating	O
physical	O
therapist	O
determined	O
the	O
patient	O
needed	O
a	O
range-of-motion	O
and	O
strength	O
examination	O
,	O
posture	O
analysis	O
,	O
and	O
special	O
tests	O
to	O
differentiate	O
among	O
the	O
potential	O
diagnoses	O
.	O
	
From	O
the	O
patient’s	O
history	O
and	O
following	O
examination	O
,	O
a	O
musculoskeletal	B-KP
diagnosis	I-KP
was	O
differentiated	O
,	O
but	O
unusual	O
and	O
atypical	O
symptoms	O
began	O
to	O
present	O
during	O
the	O
intervention	O
.	O
	
The	O
treating	O
physical	O
therapist’s	O
ability	O
to	O
recognize	O
this	O
patient’s	O
atypical	O
symptoms	O
and	O
need	O
for	O
another	O
referral	O
contribute	O
to	O
the	O
importance	O
of	O
presenting	O
this	O
case	O
report	O
.	O
	
﻿A	O
physical	B-KP
examination	I-KP
was	O
conducted	O
,	O
with	O
an	O
initial	O
clinical	B-KP
impression	I-KP
of	I-KP
supraspinatus	I-KP
tendinopathy	I-KP
and	O
impingement	O
.	O
	
Therefore	O
,	O
procedures	O
were	O
undertaken	O
in	O
an	O
attempt	O
to	O
confirm	O
the	O
initial	O
clinical	O
impression	O
.	O
	
Observation	O
of	O
the	O
patient	O
revealed	O
:	O
(	O
1	O
)	O
flu-like	B-KP
symptoms	I-KP
(	O
runny	B-KP
nose	I-KP
,	O
sinus	B-KP
congestion	I-KP
,	O
and	O
itchy	B-KP
throat	I-KP
)	O
,	O
which	O
he	O
attributed	O
to	O
a	O
recent	O
bout	O
of	O
sinus	B-KP
congestion	I-KP
due	O
to	O
seasonal	O
allergies	O
,	O
and	O
(	O
2	O
)	O
poor	O
sitting	O
posture	O
,	O
which	O
is	O
a	O
common	O
observation	O
in	O
supraspinatus	B-KP
impingement	I-KP
.	O
[	O
1	O
]	O
Palpation	B-KP
examination	I-KP
of	O
the	O
right	O
upper	O
extremity	O
revealed	O
tenderness	O
at	O
the	O
distal	O
insertion	O
of	O
the	O
supraspinatus	B-KP
tendon	I-KP
and	O
in	O
the	O
supraspinatus	B-KP
muscle	I-KP
belly	I-KP
.	O
	
A	O
painful	O
arc	O
at	O
120	O
degrees	O
of	O
abduction	O
,	O
minimal	B-KP
scapular	I-KP
dyskinesia	I-KP
on	I-KP
the	I-KP
right	I-KP
side	I-KP
,	O
and	O
pain	O
at	O
end-range	O
passive	O
shoulder	O
internal	O
rotation	O
were	O
revealed	O
in	O
right	O
shoulder	O
range-of-motion	O
testing	O
in	O
standing	O
and	O
supine	O
positions	O
as	O
described	O
by	O
Magee	O
.	O
[	O
25	O
]	O
After	O
range-ofmotion	O
testing	O
,	O
manual	B-KP
muscle	I-KP
testing	I-KP
(	O
MMT	B-KP
)	O
on	O
a	O
0	O
to	O
5	O
scale	O
was	O
conducted	O
using	O
techniques	O
suggested	O
by	O
Hislop	O
and	O
Montgomery	O
.	O
[	O
26	O
]	O
The	O
patient’s	O
strength	O
measurements	O
revealed	O
right	O
shoulder	O
strength	O
(	O
force-generating	O
capacity	O
)	O
of	O
external	O
rotation	O
and	O
abduction	O
of	O
4	O
/	O
5	O
and	O
provoked	O
pain	O
in	O
the	O
right	O
shoulder	O
.	O
	
﻿Previous	O
authors	O
have	O
documented	O
that	O
Lyme	B-KP
disease	I-KP
affects	O
the	O
shoulder	O
joint	O
,	O
[5,8]	O
and	O
the	O
avascular	O
articular	O
surface	O
of	O
the	O
distal	B-KP
supraspinatus	I-KP
tendon	I-KP
[	O
28	O
]	O
is	O
a	O
favorable	O
location	O
for	O
the	O
spirochetes	B-KP
due	O
to	O
the	O
somewhat	O
hypoxic	O
condition	O
of	O
the	O
area	O
.	O
	
It	O
appears	O
that	O
the	O
patient’s	O
distal	B-KP
supraspinatus	I-KP
tendinopathy	I-KP
,	O
with	O
consequent	O
pain	O
and	O
inflammation	O
,	O
was	O
a	O
symptom	O
of	O
Lyme	B-KP
disease	I-KP
and	O
the	O
associated	O
spirochete	B-KP
load	I-KP
and	O
secondarily	O
caused	O
supraspinatus	B-KP
impingement	I-KP
.	O
	
Several	O
symptoms	O
displayed	O
during	O
treatment	O
demonstrated	O
to	O
the	O
physical	O
therapist	O
that	O
an	O
underlying	O
condition	O
such	O
as	O
Lyme	B-KP
disease	I-KP
was	O
involved	O
.	O
	
﻿In	O
conclusion	O
,	O
many	O
overhead	O
athletes	O
lead	O
very	O
active	O
lifestyles	O
and	O
spend	O
time	O
in	O
the	O
outdoors	O
,	O
which	O
may	O
increase	O
their	O
chances	O
of	O
contracting	O
Lyme	B-KP
disease	I-KP
.	O
	
Lyme	B-KP
disease	I-KP
is	O
best	O
diagnosed	O
clinically	O
,	O
as	O
no	O
currently	O
available	O
test	O
,	O
no	O
matter	O
the	O
source	O
or	O
type	O
,	O
is	O
definitive	O
in	O
detecting	O
an	O
infection	O
with	O
this	O
pathogen	B-KP
.	O
[3,6,11,19]	O
The	O
entire	O
clinical	O
picture	O
must	O
be	O
taken	O
into	O
account	O
,	O
[	O
3	O
]	O
and	O
as	O
physical	O
therapists	O
,	O
we	O
spend	O
a	O
larger	O
portion	O
of	O
time	O
with	O
our	O
patients	O
than	O
other	O
health	O
care	O
professionals	O
and	O
may	O
be	O
best	O
positioned	O
to	O
recognize	O
the	O
signs	O
or	O
symptoms	O
of	O
atypical	B-KP
musculoskeletal	I-KP
conditions	I-KP
before	O
other	O
health	O
care	O
providers	O
.	O
	
Because	O
there	O
has	O
been	O
an	O
upward	O
trend	O
in	O
diagnosed	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
,	O
[	O
9	O
]	O
it	O
is	O
important	O
for	O
physical	O
therapists	O
to	O
recognize	O
the	O
symptoms	O
of	O
Lyme	B-KP
disease	I-KP
and	O
to	O
reach	O
the	O
appropriate	O
clinical	O
diagnosis	O
with	O
all	O
patients	O
(	O
Fig	O
.	O
	
3	O
)	O
.	O
	
It	O
also	O
is	O
important	O
for	O
physical	O
therapists	O
and	O
physicians	O
to	O
have	O
collaborative	O
relationships	O
through	O
which	O
the	O
patient	O
will	O
receive	O
high-quality	O
care	O
.	O
	
﻿Respondents	O
were	O
classified	O
as	O
having	O
had	O
personal	O
experience	O
with	O
acute	B-KP
Lyme	I-KP
disease	I-KP
or	O
PTLDS	B-KP
if	O
they	O
or	O
a	O
close	O
associate	O
had	O
the	O
disease	O
(	O
Table	O
3	O
)	O
.	O
	
Three	O
groups	O
were	O
formed	O
from	O
this	O
information	O
:	O
those	O
with	O
no	O
personal	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
or	O
PTLDS	B-KP
;	O
those	O
with	O
personal	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
,	O
but	O
not	O
PTLDS	B-KP
;	O
and	O
those	O
with	O
personal	O
experience	O
with	O
PTLDS	B-KP
with	O
or	O
without	O
personal	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
.	O
	
All	O
groups	O
agree	O
that	O
PTLDS	B-KP
can	O
be	O
severe	O
and	O
chronic	O
condition	O
that	O
can	O
last	O
for	O
many	O
years	O
.	O
	
Less	O
than	O
5	O
%	O
in	O
any	O
of	O
the	O
groups	O
think	O
that	O
PTLDS	B-KP
is	O
either	O
easy	O
to	O
treat	O
or	O
resolves	O
on	O
its	O
own	O
.	O
	
The	O
uncertainty	O
ratings	O
for	O
these	O
questions	O
were	O
particularly	O
interesting	O
to	O
see	O
.	O
	
In	O
general	O
,	O
uncertainty	O
was	O
high	O
in	O
the	O
groups	O
with	O
no	O
experience	O
with	O
PTLDS	B-KP
.	O
Uncertainty	O
regarding	O
the	O
severity	O
and	O
chronic	O
nature	O
of	O
PTLDS	B-KP
was	O
higher	O
in	O
those	O
with	O
no	O
experience	O
with	O
either	O
disease	O
(	O
34	O
%	O
)	O
and	O
those	O
with	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
,	O
but	O
not	O
PTLDS	B-KP
(	O
30	O
%	O
)	O
compared	O
with	O
those	O
faculty	O
members	O
with	O
experience	O
with	O
PTLDS	B-KP
(	O
9	O
%	O
)	O
.	O
	
A	O
similar	O
pattern	O
was	O
seen	O
for	O
the	O
question	O
of	O
ease	O
of	O
treatment	O
and	O
resolution	O
of	O
disease	O
(	O
Table	O
3	O
)	O
.	O
	
Respondents	O
were	O
asked	O
to	O
give	O
their	O
opinion	O
regarding	O
the	O
aetiology	O
of	O
PTLDS	B-KP
.	O
The	O
most	O
frequently	O
chosen	O
answer	O
was	O
‘	O
an	O
ongoing	O
host	O
inflammatory	O
response	O
triggered	O
by	O
previous	O
Lyme	B-KP
disease	I-KP
but	O
not	O
due	O
to	O
persistent	O
infection	O
,	O
regardless	O
of	O
group	O
.	O
	
In	O
contrast	O
,	O
a	O
large	O
minority	O
,	O
as	O
high	O
as	O
39	O
%	O
of	O
respondents	O
with	O
a	O
personal	O
experience	O
with	O
PTLDS	O
,	I-KP
selected	O
‘	O
continued	O
infection	O
’	O
as	O
a	O
potential	O
aetiology	O
of	O
PTLDS	O
.	I-KP
	
﻿Limitations	O
of	O
this	O
study	O
are	O
primarily	O
related	O
to	O
the	O
response	O
rate	O
of	O
the	O
survey	O
(	O
15	O
%	O
)	O
.	O
	
Due	O
to	O
the	O
low	O
number	O
of	O
published	O
studies	O
of	O
public	O
health	O
faculties	O
using	O
internet	O
based	O
surveys	O
,	O
it	O
is	O
unclear	O
if	O
this	O
is	O
an	O
acceptable	O
response	O
rate	O
or	O
how	O
it	O
compares	O
to	O
other	O
unpublished	O
studies	O
of	O
this	O
population	O
.	O
	
It	O
is	O
hypothesized	O
that	O
respondents	O
may	O
have	O
been	O
more	O
likely	O
to	O
have	O
an	O
interest	O
or	O
personal	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
,	O
meaning	O
that	O
their	O
answers	O
may	O
not	O
be	O
representative	O
of	O
others	O
in	O
the	O
field	O
.	O
	
Nevertheless	O
,	O
few	O
of	O
the	O
respondents	O
reported	O
working	O
in	O
the	O
field	O
or	O
having	O
PTLDS	B-KP
themselves	O
.	O
	
There	O
are	O
many	O
schools	O
of	O
public	O
health	O
located	O
in	O
the	O
northeastern	O
US	O
,	O
however	O
schools	O
in	O
Lyme	B-KP
endemic	I-KP
states	I-KP
represent	O
only	O
30	O
%	O
of	O
all	O
schools	O
surveyed	O
and	O
40	O
%	O
of	O
all	O
emails	O
sent	O
were	O
to	O
schools	O
in	O
endemic	B-KP
states	I-KP
.	O
	
An	O
equal	O
number	O
of	O
respondents	O
from	O
both	O
endemic	B-KP
states	I-KP
and	O
non-endemic	B-KP
states	I-KP
show	O
that	O
a	O
greater	O
percentage	O
of	O
respondents	O
from	O
endemic	O
state	O
schools	O
responded	O
to	O
the	O
survey	O
.	O
	
However	O
,	O
this	O
would	O
cause	O
us	O
to	O
hypothesize	O
that	O
there	O
would	O
be	O
an	O
overestimation	O
of	O
understanding	O
about	O
the	O
diseases	O
in	O
question	O
,	O
an	O
overestimate	O
of	O
teaching	O
rates	O
,	O
and	O
more	O
personal	O
and	O
professional	O
experience	O
.	O
	
Despite	O
the	O
higher	O
response	O
rates	O
from	O
those	O
in	O
the	O
endemic	B-KP
states	I-KP
,	O
the	O
data	O
still	O
show	O
much	O
uncertainty	O
.	O
	
﻿More	O
than	O
90	O
%	O
of	O
faculty	O
respondents	O
from	O
both	O
Lyme	B-KP
endemic	I-KP
and	O
non-endemic	B-KP
regions	I-KP
agree	O
that	O
Lyme	B-KP
disease	I-KP
is	O
common	O
in	O
certain	O
regions	O
of	O
the	O
US	O
.	O
Most	O
faculty	O
members	O
(	O
88	O
%	O
)	O
agree	O
that	O
the	O
geographical	O
range	O
of	O
Lyme	B-KP
disease	I-KP
will	O
increase	O
in	O
the	O
future	O
.	O
	
The	O
majority	O
do	O
not	O
have	O
professional	O
experience	O
,	O
defined	O
as	O
having	O
been	O
taught	O
about	O
,	O
cared	O
for	O
patients	O
with	O
,	O
or	O
done	O
research	O
on	O
,	O
Lyme	B-KP
disease	I-KP
(	O
66	O
%	O
)	O
or	O
PTLDS	B-KP
(	O
83	O
%	O
)	O
.	O
	
While	O
many	O
are	O
unsure	O
of	O
the	O
research	O
funding	O
environment	O
for	O
Lyme	B-KP
disease	I-KP
and	O
PTLDS	B-KP
(	O
82	O
%	O
)	O
,	O
17	O
%	O
believe	O
that	O
these	O
diseases	O
are	O
underfunded	O
.	O
	
Likewise	O
,	O
85	O
%	O
of	O
surveyed	O
faculty	O
members	O
believe	O
that	O
more	O
public	O
health	O
education	O
is	O
needed	O
surrounding	O
Lyme	B-KP
disease	I-KP
and	O
PTLDS	B-KP
.	O
Pvalues	O
indicating	O
statistically	O
significant	O
differences	O
between	O
the	O
Lyme	B-KP
endemic	I-KP
and	O
non-Lyme	B-KP
endemic	I-KP
groups	I-KP
for	O
these	O
analyses	O
are	O
shown	O
at	O
the	O
bottom	O
of	O
Table	O
2	O
.	O
	
﻿North	O
American	O
Lyme	B-KP
disease	I-KP
or	O
borreliosis	B-KP
results	I-KP
from	O
infection	O
by	O
the	O
tick-borne	O
spirochete	B-KP
Borrelia	I-KP
burgdorferi	I-KP
.	O
	
The	O
organism	O
is	O
uncommon	O
in	O
temperate	O
climates	O
.	O
	
The	O
geographic	O
distribution	O
reported	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
in	O
Morbidity	O
and	O
Mortality	O
Weekly	O
Report	O
reveals	O
only	O
12	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
reported	O
in	O
Florida	O
as	O
compared	O
with	O
6,418	O
in	O
New	O
York	O
and	O
1,478	O
in	O
Connecticut	O
by	O
1990	O
[	O
1	O
]	O
.	O
	
In	O
the	O
endemic	B-KP
regions	I-KP
,	O
Lyme	B-KP
disease	I-KP
is	O
often	O
included	O
in	O
a	O
differential	O
diagnosis	O
because	O
of	O
the	O
protean	B-KP
clinical	I-KP
manifestations	I-KP
involving	I-KP
skin	I-KP
,	O
heart	B-KP
,	O
musculoskeletal	B-KP
,	O
and	O
nervous	B-KP
systems	I-KP
.	O
	
The	O
clinical	O
features	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
(	O
LN	B-KP
)	O
have	O
been	O
described	O
in	O
previous	O
publications	O
[	O
2-7	O
]	O
.	O
	
Encephalopathy	B-KP
may	O
be	O
manifested	O
by	O
behavioral	B-KP
changes	I-KP
;	O
signs	O
and	O
symptoms	O
of	O
increased	O
intracranial	B-KP
pressure	I-KP
,	O
including	O
a	O
sixth	B-KP
nerve	I-KP
palsy	I-KP
;	O
and	O
unilateral	B-KP
or	I-KP
bilateral	I-KP
facial	I-KP
paralysis	I-KP
,	O
There	O
has	O
not	O
been	O
a	O
description	O
of	O
intranuclear	B-KP
ophthalmoplegia	I-KP
.	O
	
The	O
case	O
we	O
report	O
is	O
unique	O
because	O
of	O
the	O
abrupt	O
signs	O
of	O
brainstem	B-KP
dysfunction	I-KP
suggesting	O
a	O
single	O
lesion	B-KP
that	O
might	O
have	O
resulted	O
from	O
neoplasia	B-KP
.	O
	
﻿Neurologic	B-KP
manifestations	I-KP
of	I-KP
borreliosis	I-KP
are	O
less	O
common	O
in	O
children	O
than	O
in	O
adults	O
.	O
	
In	O
reports	O
of	O
139	O
LN	B-KP
patients	O
,	O
only	O
five	O
were	O
less	O
than	O
18	O
years	O
of	O
age	O
[2,3,6,11]	O
.	O
	
All	O
five	O
had	O
Lyme	B-KP
meningitis	I-KP
.	O
	
Three	O
of	O
the	O
five	O
also	O
had	O
a	O
unilateral	B-KP
facial	I-KP
palsy	I-KP
.	O
	
Excellent	O
recovery	O
followed	O
antibiotic	B-KP
therapy	I-KP
in	O
each	O
case	O
.	O
	
In	O
46	O
children	O
with	O
Lyme	B-KP
arthritis	I-KP
,	O
a	O
10	O
year	O
follow-up	O
revealed	O
neurologic	O
symptoms	O
in	O
only	O
four	O
[	O
12	O
]	O
.	O
	
The	O
symptoms	O
included	O
headache	B-KP
and	O
memory	O
impairment	O
in	O
two	O
,	O
seizures	O
in	O
one	O
,	O
and	O
optic	B-KP
neuropathy	I-KP
with	O
myelopathy	B-KP
in	O
one	O
.	O
	
The	O
neurologic	O
complaints	O
in	O
these	O
patients	O
began	O
4	O
to	O
12	O
years	O
after	O
the	O
onset	O
of	O
arthritis	O
.	O
	
﻿Treatment	O
for	O
patients	O
with	O
erythema	B-KP
migrans	I-KP
typically	O
involves	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin	B-KP
,	O
[	O
5-7	O
]	O
and	O
most	O
patients	O
treated	O
with	O
either	O
of	O
these	O
agents	O
for	O
local	O
infection	O
have	O
an	O
excellent	O
response	O
.	O
	
However	O
,	O
not	O
all	O
patients	O
given	O
oral	B-KP
antibiotics	I-KP
for	O
early	O
disease	O
have	O
a	O
favorable	O
outcome	O
,	O
[8,9]	O
perhaps	O
because	O
the	O
drugs	O
have	O
insufficient	O
activity	O
against	O
borrelia	B-KP
in	O
the	O
central	B-KP
nervous	I-KP
system	I-KP
.	O
[	O
10	O
]	O
Ceftriaxone	B-KP
is	O
highly	O
active	O
against	O
B	B-KP
.	I-KP
burgdorferi	I-KP
and	O
reaches	O
high	O
levels	O
in	O
the	O
cerebrospinal	B-KP
fluid	I-KP
and	O
synovial	B-KP
fluid	I-KP
.	O
[10,11]	O
Treatment	O
with	O
ceftriaxone	B-KP
is	O
effective	O
in	O
acute	O
disseminated	O
Lyme	B-KP
disease	I-KP
,	O
including	O
that	O
manifested	O
by	O
neuroborreliosis	B-KP
,	O
carditis	B-KP
,	O
and	O
meningitis	B-KP
.	O
[	O
11-13	O
]	O
We	O
conducted	O
a	O
study	O
to	O
compare	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
parenteral	B-KP
ceftriaxone	I-KP
and	O
standard	B-KP
oral	I-KP
therapy	I-KP
in	O
patients	O
with	O
acute	O
disseminated	O
B	B-KP
.	I-KP
burgdorferi	I-KP
infection	I-KP
but	O
without	O
meningitis	B-KP
.	O
	
﻿Patients	O
who	O
had	O
been	O
in	O
areas	O
where	O
Lyme	B-KP
disease	I-KP
is	O
endemic	O
,	O
who	O
were	O
eight	O
years	O
of	O
age	O
or	O
older	O
,	O
and	O
who	O
had	O
acute	O
disseminated	O
Lyme	B-KP
borreliosis	I-KP
were	O
eligible	O
for	O
enrollment	O
in	O
this	O
openlabel	O
,	O
controlled	O
,	O
randomized	O
,	O
multicenter	O
study	O
.	O
	
The	O
study	O
was	O
conducted	O
between	O
May	O
1990	O
and	O
June	O
1994	O
.	O
	
Erythema	B-KP
migrans	I-KP
,	O
defined	O
as	O
an	O
expanding	O
,	O
annular	O
,	O
erythematous	B-KP
skin	I-KP
lesion	I-KP
at	O
least	O
5	O
cm	O
in	O
diameter	O
,	O
was	O
required	O
for	O
study	O
entry	O
.	O
	
Disseminated	B-KP
disease	I-KP
was	O
considered	O
present	O
if	O
the	O
patient	O
had	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
more	O
than	O
one	O
erythema	B-KP
migrans	I-KP
lesion	I-KP
;	O
carditis	B-KP
manifested	I-KP
by	I-KP
heart	I-KP
block	I-KP
;	O
neurologic	O
abnormalities	O
(	O
seventh-cranial-nerve	B-KP
palsy	I-KP
or	O
radiculitis	O
of	O
less	O
than	O
three	O
months	O
’	O
duration	O
)	O
;	O
and	O
acute	B-KP
large-joint	I-KP
arthritis	I-KP
.	O
	
We	O
excluded	O
pregnant	O
or	O
nursing	O
women	O
and	O
patients	O
with	O
evidence	O
of	O
syphilis	B-KP
,	O
meningitis	B-KP
,	O
or	O
collagen	B-KP
vascular	I-KP
disease	I-KP
;	O
current	O
symptoms	O
of	O
Lyme	B-KP
disease	I-KP
for	O
which	O
they	O
had	O
previously	O
received	O
treatment	O
;	O
a	O
serious	O
underlying	O
disease	O
that	O
precluded	O
the	O
evaluation	O
of	O
the	O
response	O
to	O
treatment	O
;	O
gallbladder	B-KP
disease	I-KP
;	O
or	O
hypersensitivity	O
to	O
ceftriaxone	B-KP
or	O
doxycycline	B-KP
.	O
	
Patients	O
treated	O
with	O
antimicrobial	O
agents	O
effective	O
in	O
Lyme	B-KP
disease	I-KP
within	O
48	O
hours	O
before	O
study	O
entry	O
or	O
treated	O
with	O
an	O
investigational	O
compound	O
within	O
two	O
weeks	O
before	O
study	O
entry	O
were	O
also	O
excluded	O
,	O
as	O
were	O
patients	O
with	O
meningitis	B-KP
or	O
encephalitis	B-KP
.	O
	
﻿One	O
patient	O
in	O
each	O
treatment	O
group	O
had	O
objective	O
evidence	O
of	O
Lyme	B-KP
disease	I-KP
at	O
the	O
last	O
evaluation	O
(i.e.,	O
treatment	O
failed	O
)	O
.	O
	
A	O
patient	O
in	O
the	O
ceftriaxone	B-KP
group	I-KP
who	O
presented	O
with	O
seventh-cranial-nerve	B-KP
palsy	I-KP
and	O
normal	O
results	O
on	O
lumbar	B-KP
puncture	I-KP
continued	O
to	O
have	O
palsy	B-KP
at	O
the	O
three-month	O
follow-up	O
and	O
was	O
given	O
ceftriaxone	B-KP
for	O
an	O
additional	O
five	O
weeks	O
.	O
	
Despite	O
treatment	O
,	O
the	O
palsy	B-KP
persisted	O
.	O
	
In	O
a	O
second	O
patient	O
,	O
large-joint	B-KP
arthritis	I-KP
developed	O
during	O
treatment	O
with	O
doxycycline	B-KP
;	O
this	O
patient	O
also	O
had	O
fatigue	O
,	O
joint	B-KP
swelling	I-KP
,	O
limitation	O
of	O
joint	O
movement	O
,	O
arthralgia	B-KP
,	O
and	O
myalgia	B-KP
;	O
he	O
subsequently	O
received	O
intravenous	B-KP
ceftriaxone	I-KP
for	O
three	O
weeks	O
and	O
had	O
a	O
complete	O
resolution	O
of	O
all	O
signs	O
and	O
symptoms	O
.	O
	
﻿Signs	O
and	O
symptoms	O
attributable	O
to	O
the	O
nervous	O
or	O
musculoskeletal	B-KP
system	I-KP
have	O
been	O
noted	O
by	O
other	O
investigators	O
.	O
	
Two	O
separate	O
,	O
large	O
,	O
retrospective	O
studies	O
of	O
patients	O
treated	O
for	O
early	B-KP
Lyme	I-KP
disease	I-KP
found	O
a	O
surprisingly	O
high	O
incidence	O
of	O
continued	O
signs	O
and	O
symptoms	O
,	O
especially	O
if	O
treatment	O
was	O
delayed	O
.	O
[8,9]	O
Shadick	O
et	O
al	O
.	O
[	O
8	O
]	O
found	O
that	O
34	O
percent	O
of	O
patients	O
in	O
a	O
suburban	O
area	O
of	O
highly	B-KP
endemic	I-KP
disease	I-KP
just	O
north	O
of	O
Boston	O
who	O
had	O
been	O
treated	O
for	O
early	B-KP
Lyme	I-KP
disease	I-KP
had	O
long-term	O
sequelae	O
,	O
including	O
arthritis	B-KP
,	O
arthralgia	B-KP
,	O
cognitive	B-KP
impairment	I-KP
,	O
and	O
neuropathy	B-KP
.	O
	
A	O
similar	O
investigation	O
carried	O
out	O
in	O
Westchester	O
County	O
,	O
New	O
York	O
,	O
[	O
9	O
]	O
found	O
that	O
114	O
of	O
the	O
215	O
patients	O
studied	O
(	O
53	O
percent	O
)	O
had	O
persistent	O
signs	O
and	O
symptoms	O
,	O
including	O
neurologic	B-KP
,	O
cardiac	B-KP
,	O
and	O
musculoskeletal	B-KP
disorders	I-KP
.	O
	
Of	O
the	O
114	O
patients	O
with	O
ongoing	O
problems	O
,	O
35	O
(	O
31	O
percent	O
)	O
had	O
clinically	O
important	O
fatigue	B-KP
and	O
arthralgia	B-KP
as	O
their	O
chief	O
symptoms	O
.	O
	
These	O
retrospective	O
studies	O
suggest	O
that	O
perhaps	O
more	O
attention	O
should	O
be	O
paid	O
to	O
minor	O
post-treatment	O
symptoms	O
.	O
	
Although	O
arthralgia	O
and	O
fatigue	B-KP
have	O
been	O
reported	O
after	O
the	O
administration	O
of	O
both	O
oral	O
and	O
parenteral	O
antibiotics	B-KP
for	O
early	O
Lyme	B-KP
disease	I-KP
,	O
[6,16-18]	O
the	O
incidence	O
is	O
generally	O
low	O
.	O
	
Mild	B-KP
arthralgia	I-KP
,	O
fatigue	B-KP
,	O
and	O
headache	B-KP
were	O
noted	O
after	O
therapy	O
with	O
intravenous	B-KP
ceftriaxone	I-KP
and	O
oral	O
penicillin	B-KP
,	O
[	O
17	O
]	O
and	O
arthralgia	B-KP
was	O
noted	O
after	O
oral	O
treatment	O
with	O
amoxicillin	B-KP
plus	O
probenecid	B-KP
or	O
with	O
doxycycline	B-KP
.	O
[	O
6	O
]	O
One	O
year	O
after	O
treatment	O
with	O
cefuroxime	B-KP
axetil	I-KP
or	O
doxycycline	B-KP
,	O
approximately	O
10	O
percent	O
of	O
patients	O
reported	O
the	O
persistence	O
of	O
mild-to-severe	O
fatigue	B-KP
,	O
arthralgia	B-KP
,	O
and	O
myalgia	B-KP
.	O
[	O
16	O
]	O
﻿LNB	B-KP
is	O
,	O
inmany	O
cases	O
,	O
responsive	O
to	O
appropriate	O
antimicrobial	O
therapy	O
and	O
the	O
clinical	O
improvement	O
sustained	O
by	O
the	O
antibiotic	O
treatment	O
provide	O
further	O
evidence	O
for	O
the	O
direct	O
contribution	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
in	O
disease	B-KP
pathogenesis	I-KP
.	O
	
However	O
,	O
the	O
chronic	B-KP
persistence	I-KP
,	O
the	O
frequent	O
reoccurrence	O
of	O
LNB	B-KP
and	O
the	O
ability	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
to	O
tolerate	O
multiple	B-KP
cycles	I-KP
of	I-KP
antibiotic	I-KP
treatment	I-KP
is	O
strongly	O
suggestive	O
for	O
the	O
formation	O
of	O
biofilm	B-KP
or	O
biofilmlike	B-KP
protective	I-KP
structure	I-KP
(20–23).	O
	
Indeed	O
,	O
different	O
studies	O
have	O
shown	O
that	O
B	B-KP
.	I-KP
burgdorferi	I-KP
can	O
switch	O
fromamotile	B-KP
to	O
a	O
stationary	O
status	O
,	O
in	O
which	O
the	O
cells	O
are	O
embedded	O
within	O
a	O
biofilm	B-KP
matrix	I-KP
(	O
22	O
)	O
.	O
	
B	B-KP
.	I-KP
burgdorferi	I-KP
biofilms	I-KP
have	O
been	O
observed	O
both	O
in	O
vitro	O
and	O
in	O
human	B-KP
infected	I-KP
skin	I-KP
tissues	I-KP
(	O
22	O
,	O
23	O
)	O
.	O
	
These	O
structures	O
express	O
different	O
mucopolysaccharides	B-KP
,	O
particularly	O
alginate	B-KP
,	O
extracellular	B-KP
DNA	I-KP
and	O
calcium	O
,	O
which	O
are	O
all	O
typical	O
markers	O
of	O
biofilm	B-KP
(	O
22	O
)	O
.	O
	
The	O
presence	O
of	O
biofilm	B-KP
may	O
explain	O
the	O
low	O
rate	O
of	O
Borrelia	B-KP
detection	I-KP
in	O
the	O
blood	B-KP
of	O
infected	O
patients	O
as	O
well	O
as	O
the	O
ability	O
of	O
the	O
spirochetes	B-KP
to	O
evade	O
the	O
host	B-KP
immune	I-KP
systemand	O
resist	O
the	O
antibiotic	B-KP
therapy	I-KP
(	O
21	O
,	O
24–27).	O
	
﻿The	O
distribution	O
and	O
relative	O
frequency	O
of	O
infection	O
by	O
the	O
different	O
genospecies	O
of	O
Borrelia	B-KP
sensu	I-KP
latu	I-KP
vary	O
across	O
European	O
regions	O
.	O
	
B	B-KP
.	I-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
comprises	O
20	O
different	O
genospecies	O
and	O
this	O
diversity	O
correlates	O
with	O
the	O
large	O
variability	O
in	O
the	O
clinical	O
manifestations	O
observed	O
in	O
LB	B-KP
(	O
4	O
,	O
13	O
,	O
63	O
)	O
.	O
	
In	O
the	O
northern	O
and	O
eastern	O
Europe	O
B	B-KP
.	I-KP
afzelii	I-KP
is	O
the	O
most	O
prevalent	O
species	O
,	O
whereas	O
in	O
Western	O
European	O
countries	O
B	B-KP
.	I-KP
garinii	I-KP
is	O
the	O
most	O
common	B-KP
pathogen	I-KP
(	O
4	O
,	O
29	O
)	O
.	O
	
B	B-KP
.	I-KP
afzelii	I-KP
,	O
B	B-KP
.	I-KP
garini	I-KP
,	O
and	O
the	O
recently	O
identified	O
species	O
B	B-KP
.	I-KP
bavariensis	I-KP
are	O
major	O
cause	O
of	O
LB	B-KP
and	O
LNB	B-KP
in	O
Europe	O
(	O
52	O
,	O
64–68).	O
	
The	O
heterogeneity	O
among	O
B	B-KP
.	I-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
genospecies	I-KP
is	O
linked	O
to	O
different	O
geographical	O
areas	O
,	O
which	O
,	O
in	O
turn	O
,	O
correlates	O
with	O
the	O
different	O
clinical	O
expression	O
of	O
human	O
LB	B-KP
(	O
69	O
)	O
.	O
	
For	O
instance	O
,	O
B	B-KP
.	I-KP
afzelii	I-KP
induces	O
prevalently	O
skin	B-KP
infections	I-KP
,	O
whereas	O
B	B-KP
.	I-KP
garinii	I-KP
is	O
in	O
most	O
cases	O
neurotropic	B-KP
(	O
5	O
,	O
69	O
)	O
.	O
	
Other	O
species	O
,	O
such	O
as	O
B	B-KP
.	I-KP
lusitaniae	I-KP
or	O
B	B-KP
.	I-KP
valaisiana	I-KP
,	O
have	O
only	O
occasionally	O
been	O
associated	O
with	O
human	O
disease	O
(70–72).	O
	
In	O
endemic	B-KP
areas	I-KP
of	O
Europe	O
was	O
proposed	O
that	O
the	O
variety	O
of	O
symptoms	O
observed	O
in	O
children	O
and	O
adults	O
with	O
LNB	B-KP
correlated	O
with	O
the	O
B	B-KP
.	I-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
genotype	I-KP
(73–75).	O
	
Individuals	O
with	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B	B-KP
.	I-KP
afzelii	I-KP
and	O
B	B-KP
.	I-KP
garinii	I-KP
showed	O
distinct	O
epidemiological	B-KP
and	I-KP
clinical	I-KP
characteristics	I-KP
.	O
	
Indeed	O
,	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B	B-KP
.	I-KP
garinii	I-KP
were	O
located	O
prevalently	O
on	O
the	O
trunk	O
and	O
less	O
often	O
on	O
extremities	O
,	O
had	O
shorter	O
incubation	O
and	O
faster	O
evolution	O
,	O
leading	O
to	O
frequent	O
systemic	O
symptoms	O
,	O
abnormal	O
liver	O
function	O
test	O
results	O
than	O
individuals	O
with	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B	B-KP
.	I-KP
afzelii	I-KP
(	O
76	O
,	O
77	O
)	O
.	O
	
﻿The	O
expression	O
of	O
different	O
proteins	O
,	O
including	O
OspC	B-KP
,	O
ErpP	B-KP
,	O
ErpA	B-KP
,	O
ErpC	B-KP
,	O
and	O
enolase	B-KP
is	O
required	O
to	O
readily	O
immobilize	O
host	B-KP
plasminogen	I-KP
on	O
spirochetal	B-KP
surface	I-KP
,	O
facilitating	O
efficient	O
dissemination	O
(116–118).	O
	
Plasminogen	B-KP
is	O
a	O
glycoprotein	B-KP
produced	O
by	O
the	O
liver	O
and	O
abundant	O
in	O
the	O
plasma	O
and	O
in	O
certain	O
tissues	O
(	O
119	O
)	O
.	O
	
Conversion	O
of	O
plasminogen	B-KP
to	I-KP
active	I-KP
plasmin	I-KP
is	O
promoted	O
by	O
proteolytic	B-KP
activation	I-KP
induced	O
by	O
either	O
tissue-type	B-KP
plasminogen	I-KP
activator	I-KP
(	O
tPA	B-KP
)	O
and	O
/	O
or	O
urokinase-type	B-KP
plasminogen	I-KP
activator	I-KP
urokinase	I-KP
(	O
uPA	B-KP
)	O
.	O
	
Plasmin	B-KP
is	O
responsible	O
for	O
intravascular	B-KP
fibrinolysis	I-KP
and	O
contributes	O
to	O
numerous	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
tissue	B-KP
remodeling	I-KP
,	O
cell	B-KP
migration	I-KP
,	O
thrombolysis	B-KP
,	O
wound	O
healing	O
,	O
and	O
cancer	O
progression	O
(	O
120	O
,	O
121	O
)	O
.	O
	
Invasive	B-KP
forms	I-KP
of	I-KP
B	I-KP
.	I-KP
burgdorferi	I-KP
are	O
known	O
to	O
expresses	O
multiple	O
plasminogen-binding	B-KP
surface	I-KP
proteins	I-KP
that	O
likely	O
assist	O
pathogen	B-KP
dissemination	I-KP
through	O
host	B-KP
tissues	I-KP
(	O
120	O
,	O
122	O
)	O
.	O
	
Enolase	B-KP
is	O
an	O
integral	B-KP
enzyme	I-KP
of	I-KP
the	I-KP
glycolysis	I-KP
and	I-KP
gluconeogenesis	I-KP
pathways	I-KP
,	O
and	O
a	O
multifunctional	O
protein	O
found	O
in	O
both	O
prokaryote	O
and	O
eukaryotes	O
(	O
123	O
)	O
.	O
	
In	O
eukaryotic	B-KP
cells	I-KP
,	O
surface	B-KP
enolase	I-KP
acts	O
as	O
a	O
plasminogen	B-KP
receptor	I-KP
in	I-KP
certain	I-KP
tumor	I-KP
cells	I-KP
(	O
123	O
,	O
124	O
)	O
.	O
	
Similarly	O
,	O
this	O
enzyme	B-KP
is	O
also	O
localized	O
on	O
the	O
cell	O
surface	O
of	O
different	O
microorganisms	O
including	O
B	B-KP
.	I-KP
burgdorferi	I-KP
(	O
118	O
,	O
125–127).	O
	
The	O
surface-localized	B-KP
enolase	I-KP
acts	I-KP
as	I-KP
a	I-KP
plasminogen	I-KP
receptor	I-KP
contributing	O
to	O
spirochetal	O
survival	O
in	O
feeding	O
ticks	O
(	O
118	O
)	O
.	O
	
Although	O
dispensable	O
for	O
infection	O
,	O
plasminogen	B-KP
is	O
required	O
for	O
dissemination	O
in	O
ticks	O
,	O
and	O
its	O
absence	O
is	O
associated	O
with	O
a	O
decreased	O
spirochetemia	B-KP
in	O
plasminogen-deficient	O
mice	O
(	O
128	O
)	O
.	O
	
Surface-associated	B-KP
plasmin	I-KP
on	I-KP
B	I-KP
.	I-KP
burgdorferi	I-KP
degrade	I-KP
fibronectin	I-KP
,	O
which	O
is	O
an	O
important	O
component	O
of	O
the	O
ECM	B-KP
,	O
laminin	B-KP
and	O
vitronectin	B-KP
(	O
129	O
,	O
130	O
)	O
.	O
	
B	B-KP
.	I-KP
burgdorferi	I-KP
also	O
induces	O
the	O
release	O
of	O
host	B-KP
matrix	I-KP
metalloproteases	I-KP
9	I-KP
(	O
MMP-9	B-KP
)	O
and	O
MMP-1	B-KP
,	O
and	O
plasmin-coated	B-KP
B	I-KP
.	I-KP
burgdorferi	I-KP
activates	I-KP
pro-MMP-9	I-KP
,	O
leading	O
to	O
degradation	O
of	O
basement	O
membranes	O
(	O
131	O
)	O
.	O
	
﻿Biofilm	B-KP
production	I-KP
in	I-KP
Borrelia	I-KP
requires	O
the	O
modulation	O
of	O
a	O
complex	B-KP
array	I-KP
of	I-KP
signaling	I-KP
processes	I-KP
which	O
allows	O
spirochetes	B-KP
to	O
communicate	O
with	O
the	O
surrounding	O
environment	O
.	O
	
The	O
RpoN–RpoS	B-KP
alternative	I-KP
sigma	I-KP
factor	I-KP
and	O
the	O
LuxS	B-KP
quorumsensing	I-KP
pathways	I-KP
,	O
which	O
are	O
involved	O
in	O
several	B-KP
cellular	I-KP
functions	I-KP
in	O
response	O
to	O
environmental	O
stresses	O
(	O
pH	B-KP
and	I-KP
temperature	I-KP
variations	I-KP
,	O
high	B-KP
osmolarity	I-KP
,	O
oxidative	B-KP
stress	I-KP
,	O
high	B-KP
cell	I-KP
density	I-KP
,	O
nutrient	B-KP
starvation	I-KP
,	O
host	B-KP
infection	I-KP
)	O
,	O
participate	O
in	O
biofilm	B-KP
production	I-KP
in	I-KP
B	I-KP
.	I-KP
burgdorferi	I-KP
(	O
22	O
,	O
192	O
)	O
.	O
	
The	O
RpoN–RpoS	B-KP
pathway	I-KP
,	O
also	O
known	O
as	O
the	O
σ^{54}-σ^{S}	O
cascade	O
,	O
regulates	O
adaptive	B-KP
changes	I-KP
in	I-KP
B	I-KP
.	I-KP
burgdorferi	I-KP
during	O
the	O
transition	O
between	O
the	O
tick	B-KP
vector	I-KP
and	O
mammalian	B-KP
host	I-KP
(	O
91	O
,	O
95	O
)	O
.	O
	
The	O
RpoN–RpoS	B-KP
pathway	I-KP
relies	O
on	O
the	O
activity	B-KP
of	I-KP
RpoN	I-KP
(σ^{54}),	O
which	O
controls	O
the	O
transcription	B-KP
of	I-KP
RpoS	I-KP
(σ^{S})	O
through	O
the	O
binding	O
to	O
a	O
canonical	O
−24	O
/	O
−12	O
RpoN-type	B-KP
promoter	I-KP
sequence	I-KP
(	O
95	O
,	O
193	O
)	O
.	O
	
The	O
activation	O
of	O
the	O
σ^{54}-σ^{S}	B-KP
cascade	I-KP
,	O
in	O
turn	O
,	O
is	O
modulated	O
by	O
a	O
bacterial	B-KP
enhancer-binding	I-KP
protein	I-KP
(bEBP)	O
/	O
σ^{54}-dependent	B-KP
activator	O
(	O
Rrp2	B-KP
)	O
in	O
concert	O
with	O
BosR	B-KP
(	O
91	O
,	O
95	O
,	O
193–198).	O
	
After	O
the	O
activation	O
,	O
RpoS	B-KP
acts	O
as	O
a	O
global	B-KP
gene	I-KP
regulator	I-KP
controlling	O
the	O
expression	O
of	O
over	O
100	O
different	O
genes	O
involved	O
in	O
stress	B-KP
responses	I-KP
,	O
host	B-KP
infection	I-KP
and	I-KP
survival	I-KP
,	O
including	O
biofilm	B-KP
formation	I-KP
(	O
87	O
,	O
95	O
,	O
182	O
)	O
.	O
	
﻿In	O
addition	O
to	O
biofilm	B-KP
formation	I-KP
,	O
the	O
ability	O
of	O
Borrelia	B-KP
to	I-KP
localize	I-KP
intracellularly	I-KP
in	I-KP
the	I-KP
host	I-KP
has	O
been	O
proposed	O
as	O
a	O
echanismwhichmight	O
favor	O
chronic	B-KP
or	I-KP
persistent	I-KP
infection	I-KP
and	O
may	O
contribute	O
in	O
reducing	O
the	O
efficacy	B-KP
of	I-KP
antibiotics	I-KP
.	O
	
However	O
,	O
Borrelia	O
predominantly	O
occupies	O
the	O
extracellularmatrix	B-KP
,	O
and	O
the	O
antibiotics	B-KP
recommended	O
for	O
the	O
treatment	O
of	O
LB	B-KP
are	O
first-line	O
drugs	O
in	O
several	O
intracellular	B-KP
infections	I-KP
(	O
216	O
,	O
217	O
)	O
.	O
	
Doxycycline	B-KP
and	O
azithromycin	B-KP
are	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
Mycoplasma	B-KP
,	O
Chlamydia	B-KP
,	O
and	O
Legionella	B-KP
,	O
while	O
ceftriaxone	B-KP
is	O
effective	O
against	O
Salmonella	B-KP
and	O
Neisseria	B-KP
,	O
and	O
amoxicillin	B-KP
is	O
used	O
to	O
treat	O
Listeria	B-KP
infections	I-KP
(	O
217	O
,	O
218	O
)	O
.	O
	
Nevertheless	O
,	O
biofilm	O
production	O
by	O
extracellular	O
bacteria	O
and	O
intracellular	B-KP
localization	I-KP
of	I-KP
Borrelia	I-KP
are	O
not	O
mutually	O
exclusive	O
and	O
may	O
both	O
participate	O
in	O
supporting	O
chronic	B-KP
bacterial	I-KP
persistence	I-KP
in	I-KP
the	I-KP
host	I-KP
.	O
	
﻿LNB	B-KP
is	O
the	O
most	O
dangerous	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
Although	O
the	O
early	O
antimicrobial	B-KP
treatment	I-KP
is	O
effective	O
in	O
the	O
majority	O
of	O
patients	O
,	O
persistent	O
forms	O
are	O
relatively	O
common	O
.	O
	
The	O
mechanisms	O
underlying	O
chronic	B-KP
LNB	I-KP
and	O
other	O
persistent	B-KP
forms	I-KP
of	I-KP
Lyme	I-KP
are	O
unknown	O
.	O
	
Patients	O
who	O
have	O
late	O
manifestations	O
of	O
LB	B-KP
generally	O
show	O
a	O
slower	O
response	O
to	O
therapy	O
with	O
incomplete	O
resolution	O
.	O
	
Persistent	B-KP
Borrelia	I-KP
infection	I-KP
requires	O
prolonged	O
antimicrobial	B-KP
treatment	I-KP
,	O
with	O
limited	O
and	O
controversial	O
clinical	O
efficacy	O
.	O
	
Recent	O
evidences	O
suggest	O
that	O
the	O
antibiotic	B-KP
resistance	I-KP
and	O
the	O
reoccurrence	O
of	O
LB	B-KP
are	O
associated	O
with	O
biofilm-like	B-KP
aggregates	I-KP
,	O
which	O
allow	O
Borrelia	B-KP
spp	I-KP
.	I-KP
to	O
resist	O
to	O
adverse	O
environmental	O
conditions	O
.	O
	
Several	O
promising	O
FDA-approved	O
drugs	O
have	O
been	O
shown	O
to	O
have	O
excellent	O
antipersister	O
activity	O
when	O
used	O
in	O
combination	O
while	O
their	O
use	O
in	O
monotherapy	B-KP
regimens	I-KP
showed	O
a	O
poor	O
effectiveness	O
.	O
	
This	O
notion	O
should	O
be	O
taken	O
into	O
careful	O
consideration	O
for	O
the	O
clinical	O
management	O
of	O
Lyme	B-KP
Disease	I-KP
in	O
order	O
to	O
prevent	O
long-term	O
complications	O
.	O
	
﻿PCR	O
products	O
were	O
analyzed	O
by	O
ethidium	B-KP
bromide	I-KP
staining	I-KP
of	O
agarose	O
gels	O
and	O
confirmed	O
by	O
Southern	B-KP
blot	I-KP
hybridization	I-KP
,	O
performed	O
as	O
described	O
previously	O
with	O
nested	O
probes	O
.	O
[	O
11	O
]	O
Briefly	O
,	O
30	O
to	O
50	O
pl	O
from	O
each	O
PCR-amplified	B-KP
fraction	I-KP
was	O
applied	O
to	O
1.5%	O
agarose	O
gel	O
and	O
electrophoresis	B-KP
performed	O
at	O
100	O
V	O
for	O
3	O
to	O
4	O
hours	O
.	O
	
Gels	O
were	O
then	O
rinsed	O
in	O
deionized	O
water	O
,	O
denatured	O
in	O
1.0	O
mmol	O
/	O
L	O
NaCl	O
,	O
0.5	O
mol	O
/	O
L	O
NaOH	O
twice	O
for	O
15	O
minutes	O
,	O
and	O
then	O
neutralized	O
by	O
soaking	O
in	O
0.5	O
mol	O
/	O
L	O
TRIS	O
(	O
pH	O
7.4)	O
/	O
1.5	O
mol	O
/	O
L	O
NaCl	O
twice	O
for	O
15	O
minutes	O
.	O
	
Gels	O
were	O
then	O
transferred	O
into	O
a	O
nylon	B-KP
membrane	I-KP
by	I-KP
capillary	I-KP
blotting	I-KP
and	O
baked	O
for	O
2	O
hours	O
at	O
80	O
”	O
C	O
in	O
a	O
vacuum	O
oven	O
.	O
	
Filters	O
were	O
then	O
prehybridized	O
at	O
42	O
”	O
C	O
for	O
3	O
to	O
6	O
hours	O
in	O
a	O
solution	O
of	O
5x	B-KP
saline-sodium	I-KP
citrate	I-KP
(	O
SSC	B-KP
)	O
(	O
1	O
x	O
SSC	O
=	O
0.15	O
mol	O
/	O
L	O
NaCl	O
and	O
0.015	O
mol	O
/	O
L	O
sodium	O
citrate	O
pH	O
7.4),	O
50	O
mmolIL	O
sodium	O
phosphate	O
pH	O
7.0,	O
0.1%	O
sodium	O
pyrophosphate	O
,	O
10X	O
Denhardt’s	O
solution	O
(0.2%	O
bovine	O
serum	O
albumin	O
,	O
Ficoll	O
,	O
and	O
polyvinyl	O
pyrrolidone	O
)	O
,	O
and	O
100	O
ug	O
/	O
rnl	O
denatured	O
herring	O
sperm	O
DNA	O
,	O
and	O
then	O
hybridized	O
at	O
37	O
”	O
C	O
in	O
a	O
fresh	O
solution	O
containing	O
a	O
phosphorus	O
32	O
end-labeled	O
oligonucleotide	O
probe	O
for	O
20	O
to	O
25	O
hours9	O
,	O
l2	O
Blots	O
were	O
washed	O
in	O
2X	B-KP
SSC	I-KP
,	O
0.5%	O
SDS	O
twice	O
for	O
15	O
minutes	O
at	O
room	O
temperature	O
,	O
then	O
in	O
0.1%	O
SSC	O
,	O
0.5%	O
SDS	O
four	O
times	O
for	O
15	O
minutes	O
at	O
40	O
”	O
C	O
,	O
and	O
finally	O
in	O
0.1%	O
SSC	O
twice	O
for	O
15	O
minutes	O
at	O
40	O
”	O
C	O
.	O
Filters	O
were	O
then	O
exposed	O
to	O
Kodax	O
X-AR	O
fiti	O
(	O
Eastman	O
Kodak	O
,	O
Rochester	O
,	O
N.Y.)	O
with	O
a	O
Comex	O
Lighting	O
Plus	O
intensifying	O
screen	O
@	O
u	O
Pont	O
,	O
Boston	O
,	O
Mass	O
.	O
)	O
at	O
-70”	O
C	O
for	O
1	O
to	O
3	O
days	O
.	O
	
﻿Cranial	B-KP
neuropathy	I-KP
is	O
the	O
most	O
frequent	O
objective	O
neurological	O
sign	O
in	O
Lyme	B-KP
neuroborreliosis	I-KP
and	O
has	O
been	O
found	O
in	O
47%-82%	O
of	O
patients	O
with	O
early	B-KP
neurological	I-KP
involvement	I-KP
[	O
1	O
]	O
.	O
	
Although	O
Borrelia	B-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
may	O
affect	O
most	O
cranial	B-KP
nerves	I-KP
,	O
facial	B-KP
nerve	I-KP
paresis	I-KP
is	O
the	O
most	O
common	O
manifestation	O
of	O
infection	O
.	O
	
Unilateral	B-KP
or	I-KP
bilateral	I-KP
facial	I-KP
palsy	I-KP
has	O
been	O
described	O
in	O
72%-92%	O
of	O
patients	O
with	O
cranial	B-KP
nerve	I-KP
affection	I-KP
[1,2]	O
.	O
	
In	O
previous	O
Scandinavian	O
studies	O
of	O
patients	O
with	O
Lyme	B-KP
neuroborreliosis	I-KP
,	O
facial	B-KP
palsy	I-KP
was	O
seen	O
in	O
35%-51%	O
of	O
the	O
cases	O
[3,4]	O
.	O
	
Lyme	B-KP
disease-associated	I-KP
facial	I-KP
weakness	I-KP
is	O
often	O
rapid	O
in	O
onset	O
and	O
is	O
frequently	O
accompanied	O
by	O
painful	O
meningoradiculoneuritis	B-KP
,	O
earlier	O
described	O
as	O
Garin-Bujadoux-Bannwarth's	B-KP
syndrome	I-KP
[	O
1	O
]	O
.	O
	
Facial	B-KP
palsy	I-KP
in	O
Lyme	B-KP
disease	I-KP
has	O
often	O
been	O
viewed	O
as	O
a	O
peripheral	B-KP
neuropathy	I-KP
,	O
although	O
most	O
patients	O
have	O
CSF	B-KP
abnormalities	I-KP
with	O
lymphocytic	B-KP
pleocytosis	I-KP
and	O
an	O
increased	O
number	O
of	O
plasma	B-KP
cells	I-KP
,	O
increased	O
CSF	B-KP
protein	I-KP
concentrations	I-KP
indicating	O
blood-CSF	B-KP
barrier	I-KP
damage	I-KP
,	O
intrathecal	B-KP
Ig	I-KP
production	I-KP
,	O
and	O
increased	O
levels	O
of	O
a	O
CSF	B-KP
glial	I-KP
protein	I-KP
marker	I-KP
(	O
glial	B-KP
fibrillary	I-KP
acidic	I-KP
protein	I-KP
)	O
[	O
5	O
]	O
.	O
	
These	O
findings	O
imply	O
that	O
the	O
brain	O
parenchyma	I-KP
is	O
likely	O
to	O
be	O
involved	O
even	O
in	O
early	O
Lyme	I-KP
neuroborreliosis	I-KP
.	I-KP
	
﻿The	O
tick	O
life	O
cycle	O
for	O
the	O
majority	O
of	O
tick	O
species	O
found	O
in	O
the	O
UK	O
takes	O
on	O
average	O
three	O
years	O
and	O
is	O
made	O
up	O
of	O
three	O
active	O
life	B-KP
stages	I-KP
-	O
the	O
larvae	O
,	O
nymphs	O
and	O
adults	O
.	O
	
Unlike	O
biting	O
insects	O
,	O
each	O
tick	O
feeds	O
only	O
once	O
per	O
life	O
stage	O
,	O
but	O
each	O
feed	O
takes	O
a	O
number	O
of	O
days	O
.	O
	
The	O
six-legged	O
larvae	O
feed	O
on	O
average	O
two	O
to	O
six	O
days	O
on	O
small	O
mammals	O
or	O
birds	O
.	O
	
Once	O
fully	O
engorged	O
,	O
they	O
drop	O
off	O
the	O
host	B-KP
and	O
rest	O
in	O
the	O
vegetation	O
layer	O
on	O
the	O
ground	O
,	O
before	O
moulting	O
to	O
the	O
nymph	O
stage	O
.	O
	
The	O
nymphs	O
are	O
slightly	O
larger	O
,	O
have	O
eight	O
legs	O
and	O
feed	O
for	O
three	O
to	O
eight	O
days	O
on	O
slightly	O
larger	O
mammalian	B-KP
or	I-KP
avian	I-KP
hosts	I-KP
.	O
	
Again	O
,	O
once	O
fully	O
engorged	O
,	O
they	O
drop	O
off	O
the	O
host	B-KP
and	O
undergo	O
the	O
moult	O
to	O
the	O
adult	O
stage	O
.	O
	
The	O
emergent	O
male	O
adults	O
of	O
some	O
species	O
only	O
feed	O
intermittently	O
and	O
do	O
not	O
engorge	O
.	O
	
The	O
female	O
adults	O
of	O
I	B-KP
.	I-KP
ricinus	I-KP
feed	O
for	O
five	O
to	O
12	O
days	O
on	O
larger	O
mammals	O
such	O
as	O
deer	O
and	O
livestock	O
.	O
	
Following	O
engorgement	O
and	O
mating	O
,	O
the	O
females	O
drop	O
off	O
the	O
host	O
to	O
lay	O
several	O
thousand	O
eggs	O
before	O
dying	O
.	O
	
In	O
a	O
three-year	O
life	O
cycle	O
,	O
a	O
tick	O
will	O
only	O
spend	O
about	O
three	O
weeks	O
on	O
animals	O
.	O
	
The	O
processes	O
of	O
blood	O
meal	O
digestion	O
,	O
moulting	O
and	O
egg	O
laying	O
occur	O
over	O
a	O
period	O
of	O
months	O
,	O
during	O
which	O
time	O
,	O
the	O
ticks	O
rest	O
in	O
the	O
vegetation	O
layer	O
.	O
	
They	O
are	O
sensitive	O
to	O
climatic	O
conditions	O
,	O
particularly	O
temperature	O
and	O
humidity	O
,	O
but	O
dense	O
ground	O
cover	O
vegetation	O
or	O
leaf	O
litter	O
,	O
where	O
the	O
humidity	O
is	O
higher	O
,	O
will	O
prevent	O
the	O
ticks	O
from	O
drying	O
out	O
.	O
	
﻿Among	O
the	O
approximately	O
50	O
000	O
locally	O
acquired	O
vector-borne	B-KP
disease	I-KP
cases	O
reported	O
annually	O
from	O
the	O
contiguous	O
United	O
States	O
,	O
roughly	O
95	O
%	O
are	O
caused	O
by	O
tick-borne	B-KP
pathogens	I-KP
and	O
>70%	O
are	O
Lyme	B-KP
disease	I-KP
[	O
1	O
]	O
.	O
	
Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
the	O
spirochetes	B-KP
Borrelia	I-KP
burgdorferi	I-KP
sensu	I-KP
stricto	I-KP
(	O
herein	O
referred	O
to	O
as	O
B	B-KP
.	I-KP
burgdorferi	I-KP
)	O
[	O
2	O
]	O
,	O
or	O
much	O
less	O
commonly	O
by	O
Borrelia	B-KP
mayonii	I-KP
[	O
3	O
]	O
;	O
both	O
are	O
transmitted	O
by	O
the	O
blacklegged	O
tick	O
,	O
Ixodes	B-KP
scapularis	I-KP
(	O
including	O
the	O
junior	O
synonym	O
,	O
Ixodes	B-KP
dammini	I-KP
)	O
in	O
the	O
eastern	O
United	O
States	O
where	O
the	O
vast	O
majority	O
of	O
cases	O
occur	O
[4,5]	O
.	O
	
Over	O
the	O
past	O
two	O
decades	O
,	O
we	O
have	O
seen	O
expansions	O
in	O
both	O
the	O
geographic	O
range	O
of	O
I	B-KP
.	I-KP
scapularis	I-KP
[	O
6	O
]	O
(	O
Figure	O
1A,B)	O
and	O
the	O
incidence	O
and	O
geographic	O
range	O
of	O
Lyme	B-KP
disease	I-KP
and	O
other	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
diseases	I-KP
[7,8]	O
(	O
Figure	O
1C,D).	O
	
In	O
addition	O
,	O
new	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
human	I-KP
pathogens	I-KP
continue	O
to	O
be	O
discovered	O
.	O
	
As	O
of	O
2017	O
,	O
seven	O
microorganisms	O
transmitted	O
by	O
I	B-KP
.	I-KP
scapularis	I-KP
-	O
including	O
five	O
bacteria	O
(	O
Anaplasma	B-KP
phagocytophilum	I-KP
,	O
Bo	B-KP
.	I-KP
burgdorferi	I-KP
,	O
Bo	B-KP
.	I-KP
mayonii	I-KP
,	O
Bo	B-KP
.	I-KP
miyamotoi	I-KP
,	O
and	O
E	B-KP
.	I-KP
muris	I-KP
eauclarensis	I-KP
)	O
,	O
one	O
protozoan	O
parasite	O
(	O
Babesia	B-KP
microti	O
)	O
,	O
and	O
one	O
virus	O
(	O
Powassan	B-KP
virus	I-KP
)	O
-	O
are	O
known	O
to	O
cause	O
illness	O
in	O
humans	O
[7,9]	O
.	O
	
The	O
recognition	O
of	O
this	O
diverse	O
guild	O
of	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
pathogens	I-KP
over	O
the	O
last	O
five	O
decades	O
marks	O
a	O
significant	O
shift	O
in	O
the	O
perceived	O
medical	O
importance	O
of	O
the	O
tick	O
;	O
prior	O
to	O
1970	O
,	O
I	B-KP
.	I-KP
scapularis	I-KP
was	O
not	O
considered	O
an	O
important	B-KP
vector	I-KP
of	I-KP
human	I-KP
pathogens	I-KP
(	O
Figure	O
2	O
)	O
.	O
	
﻿Tick	O
surveillance	O
is	O
not	O
standardized	O
or	O
routine	O
,	O
thus	O
hampering	O
our	O
ability	O
to	O
monitor	O
changes	O
in	O
the	O
distribution	O
and	O
abundance	O
of	O
I	B-KP
.	I-KP
scapularis	I-KP
[6,30]	O
.	O
	
Retrospective	O
review	O
of	O
I	B-KP
.	I-KP
scapularis	I-KP
records	O
reveals	O
remarkable	O
range	O
expansion	O
over	O
the	O
past	O
century	O
,	O
particularly	O
in	O
the	O
northern	O
portion	O
of	O
the	O
eastern	O
United	O
States	O
.	O
	
The	O
earliest	O
record	O
of	O
the	O
tick	O
in	O
the	O
northeast	O
dates	O
back	O
to	O
the	O
1920s	O
near	O
Cape	O
Cod	O
,	O
Massachusetts	O
[	O
31	O
]	O
.	O
	
By	O
1945	O
,	O
I	B-KP
.	I-KP
scapularis	I-KP
was	O
recorded	O
sporadically	O
from	O
states	O
along	O
the	O
northern	O
Atlantic	O
coast	O
,	O
but	O
its	O
core	B-KP
distribution	I-KP
was	O
primarily	O
in	O
the	O
Gulf	O
Coast	O
states	O
and	O
the	O
southeast	O
[	O
10	O
]	O
.	O
	
In	O
the	O
early	O
1960s	O
,	O
focal	O
populations	O
were	O
reported	O
along	O
the	O
New	O
England	O
coast	O
and	O
in	O
Rhode	O
Island	O
,	O
and	O
later	O
in	O
that	O
decade	O
records	O
emerged	O
from	O
Long	O
Island	O
,	O
New	O
York	O
,	O
and	O
northwestern	O
Wisconsin	O
.	O
	
During	O
the	O
1970s	O
,	O
the	O
reported	O
distribution	O
of	O
the	O
tick	O
expanded	O
,	O
and	O
its	O
abundance	O
increased	O
along	O
the	O
Atlantic	O
coast	O
from	O
New	O
England	O
to	O
the	O
mid-Atlantic	O
states	O
;	O
expansion	O
inland	O
continued	O
through	O
the	O
1980s	O
and	O
1990s	O
[30,31]	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
was	O
first	O
recognized	O
in	O
the	O
United	O
States	O
as	O
a	O
new	O
form	O
of	O
inflammatory	B-KP
arthritis	I-KP
in	O
1975	O
[	O
52	O
]	O
.	O
	
In	O
1982	O
,	O
a	O
spirochete	O
,	O
later	O
namedBo	O
.	I-KP
burgdorferi	I-KP
[	O
53	O
]	O
,	O
was	O
identified	O
as	O
the	O
etiological	B-KP
agent	I-KP
and	O
shown	O
to	O
be	O
transmissible	O
by	O
I	B-KP
.	I-KP
scapularis	I-KP
[2,5]	O
.	O
	
Although	O
numerous	O
small	O
mammals	O
and	O
birds	O
have	O
been	O
implicated	O
as	O
reservoirs	B-KP
of	I-KP
Bo	I-KP
.	I-KP
burgdorferi	I-KP
,	O
the	O
white-footed	O
mouse	O
is	O
among	O
the	O
most	O
important	O
reservoirs	O
in	O
the	O
eastern	O
United	O
States	O
[15,36,54,55]	O
.	O
	
Human	B-KP
granulocytic	I-KP
anaplasmosis	I-KP
,	O
originally	O
described	O
as	O
human	B-KP
granulocytic	I-KP
ehrlichiosis	I-KP
(	O
Ehrlichia	B-KP
phagocytophila	I-KP
)	O
,	O
was	O
first	O
identified	O
in	O
six	O
patients	O
from	O
northern	O
Minnesota	O
and	O
Wisconsin	O
presenting	O
with	O
acute	B-KP
febrile	I-KP
illnesses	I-KP
between	O
1990	O
and	O
1993	O
.	O
	
The	O
timing	O
of	O
onset	O
of	O
cases	O
was	O
consistent	O
with	O
host-seeking	O
activity	O
of	O
I	B-KP
.	I-KP
scapularis	I-KP
and	O
Dermacentor	B-KP
variabilis	I-KP
and	O
the	O
former	O
was	O
implicated	O
as	O
a	O
vector	O
based	O
on	O
evidence	O
that	O
the	O
closely	O
related	O
Ixodes	B-KP
ricinus	I-KP
transmits	O
E	B-KP
.	I-KP
phagocytophila	I-KP
in	O
Europe	O
[	O
56	O
]	O
.	O
	
In	O
1996	O
,	O
I	B-KP
.	I-KP
scapularis	I-KP
was	O
experimentally	O
confirmed	O
as	O
a	O
vector	O
of	O
E	B-KP
.	I-KP
phagocytophila	I-KP
,	O
and	O
P	B-KP
.	I-KP
leucopus	I-KP
was	O
shown	O
to	O
be	O
a	O
competent	O
reservoir	O
[	O
57	O
]	O
.	O
	
In	O
2001	O
,	O
this	O
intraleukocytic	O
bacterium	I-KP
was	O
renamed	O
A	B-KP
.	I-KP
phagocytophilum	I-KP
[	O
58	O
]	O
.	O
	
﻿Bo	B-KP
.	I-KP
burgdorferi	I-KP
and	O
Ba	B-KP
.	I-KP
microti	I-KP
share	O
a	O
common	B-KP
reservoir	I-KP
,	O
the	O
white-footed	O
mouse	O
,	O
explaining	O
the	O
increased	O
likelihood	O
of	O
finding	O
coinfections	O
more	O
often	O
than	O
expected	O
by	O
chance	O
[85,86,91]	O
.	O
	
Recent	O
evidence	O
suggests	O
that	O
Bo	B-KP
.	I-KP
burgdorferi	I-KP
promotes	O
transmission	O
of	O
Ba	B-KP
.	I-KP
microti	I-KP
,	O
and	O
the	O
former	O
typically	O
becomes	O
established	O
in	O
new	O
foci	O
before	O
the	O
latter	O
[85,86,91,92]	O
.	O
	
By	O
contrast	O
,	O
coinfection	O
with	O
Bo	B-KP
.	I-KP
burgdorferi	I-KP
and	O
A	B-KP
.	I-KP
phagocytophilum	I-KP
are	O
typically	O
observed	O
at	O
rates	O
expected	O
based	O
on	O
prevalence	O
of	O
each	O
infection	O
individually	O
,	O
suggesting	O
independent	B-KP
enzootic	I-KP
transmission	I-KP
maintenance	I-KP
cycles	I-KP
[83,84,87,93]	O
.	O
	
Although	O
,	O
the	O
efficiency	O
of	O
I	B-KP
.	I-KP
scapularis	I-KP
to	O
transmit	O
Bo	B-KP
.	I-KP
burgdorferi	I-KP
or	O
A	B-KP
.	I-KP
phagocytophilum	I-KP
is	O
not	O
affected	O
by	O
coinfection	O
[	O
84	O
]	O
,	O
coinfection	O
in	O
mice	O
has	O
been	O
shown	O
to	O
increase	O
pathogen	B-KP
acquisition	I-KP
by	O
feeding	O
larvae	O
,	O
compared	O
with	O
rates	O
observed	O
when	O
feeding	O
on	O
singly	O
infected	O
mice	O
[	O
94	O
]	O
.	O
	
The	O
relative	O
abundance	O
of	O
various	O
hosts	O
in	O
a	O
community	O
likely	O
influences	O
the	O
probability	O
of	O
coinfections	B-KP
occurring	O
.	O
	
Although	O
reported	O
less	O
commonly	O
as	O
a	O
coinfection	B-KP
with	O
Bo	B-KP
.	I-KP
burgdorferi	I-KP
compared	O
with	O
A	B-KP
.	I-KP
phagocytophilum	I-KP
or	O
Ba	B-KP
.	I-KP
microti	I-KP
,	O
coinfection	O
with	O
Bo	B-KP
.	I-KP
miyamotoi	I-KP
appears	O
to	O
occur	O
at	O
rates	O
expected	O
by	O
chance	O
,	O
or	O
lower	O
,	O
again	O
suggesting	O
independent	O
mechanisms	O
of	O
persistence	O
[76,82]	O
.	O
	
﻿Compared	O
with	O
Lyme	B-KP
disease	I-KP
,	O
the	O
incidence	O
of	O
reported	O
anaplasmosis	B-KP
,	O
Powassan	B-KP
virus	I-KP
disease	I-KP
,	O
and	O
babesiosis	B-KP
is	O
several	O
orders	O
of	O
magnitude	O
lower	O
,	O
and	O
their	O
geographic	O
distribution	O
appears	O
to	O
be	O
similar	O
but	O
more	O
restricted	O
;	O
like	O
the	O
distribution	O
of	O
Lyme	B-KP
disease	I-KP
cases	I-KP
,	O
the	O
geographic	O
range	O
of	O
anaplasmosis	B-KP
and	O
babesiosis	B-KP
has	O
similarly	O
spread	O
over	O
time	O
(	O
Figure	O
4	O
)	O
[7,19,95,98,99]	O
.	O
	
Over	O
96	O
%	O
of	O
Lyme	B-KP
disease	I-KP
cases	I-KP
are	O
reported	O
from	O
just	O
14	O
states	O
in	O
the	O
northeast	O
,	O
mid-Atlantic	O
and	O
the	O
upper	O
Midwest	O
[	O
95	O
]	O
.	O
	
Since	O
the	O
mid-1990s	O
,	O
the	O
number	O
of	O
counties	O
with	O
a	O
high	O
incidence	O
of	O
Lyme	B-KP
disease	I-KP
has	O
increased	O
by	O
approximately	O
300	O
%	O
[	O
48	O
]	O
.	O
	
As	O
it	O
is	O
not	O
a	O
notifiable	O
condition	O
,	O
trends	O
in	O
incidence	O
and	O
geographic	O
range	O
of	O
Bo	B-KP
.	I-KP
miyamotoi	I-KP
disease	I-KP
cases	I-KP
are	O
not	O
well	O
characterized	O
,	O
but	O
the	O
geographic	O
range	O
is	O
likely	O
similer	O
to	O
that	O
of	O
Lyme	B-KP
disease	I-KP
[	O
100	O
]	O
.	O
	
By	O
contrast	O
,	O
ehrlichiosis	B-KP
,	O
caused	O
by	O
E	B-KP
.	I-KP
muris	I-KP
eauclarensis	I-KP
,	O
thus	O
far	O
has	O
been	O
reported	O
only	O
from	O
the	O
upper	O
Midwest	O
[	O
65	O
]	O
.	O
	
﻿Potential	O
future	O
magic	O
bullet	O
solutions	O
,	O
capable	O
of	O
both	O
ensuring	O
that	O
the	O
bite	O
of	O
an	O
infected	O
tick	O
does	O
not	O
result	O
in	O
illness	O
and	O
having	O
the	O
potential	O
to	O
rapidly	O
and	O
dramatically	O
reduce	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
human	I-KP
infections	I-KP
at	O
the	O
population	O
level	O
,	O
include	O
(	O
i	O
)	O
human	B-KP
vaccines	I-KP
or	I-KP
prophylactic	I-KP
antibody	I-KP
treatments	I-KP
against	O
Lyme	B-KP
disease	I-KP
spirochetes	I-KP
or	O
other	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
pathogens	I-KP
[104,105,109,110],	O
and	O
(	O
ii	O
)	O
transmission-blocking	B-KP
anti-tick	I-KP
vaccines	I-KP
for	O
human	O
use	O
with	O
potential	O
for	O
simultaneous	O
protection	O
against	O
multiple	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
pathogens	I-KP
[111–115]	O
.	O
	
These	O
approaches	O
would	O
not	O
require	O
daily	O
action	O
and	O
vigilance	O
,	O
and	O
they	O
would	O
be	O
effective	O
regardless	O
of	O
whether	O
or	O
not	O
bites	O
by	O
infected	O
ticks	O
are	O
noticed	O
.	O
	
If	O
proven	O
to	O
be	O
safe	O
,	O
effective	O
,	O
and	O
acceptable	O
for	O
widespread	O
use	O
,	O
there	O
is	O
no	O
question	O
that	O
the	O
re-emergence	O
of	O
a	O
human	O
vaccine	B-KP
against	I-KP
Bo	I-KP
.	I-KP
burgdorferi	I-KP
,	O
or	O
the	O
emergence	O
of	O
a	O
prophylactic	B-KP
antibody	I-KP
treatment	I-KP
,	O
would	O
be	O
the	O
most	O
effective	O
ways	O
to	O
rapidly	O
reduce	O
Lyme	B-KP
disease	I-KP
cases	O
.	O
	
However	O
,	O
neither	O
approach	O
would	O
address	O
the	O
remaining	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
pathogens	I-KP
,	O
several	O
of	O
which	O
are	O
on	O
the	O
rise	O
(	O
Figure	O
4	O
)	O
.	O
	
A	O
transmission-blocking	B-KP
anti-tick	I-KP
vaccine	I-KP
could	O
potentially	O
address	O
that	O
shortcoming	O
,	O
but	O
only	O
if	O
it	O
proves	O
to	O
act	O
quickly	O
and	O
effectively	O
enough	O
on	O
an	O
infected	O
tick	O
to	O
prevent	O
or	O
substantially	O
reduce	O
the	O
likelihood	O
of	O
pathogen	B-KP
transmission	I-KP
occurring	O
before	O
the	O
tick	O
is	O
incapacitated	O
.	O
	
These	O
urgently	O
needed	O
approaches	O
merit	O
greater	O
resources	O
to	O
expeditiously	O
move	O
them	O
forward	O
in	O
a	O
pipeline	O
from	O
prevention	O
concept	O
to	O
proven	O
solution	O
and	O
become	O
,	O
should	O
they	O
be	O
successful	O
,	O
cornerstones	O
in	O
public	O
health	O
programs	O
to	O
reduce	O
I	B-KP
.	I-KP
scapularis-borne	I-KP
infections	I-KP
.	O
	
﻿An	O
additional	O
problem	O
is	O
that	O
the	O
clinical	O
spectrum	O
of	O
these	O
patients	O
now	O
encompasses	O
a	O
more	O
diverse	O
number	O
of	O
causes	O
other	O
than	O
nonpolio	B-KP
enteroviruses	I-KP
,	O
including	O
:	O
(	O
1	O
)	O
meningitis	B-KP
due	O
to	O
culturable	O
pathogens	O
in	O
which	O
the	O
pathogen	B-KP
concentration	I-KP
in	I-KP
CSF	I-KP
is	O
below	O
the	O
diagnostic	O
sensitivity	O
of	O
standard	B-KP
microbiologic	I-KP
stains	I-KP
(	O
eg	O
,	O
Mycobacterium	B-KP
tuberculosis	I-KP
,	O
Listeria	B-KP
monocytogenes	I-KP
,	O
Cryptococcus	B-KP
neoformans	I-KP
)	O
[	O
6	O
]	O
;	O
(	O
2	O
)	O
meningitis	B-KP
due	O
to	O
treatable	O
causes	O
not	O
culturable	O
from	O
CSF	B-KP
under	O
routine	O
conditions	O
(	O
eg	O
,	O
human	B-KP
immuno-deficiency	I-KP
virus	I-KP
[	O
HIV	B-KP
]	O
,	O
Lyme	B-KP
disease	I-KP
,	O
syphilis	B-KP
)	O
;	O
and	O
(	O
3	O
)	O
systemic	O
illnesses	O
(	O
eg	O
,	O
bacteremia	O
,	O
endocarditis	O
,	O
vasculitis	O
)	O
or	O
parameningeal	O
focal	I-KP
processes	I-KP
(	O
eg	O
,	O
brain	O
tumor	I-KP
,	I-KP
brain	O
or	I-KP
paraspinal	I-KP
abscess	I-KP
,	I-KP
transverse	O
myelitis	I-KP
,	I-KP
herpes	O
simplex	I-KP
encephalitis	I-KP
)	I-KP
,	O
many	O
of	O
which	O
are	O
inherently	O
treatable	O
.	O
	
An	O
increasingly	O
complex	O
host	O
population	O
with	O
an	O
expanding	O
array	O
of	O
treatable	O
possibilities	O
fosters	O
confusion	O
in	O
management	O
,	O
unnecessary	O
diagnostic	O
testing	O
,	O
and	O
misdirected	O
expenditures	O
.	O
	
﻿We	O
believe	O
the	O
observations	O
in	O
this	O
study	O
highlight	O
the	O
need	O
for	O
an	O
improved	O
taxonomy	O
of	O
this	O
clinical	B-KP
syndrome	I-KP
.	O
	
Aseptic	B-KP
meningitis	I-KP
is	O
by	O
definition	O
a	O
diagnosis	O
in	O
retrospect	O
,	O
is	O
often	O
inappropriately	O
used	O
in-terchangeably	O
with	O
viral	B-KP
meningitis	I-KP
,	O
[13,15]	O
and	O
does	O
not	O
accurately	O
reflect	O
the	O
prospective	O
management	O
dilemmas	O
faced	O
by	O
the	O
clinician	O
.	O
	
Recent	O
technical	O
advances	O
using	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
assays	I-KP
for	O
enteroviral	B-KP
ribonucleic	I-KP
acid	I-KP
[16,17]	O
and	O
cytokine	B-KP
levels	I-KP
(	O
interleukin-1	B-KP
,	O
tumor	B-KP
necrosis	I-KP
factor	I-KP
)	O
[18,19]	O
in	O
CSF	B-KP
to	O
distinguish	O
viral	O
from	O
bacterial	B-KP
meningitis	I-KP
are	O
important	O
,	O
but	O
are	O
not	O
widely	O
available	O
and	O
oversimplify	O
the	O
complexity	O
of	O
differential	O
diagnoses	O
and	O
management	O
dilemmas	O
.	O
	
The	O
terms	O
"	O
enigmatic	B-KP
meningitis	I-KP
"	O
or	O
"	O
meningitis	O
of	O
unknown	O
origin	O
"	O
(	O
ie	O
,	O
acute	B-KP
meningitis	I-KP
with	O
a	O
negative	O
CSF	B-KP
Gram's	B-KP
stain	I-KP
)	O
would	O
be	O
more	O
precise	O
,	O
inclusive	O
,	O
and	O
realistic	O
for	O
practitioners	O
,	O
and	O
would	O
provide	O
an	O
improved	O
taxonomy	O
for	O
future	O
prospective	O
studies	O
.	O
	
This	O
study	O
shows	O
that	O
the	O
clinical	O
presentation	O
of	O
patients	O
with	O
acute	B-KP
meningitis	I-KP
with	O
a	O
Gram's	B-KP
stain	I-KP
negative	O
for	O
bacteria	O
(	O
or	O
enigmatic	B-KP
meningitis	I-KP
)	O
is	O
a	O
common	O
presenting	O
emergency	O
department	O
problem	O
:	O
approximately	O
86	O
cases	O
per	O
year	O
in	O
an	O
emergency	O
department	O
with	O
71,000	O
visits	O
per	O
year	O
.	O
	
A	O
conservative	O
estimate	O
,	O
therefore	O
,	O
is	O
about	O
1	O
case	O
per	O
1,000	O
visits	O
per	O
year	O
.	O
	
Extrapolating	O
this	O
estimate	O
to	O
short-term	O
,	O
general	O
,	O
nonfederal	O
hospitals	O
in	O
the	O
United	O
States	O
(	O
n	O
=	O
5,202)	O
in	O
which	O
there	O
were	O
an	O
estimated	O
85,143,562	O
total	O
emergency	O
department	O
visits	O
in	O
1990	O
,	O
[	O
20	O
]	O
one	O
would	O
anticipate	O
about	O
85,000	O
cases	O
of	O
enigmatic	B-KP
meningitis	I-KP
per	O
year	O
in	O
the	O
United	O
States	O
.	O
	
Given	O
recent	O
data	O
documenting	O
the	O
high	O
expenditures	O
for	O
inpatient	O
care	O
in	O
the	O
United	O
States	O
($4,814	O
per	O
admission	O
)	O
,	O
[	O
21	O
]	O
it	O
can	O
be	O
estimated	O
that	O
over	O
300	O
million	O
dollars	O
is	O
being	O
spent	O
annually	O
on	O
these	O
patients	O
.	O
	
Although	O
this	O
is	O
only	O
an	O
estimate	O
,	O
the	O
high	O
cost	O
of	O
potentially	O
inappropriate	O
evaluation	O
and	O
hospitalization	O
supports	O
the	O
concept	O
that	O
this	O
is	O
a	O
formidable	O
but	O
neglected	O
problem	O
.	O
	
Efforts	O
to	O
identify	O
and	O
reduce	O
unnecessary	O
hospitalization	O
,	O
use	O
of	O
antibiotics	B-KP
,	O
and	O
imaging	O
are	O
urgently	O
needed	O
.	O
	
﻿The	O
patient	O
had	O
a	O
history	O
of	O
diffuse	O
large	O
non-Hodgkin’s	B-KP
B	I-KP
cell	I-KP
CNS	I-KP
lymphoma	I-KP
.	O
	
This	O
had	O
been	O
diagnosed	O
10	O
years	O
before	O
admission	O
and	O
treated	O
with	O
chemotherapeutic	O
doses	O
of	O
methotrexate	B-KP
(	O
MTX	B-KP
)	O
,	O
and	O
was	O
followed	O
by	O
maintenance	O
MTX	B-KP
infusions	I-KP
.	O
	
She	O
had	O
achieved	O
a	O
complete	O
remission	O
for	O
4	O
years	O
on	O
this	O
regimen	O
.	O
	
Six	O
years	O
before	O
admission	O
,	O
the	O
patient	O
had	O
experienced	O
a	O
recurrence	O
of	O
her	O
CNS	B-KP
lymphoma	I-KP
,	O
manifested	O
by	O
cognitive	O
changes	O
and	O
accompanied	O
by	O
radiologic	O
evidence	O
of	O
new	O
lesions	B-KP
on	O
a	O
brain	B-KP
MRI	I-KP
scan	I-KP
.	O
	
She	O
resumed	O
therapy	O
with	O
MTX	O
,	I-KP
which	O
continued	O
through	O
2004	O
.	O
	
In	O
2005	O
,	O
she	O
developed	O
new	O
brain	O
lesions	I-KP
that	O
were	O
treated	O
with	O
the	O
combination	O
of	O
high-dose	O
MTX	I-KP
,	I-KP
rituximab	O
,	I-KP
and	O
temozolomide	O
.	I-KP
	
This	O
regimen	O
induced	O
another	O
complete	O
remission	O
,	O
but	O
she	O
experienced	O
a	O
third	O
recurrence	O
in	O
2006	O
,	O
at	O
which	O
time	O
she	O
was	O
treated	O
with	O
myeloablative	O
chemotherapy	I-KP
consisting	O
of	O
cytarabine	O
(Ara-C)	O
/	O
etoposide	O
(	O
VP-16	O
)	I-KP
,	O
followed	O
by	O
autologous	O
bone	O
marrow	O
rescue	O
.	O
	
Following	O
her	O
bone	O
marrow	O
transplant	O
,	O
she	O
had	O
remained	O
in	O
remission	O
until	O
the	O
time	O
of	O
the	O
current	O
presentation	O
.	O
	
Aside	O
from	O
her	O
oncologic	O
history	O
,	O
the	O
only	O
other	O
past	O
medical	O
history	O
of	O
note	O
was	O
a	O
caesarean	O
section	O
delivery	O
performed	O
in	O
early	O
2002	O
,	O
followed	O
by	O
a	O
hysterectomy	O
for	O
placenta	O
previa	I-KP
.	I-KP
	
﻿Upon	O
arrival	O
in	O
the	O
Cardiac	O
Unit	O
,	O
her	O
temperature	O
was	O
98.2°F,	O
her	O
pulse	O
was	O
60	O
beats	O
/	O
minute,	O
her	O
blood	B-KP
pressure	I-KP
was	O
112	O
/	O
60	O
mm	O
Hg	O
,	O
and	O
her	O
respiratory	B-KP
rate	I-KP
and	O
room	B-KP
air	I-KP
oxygen	I-KP
saturation	I-KP
were	O
16	O
breaths	O
/	O
minute	O
and	O
98	O
%	O
,	O
respectively	O
.	O
	
She	O
appeared	O
comfortable	O
lying	O
in	O
bed	O
.	O
	
Her	O
mucous	B-KP
membranes	I-KP
were	O
moist	O
and	O
the	O
conjunctivae	O
were	O
not	O
injected	O
.	O
	
She	O
had	O
no	O
oral	B-KP
lesions	I-KP
.	O
	
She	O
had	O
easily	O
palpable	O
,	O
nontender	B-KP
temporal	I-KP
arteries	I-KP
.	O
	
No	O
lymphadenopathy	B-KP
was	O
appreciated	O
at	O
the	O
cervical	B-KP
,	O
supraclavicular	B-KP
,	O
axillary	B-KP
,	O
abdominal	B-KP
,	O
or	O
inguinal	B-KP
sites	I-KP
.	O
	
Her	O
neck	O
was	O
supple	O
,	O
and	O
inspection	O
revealed	O
a	O
right-sided	B-KP
internal	I-KP
jugular	I-KP
venous-access	I-KP
catheter	I-KP
.	O
	
The	O
lung	O
fields	O
were	O
clear	O
to	O
auscultation	B-KP
.	O
	
Her	O
cardiac	O
examination	O
was	O
notable	O
for	O
a	O
paced	O
rhythm	O
of	O
60	O
beats	O
/	O
minute	O
without	O
murmurs	B-KP
,	O
rubs	B-KP
,	O
or	O
gallops	B-KP
.	O
	
There	O
were	O
no	O
subclavian	B-KP
or	I-KP
carotid	I-KP
bruits	I-KP
.	O
	
The	O
abdominal	O
examination	O
showed	O
no	O
organomegaly	B-KP
and	O
a	O
soft	O
,	O
nontender	O
abdomen	O
.	O
	
She	O
had	O
no	O
clubbing	B-KP
,	O
cyanosis	B-KP
,	O
or	O
edema	B-KP
on	O
any	O
extremity	O
.	O
	
The	O
fingers	O
were	O
without	O
tapering	B-KP
or	O
dilatation	O
of	O
her	O
nailbed	B-KP
capillaries	I-KP
,	O
and	O
her	O
peripheral	B-KP
pulses	I-KP
were	O
full	O
and	O
symmetric	O
throughout	O
.	O
	
There	O
was	O
no	O
rash	B-KP
.	O
	
The	O
neurologic	O
examination	O
revealed	O
a	O
patient	O
who	O
was	O
awake	O
,	O
alert	O
,	O
and	O
oriented	O
.	O
	
The	O
extraocular	O
movements	O
were	O
full	O
and	O
the	O
visual	O
fields	O
were	O
intact	O
.	O
	
Cranial	B-KP
nerve	I-KP
V	I-KP
was	O
intact	O
in	O
all	O
3	O
distributions	O
,	O
as	O
were	O
cranial	B-KP
nerves	I-KP
VII–XII.	O
There	O
was	O
normal	O
bulk	O
,	O
tone	O
,	O
and	O
power	O
of	O
the	O
muscles	O
,	O
and	O
the	O
sensory	O
examination	O
was	O
intact	O
to	O
light	O
touch	O
,	O
pinprick	O
,	O
and	O
vibration	O
.	O
	
The	O
deep	B-KP
tendon	I-KP
reflexes	I-KP
were	O
2	O
and	O
symmetric	O
,	O
and	O
the	O
plantar	B-KP
responses	I-KP
were	I-KP
flexor	I-KP
.	O
	
The	O
patient’s	O
speech	O
was	O
normal	O
.	O
	
﻿Lyme	B-KP
carditis	I-KP
is	O
estimated	O
to	O
occur	O
in	O
4	O
–	O
10	O
%	O
of	O
untreated	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US	O
(17,18).	O
	
It	O
occurs	O
most	O
often	O
during	O
stage	B-KP
2	I-KP
of	I-KP
the	I-KP
B	I-KP
burgdorferi	I-KP
infection	I-KP
,	O
the	O
early	O
disseminated	O
stage	O
,	O
accompanied	O
by	O
neurologic	B-KP
symptoms	I-KP
and	O
musculoskeletal	B-KP
symptoms	I-KP
.	O
	
The	O
early	O
disseminated	O
stage	O
usually	O
develops	O
weeks	O
to	O
months	O
after	O
the	O
appearance	O
of	O
an	O
erythema	B-KP
migrans	I-KP
lesion	I-KP
(	O
14	O
)	O
.	O
	
Our	O
patient	O
indicated	O
that	O
she	O
had	O
an	O
erythematous	B-KP
rash	I-KP
on	O
her	O
thigh	O
several	O
months	O
before	O
these	O
symptoms	O
,	O
and	O
this	O
most	O
likely	O
represented	O
an	O
erythema	B-KP
migrans	I-KP
lesion	I-KP
.	O
	
The	O
principal	O
manifestation	O
of	O
Lyme	B-KP
carditis	I-KP
is	O
a	O
self-limited	O
conduction	O
defect	O
,	O
usually	O
consisting	O
of	O
variable	O
degrees	O
of	O
AV	O
conduction	O
delay	O
.	O
	
Carditis	O
can	O
lead	O
to	O
lightheadedness	B-KP
,	O
syncope	B-KP
,	O
dyspnea	B-KP
,	O
palpitations	B-KP
,	O
and	O
chest	B-KP
pain	I-KP
,	O
but	O
it	O
can	O
also	O
be	O
asymptomatic	O
,	O
a	O
fact	O
that	O
probably	O
contributes	O
to	O
an	O
underestimation	O
of	O
this	O
complication’s	O
true	O
prevalence	O
.	O
	
B	B-KP
burgdorferi	I-KP
infections	I-KP
have	O
also	O
been	O
reported	O
to	O
cause	O
pericarditis	B-KP
,	O
endocarditis	B-KP
,	O
myocarditis	B-KP
,	O
pericardial	B-KP
effusion	I-KP
,	O
myocardial	B-KP
infarction	I-KP
,	O
coronary	B-KP
artery	I-KP
aneurysm	I-KP
,	O
prolonged	B-KP
QT	I-KP
interval	I-KP
,	O
and	O
congestive	B-KP
heart	I-KP
failure	I-KP
.	O
	
The	O
conduction	O
abnormalities	O
are	O
generally	O
limited	O
,	O
with	O
CHB	B-KP
resolving	O
by	O
an	O
average	O
of	O
one	O
week	O
and	O
lesser	O
degrees	O
of	O
block	O
by	O
one	O
month	O
.	O
	
Temporary	O
pacemakers	O
are	O
required	O
in	O
a	O
minority	O
of	O
cases	O
.	O
	
The	O
need	O
for	O
permanent	O
pacing	O
despite	O
antibiotics	B-KP
is	O
quite	O
rare	O
.	O
	
﻿Patients	O
were	O
considered	O
to	O
have	O
LM	B-KP
if	O
the	O
cerebrospinal	B-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
examination	O
showed	O
.	O
8	I-KP
white	I-KP
blood	I-KP
cells	I-KP
per	O
cubic	O
millimeter	O
(	O
nontraumatic	O
tap	O
)	O
and	O
they	O
had	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
)	O
and	O
/	O
or	O
positive	O
Lyme	B-KP
serology	I-KP
.	O
	
Serologic	B-KP
tests	I-KP
for	O
Borrelia	B-KP
burgdorferi	I-KP
were	O
performed	O
in	O
our	O
laboratory	O
by	O
previously	O
described	O
techniques	O
,	O
[	O
5	O
]	O
although	O
some	O
patients	O
had	O
tests	O
performed	O
by	O
offsite	O
commercial	O
laboratories	O
.	O
	
A	O
positive	B-KP
western	I-KP
blot	I-KP
test	I-KP
(	O
by	O
laboratory-determined	O
criteria,5	O
because	O
most	O
cases	O
occurred	O
before	O
standardized	O
western	O
blot	O
interpretive	O
criteria	O
[	O
6	O
]	O
)	O
was	O
considered	O
to	O
be	O
evidence	O
of	O
Lyme	B-KP
disease	I-KP
.	O
	
In	O
cases	O
where	O
western	B-KP
blotting	I-KP
was	O
not	O
performed	O
,	O
the	O
enzyme	B-KP
immunoassays	I-KP
were	O
considered	O
true	O
positives	O
if	O
the	O
results	O
were	O
greater	O
than	O
twice	O
the	O
lower	O
limit	O
of	O
a	O
reactive	O
result	O
.	O
	
VM	B-KP
was	O
identified	O
by	O
using	O
the	O
same	O
CSF	B-KP
criteria	O
,	O
in	O
addition	O
to	O
laboratory	O
confirmation	O
of	O
viral	B-KP
infection	I-KP
(	O
ie	O
,	O
positive	B-KP
CSF	I-KP
,	O
nasopharyngeal	B-KP
,	O
or	O
rectal	B-KP
cultures	I-KP
[	O
poliovirus	B-KP
in	I-KP
rectal	I-KP
cultures	I-KP
was	O
considered	O
to	O
be	O
vaccine	O
related	O
and	O
not	O
causal	O
for	O
meningitis	B-KP
]	O
)	O
.	O
	
﻿Aseptic	B-KP
meningitis	I-KP
,	O
a	O
clinical	O
syndrome	O
of	O
meningeal	B-KP
inflammation	I-KP
in	O
which	O
common	O
bacterial	O
agents	O
cannot	O
be	O
identified	O
in	O
CSF	B-KP
,	O
is	O
associated	O
with	O
a	O
variety	O
of	O
infectious	O
and	O
noninfectious	O
causes	O
.	O
	
A	O
recent	O
review	O
of	O
168	O
adult	O
and	O
pediatric	O
patients	O
with	O
meningitis	B-KP
and	O
a	O
negative	O
Gram	O
stain	O
reported	O
that	O
a	O
definitive	O
cause	O
was	O
established	O
in	O
23	O
%	O
of	O
patients	O
.	O
[	O
7	O
]	O
Transverse	B-KP
myelitis	I-KP
,	O
malignancy	B-KP
,	O
syphilis	B-KP
,	O
bacteremia	B-KP
,	O
Lyme	B-KP
disease	I-KP
,	O
and	O
viral	B-KP
meningoencephalitis	I-KP
were	O
the	O
most	O
common	O
diagnoses	O
.	O
	
In	O
children	O
,	O
viral	B-KP
agents	I-KP
,	O
especially	O
Coxsackie	B-KP
and	I-KP
echoviruses	I-KP
,	O
are	O
the	O
most	O
common	O
causes	O
of	O
aseptic	B-KP
meningitis	I-KP
.	O
[	O
8	O
]	O
Lyme	B-KP
disease	I-KP
is	O
the	O
most	O
common	O
vector-borne	B-KP
infection	I-KP
in	O
the	O
United	O
States	O
and	O
children	O
comprise	O
a	O
large	O
proportion	O
of	O
cases	O
.	O
[	O
9	O
]	O
Reported	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
in	O
children	O
exceeded	O
7	O
per	O
100	O
000	O
in	O
1996	O
,	O
[	O
9	O
]	O
but	O
frequencies	O
manyfold	O
higher	O
are	O
reported	O
in	O
endemic	B-KP
areas	I-KP
in	O
the	O
northeastern	O
and	O
north	O
central	O
United	O
States	O
.	O
[	O
10	O
]	O
Because	O
of	O
underreporting	O
of	O
cases	O
,	O
it	O
is	O
likely	O
that	O
the	O
true	O
rates	O
are	O
even	O
higher	O
.	O
[	O
11	O
]	O
The	O
importance	O
and	O
spectrum	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
in	O
children	O
has	O
been	O
reported	O
in	O
both	O
the	O
United	O
States	O
and	O
Europe	O
,	O
and	O
differences	O
from	O
adult	O
disease	O
have	O
been	O
noted	O
.	O
[12,13]	O
﻿The	O
fact	O
that	O
LM	B-KP
and	O
VM	B-KP
are	O
both	O
most	O
frequent	O
during	O
the	O
warmer	O
months	O
may	O
lead	O
to	O
confusion	O
in	O
diagnosis	O
and	O
errors	O
in	O
management	O
(	O
ie	O
,	O
failure	O
to	O
provide	B-KP
effective	I-KP
therapy	I-KP
for	O
LM	B-KP
and	O
unnecessary	O
antibiotic	B-KP
treatment	I-KP
for	O
VM	B-KP
)	O
.	O
	
Rapid	O
techniques	O
for	O
diagnosis	O
of	O
VM	B-KP
will	O
facilitate	O
appropriate	O
management	O
,	O
[	O
8	O
]	O
but	O
such	O
technology	O
is	O
not	O
widely	O
available	O
.	O
	
The	O
diagnosis	O
of	O
LM	B-KP
is	O
most	O
often	O
based	O
on	O
the	O
finding	O
of	O
CSF	B-KP
pleocytosis	I-KP
associated	O
with	O
the	O
occurrence	O
of	O
EM	B-KP
and	O
/	O
or	O
positive	B-KP
serologic	I-KP
tests	I-KP
.	O
	
However	O
,	O
both	O
enzyme	B-KP
immunoassay	I-KP
and	O
western	B-KP
blot	I-KP
tests	I-KP
for	O
antibody	O
may	O
be	O
negative	O
or	O
indeterminate	O
early	O
in	O
infection	O
when	O
dissemination	O
to	O
the	O
nervous	B-KP
system	I-KP
occurs	O
.	O
[	O
3	O
]	O
Also	O
,	O
delays	O
in	O
performing	O
or	O
reporting	O
these	O
tests	O
may	O
lead	O
to	O
delays	O
that	O
can	O
hinder	O
diagnosis	O
and	O
treatment	O
.	O
	
More	O
specific	O
techniques	O
for	O
confirming	O
LM	B-KP
include	O
tests	O
for	O
intrathecal	O
production	O
of	O
specific	O
antibody	B-KP
[16,17]	O
and	O
demonstration	O
of	O
Borrelia	B-KP
burgdorferi	I-KP
DNA	B-KP
by	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
.	O
[2,18]	O
However	O
,	O
the	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
test	O
usually	O
is	O
not	O
rapid	O
and	O
is	O
not	O
very	O
sensitive	O
.	O
[2,18]	O
﻿A	O
5-year-old	O
girl	O
with	O
no	O
significant	O
medical	O
history	O
presented	O
with	O
unsteady	O
gait	O
that	O
first	O
appeared	O
4	O
days	O
prior	O
to	O
examination	O
.	O
	
In	O
the	O
intervening	O
period	O
,	O
her	O
gait	O
progressively	O
worsened	O
until	O
she	O
was	O
unable	O
to	O
walk	O
.	O
	
There	O
was	O
no	O
history	O
of	O
fever	B-KP
,	O
rash	B-KP
,	O
recent	O
immunizations	O
,	O
tick	O
bite	O
,	O
or	O
exposures	O
to	O
infectious	B-KP
disease	I-KP
.	O
	
Medical	O
history	O
was	O
unremarkable	O
.	O
	
The	O
family	O
lives	O
in	O
Silifke	O
/	O
Mersin,	O
which	O
is	O
a	O
semiurban	O
area	O
in	O
southern	O
coast	O
of	O
Anatolia	O
(	O
Mediterranean	O
region	O
)	O
.	O
	
Vital	O
signs	O
and	O
physical	O
examination	O
were	O
normal	O
.	O
	
On	O
neurological	B-KP
examination	I-KP
,	O
her	O
higher	O
mental	O
functions	O
and	O
cranial	B-KP
nerve	I-KP
functions	I-KP
were	O
normal	O
and	O
there	O
were	O
no	O
signs	O
of	O
meningitis	B-KP
.	O
	
She	O
had	O
bilateral	B-KP
cerebellar	I-KP
signs	I-KP
in	O
the	O
form	O
of	O
hypotonia	B-KP
of	O
all	O
limbs	B-KP
,	O
dysarthria	B-KP
,	O
nystagmus	B-KP
,	O
bilateral	B-KP
dysmetria	I-KP
,	O
and	O
intention	B-KP
tremor	I-KP
.	O
	
She	O
also	O
exhibited	O
marked	B-KP
ataxia	I-KP
.	O
	
Superficial	B-KP
and	I-KP
deep	I-KP
tendon	I-KP
reflexes	I-KP
were	O
normal	O
and	O
plantar	O
responses	O
were	O
flexor	O
.	O
	
Laboratory	O
analyses	O
revealed	O
normal	O
blood	B-KP
leukocyte	I-KP
count	O
(5670	O
/	O
mm3),	O
serum	B-KP
C-reactive	I-KP
protein	I-KP
(	O
3	O
mg	O
/	O
L),	O
and	O
erythrocyte	B-KP
sedimentation	I-KP
rate	I-KP
(	O
30	O
mm	O
/	O
h).	O
	
Neither	O
computed	B-KP
tomography	I-KP
(	O
CT	B-KP
)	O
nor	O
magnetic	B-KP
resonance	I-KP
imaging	I-KP
(	O
MRI	B-KP
)	O
revealed	O
any	O
abnormalities	O
in	O
the	O
brain	B-KP
.	O
	
Cerebrospinal	B-KP
fluid	I-KP
(	O
CSF	B-KP
)	O
showed	O
a	O
mild	B-KP
pleocytosis	I-KP
(	O
30	O
cells	O
/	O
mm3,	O
all	O
mononuclear	O
)	O
but	O
normal	O
protein	B-KP
and	O
glucose	B-KP
concentrations	I-KP
.	O
	
Acyclovir	B-KP
,	O
cefotaxime	B-KP
,	O
and	O
clarithromycin	B-KP
were	O
administered	O
empirically	O
.	O
	
Serum	O
markers	O
for	O
herpes	B-KP
simplex	I-KP
virus	I-KP
,	O
cytomegalovirus	B-KP
,	O
varicella	B-KP
zoster	I-KP
,	O
mumps	B-KP
,	O
rubella	B-KP
,	O
rubeola	B-KP
,	O
Epstein-Barr	B-KP
virus	I-KP
,	O
and	O
mycoplasma	B-KP
were	O
all	O
negative	O
.	O
	
Intravenous	B-KP
immunoglobulin	I-KP
(	O
IVIG	B-KP
)	O
infusion	O
was	O
started	O
on	O
day	O
7	O
to	O
suppress	O
the	O
postviral	B-KP
immune	I-KP
response	I-KP
that	O
may	O
be	O
responsible	O
for	O
acute	B-KP
cerebellar	I-KP
ataxia	I-KP
.	O
	
On	O
the	O
fifth	O
day	O
after	O
admission	O
,	O
serologic	O
evaluation	O
for	O
Borrelia	B-KP
burgdorferi	I-KP
was	O
positive	O
for	O
pathogen-specific	B-KP
IgM	I-KP
but	O
negative	O
for	O
IgG	B-KP
.	O
After	O
we	O
obtained	O
these	O
results	O
,	O
the	O
history	O
of	O
the	O
patient	O
was	O
reevaluated	O
for	O
tick	O
bite	O
.	O
	
She	O
did	O
not	O
recall	O
any	O
injury	O
,	O
rash	B-KP
,	O
or	O
tick	O
bite	O
.	O
	
Acyclovir	B-KP
and	O
clarithromycin	B-KP
were	O
discontinued	O
on	O
day	O
10	O
and	O
she	O
was	O
administered	O
intravenous	B-KP
cefotaxime	I-KP
200	O
mg	O
/	O
kg	O
per	O
day	O
for	O
the	O
next	O
28	O
days	O
.	O
	
Because	O
the	O
patient	O
did	O
not	O
give	O
permission	O
for	O
a	O
new	O
lumbar	O
puncture	O
,	O
CSF	B-KP
Lyme	I-KP
serology	I-KP
could	O
not	O
be	O
performed	O
.	O
	
Her	O
gait	O
improved	O
gradually	O
during	O
cefotaxime	O
treatment	O
.	O
	
At	O
the	O
time	O
of	O
discharge	O
on	O
day	O
28	O
,	O
her	O
neurologic	B-KP
examination	I-KP
was	O
normal	O
.	O
	
Serum	O
was	O
positive	O
for	O
both	O
B	B-KP
.	I-KP
burgdorferi	I-KP
IgM	I-KP
and	I-KP
IgG	I-KP
antibodies	I-KP
on	O
day	O
28	O
but	O
only	O
for	O
IgG	B-KP
on	O
day	O
120	O
.	O
	
﻿The	O
onset	O
of	O
acute	O
cerebellar	O
ataxia	O
varies	O
from	O
a	O
few	O
days	O
to	O
several	O
weeks	O
after	O
an	O
acute	O
febrile	I-KP
illness	I-KP
.	I-KP
	
Cerebellar	O
signs	O
are	O
observed	O
following	O
many	O
infectious	O
diseases	I-KP
,	I-KP
including	O
varicella-zoster	O
,	I-KP
Epstein-Barr	O
,	I-KP
entero-virus	O
,	I-KP
rubeola	O
,	I-KP
parvovirus	O
,	I-KP
and	O
mycoplasma	O
infections	I-KP
.	I-KP
	
Varicella	O
is	O
among	O
the	O
most	O
common	O
of	O
these	O
infectious	O
agents	I-KP
in	O
young	O
children	O
.	O
	
The	O
pathogenesis	O
of	I-KP
ataxia	I-KP
remains	O
unclear	O
,	O
but	O
emerging	O
evidence	O
suggests	O
that	O
an	O
autoimmune	O
mechanism	I-KP
may	O
be	O
involved	O
.	O
	
Antiviral	O
antibodies	I-KP
and	I-KP
autoreactive	I-KP
antibodies	I-KP
targeting	I-KP
cerebellar	I-KP
neurons	I-KP
,	I-KP
possibly	O
autoantibodies	O
specific	O
for	O
the	O
centrosome	O
protein	I-KP
pericentrin	I-KP
,	I-KP
have	O
been	O
detected	O
in	O
the	O
CSF	O
of	O
varicella	O
patients	O
.	O
	
In	O
other	O
cases	O
,	O
viral	O
nucleic	I-KP
acids	I-KP
have	O
been	O
identified	O
in	O
the	O
CSF	O
,	I-KP
suggesting	O
that	O
the	O
pathogen	O
may	O
directly	O
invade	O
the	O
central	O
nervous	I-KP
system	I-KP
[12,13]	O
.	O
	
As	O
can	O
be	O
seen	O
in	O
Table	O
1	O
,	O
cerebellar	O
involvement	O
in	O
the	O
form	O
of	O
cerebritis	O
or	O
acute	O
demyelinating	I-KP
encephalomyelitis	I-KP
are	O
described	O
in	O
patients	O
with	O
Lyme	O
disease	I-KP
;	I-KP
however	O
,	O
this	O
case	O
is	O
the	O
first	O
report	O
of	O
acute	O
cerebellar	I-KP
ataxia	I-KP
associated	O
with	O
Lyme	O
disease	I-KP
in	O
the	O
literature	O
.	O
	
﻿While	O
on	O
a	O
2-week	O
summer	O
camping	O
trip	O
in	O
southern	O
Pennsylvania	O
,	O
a	O
previously	O
healthy	O
15	O
year-old	O
boy	O
presented	O
to	O
a	O
nearby	O
emergency	O
department	O
after	O
several	O
days	O
of	O
subjective	O
fever	B-KP
,	O
malaise	B-KP
,	O
and	O
severe	B-KP
left	I-KP
arm	I-KP
radicular	I-KP
pain	I-KP
.	O
	
He	O
was	O
diagnosed	O
with	O
dehydration	O
,	O
administered	O
intravenous	B-KP
fluids	I-KP
,	O
and	O
discharged	O
.	O
	
Several	O
days	O
later	O
after	O
returning	O
home	O
his	O
arm	O
pain	O
resolved	O
,	O
but	O
then	O
he	O
developed	O
right-sided	B-KP
neck	I-KP
pain	I-KP
,	O
headache	B-KP
,	O
and	O
difficulty	O
concentrating	O
.	O
	
One	O
week	O
later	O
,	O
he	O
complained	O
of	O
tinnitus	B-KP
,	O
taste	O
disturbance	O
,	O
otalgia	B-KP
,	O
and	O
subjective	B-KP
hearing	I-KP
loss	I-KP
in	O
his	O
right	O
ear	O
.	O
	
Three	O
weeks	O
into	O
his	O
illness	O
,	O
the	O
patient	O
presented	O
to	O
a	O
local	O
emergency	O
department	O
for	O
right-sided	O
,	O
upper	O
,	O
and	O
lower	B-KP
facial	I-KP
muscle	I-KP
weakness	I-KP
.	O
	
He	O
had	O
no	O
previous	O
complaints	O
of	O
erythema	B-KP
chronicum	I-KP
migrans	I-KP
,	O
arthralgias	B-KP
,	O
or	O
arthritis	B-KP
.	O
	
He	O
was	O
diagnosed	O
with	O
Bell’s	B-KP
Palsy	I-KP
,	O
and	O
serologies	O
for	O
Lyme	B-KP
disease	I-KP
,	O
herpes	B-KP
simplex	I-KP
virus	I-KP
1	I-KP
and	I-KP
2	I-KP
,	O
and	O
Epstein-Barr	B-KP
virus	I-KP
were	O
obtained	O
.	O
	
His	O
primary	O
care	O
physician	O
prescribed	O
doxy-cycline	B-KP
for	O
a	O
positive	B-KP
Lyme	I-KP
antibody	I-KP
test	I-KP
and	O
referred	O
to	O
the	O
pediatric	O
infectious	O
disease	O
clinic	O
.	O
	
﻿The	O
most	O
common	O
manifestations	O
of	O
pediatric	B-KP
neuroborreliosis	I-KP
is	O
CN	B-KP
VII	I-KP
palsy	I-KP
(	O
unilateral	O
or	O
bilateral	O
)	O
and	O
lymphocytic	B-KP
meningitis	I-KP
.	O
	
Among	O
pediatric	O
patients	O
with	O
neuroborreliosis	B-KP
,	O
approximately	O
15	O
%	O
will	O
have	O
CN	B-KP
VII	I-KP
palsy	I-KP
,	O
and	O
of	O
those	O
,	O
between	O
30%-40%	O
present	O
with	O
bilateral	O
deficits	O
.	O
[	O
2	O
]	O
CNs	B-KP
III	I-KP
,	I-KP
VI	I-KP
,	I-KP
and	I-KP
VIII	I-KP
are	O
the	O
next	O
most	O
commonly	O
affected	O
.	O
	
Although	O
involvement	O
of	O
these	O
CNs	B-KP
is	O
often	O
diagnosed	O
clinically	O
,	O
MRI	B-KP
has	O
been	O
used	O
as	O
a	O
noninvasive	O
imaging	O
modality	O
to	O
confirm	O
clinical	O
findings	O
.	O
	
Our	O
patient	O
only	O
presented	O
with	O
signs	O
of	O
right-sided	B-KP
CNs	I-KP
VII	I-KP
and	I-KP
VIII	I-KP
involvement	O
on	O
examination	O
but	O
was	O
found	O
to	O
have	O
inflammation	O
of	O
right	O
CN	B-KP
III	I-KP
,	I-KP
X	I-KP
,	O
and	O
CN	B-KP
V	I-KP
bilaterally	O
on	O
post-gadolinium	O
MRI	B-KP
without	O
concomitant	O
clinical	O
manifestations	O
.	O
	
Clinically	O
“	O
silent	O
”	O
enhancement	O
of	O
CNs	B-KP
on	O
MRI	B-KP
has	O
previously	O
been	O
reported	O
in	O
pediatric	B-KP
cases	I-KP
of	I-KP
neuroborreliosis	I-KP
.	O
	
Baumann	O
et	O
al	O
.	O
[	O
3	O
]	O
presented	O
a	O
case	O
of	O
pediatric	B-KP
neuroborreliosis	I-KP
with	O
only	O
a	O
clinically	O
apparent	O
,	O
right-sided	B-KP
CN	I-KP
VI	I-KP
palsy	I-KP
despite	O
an	O
MRI	B-KP
demonstrating	O
abnormal	O
enhancement	O
of	O
CN	B-KP
VI	I-KP
bilaterally	I-KP
as	O
well	O
as	O
CN	B-KP
III	I-KP
ipsilaterally	I-KP
.	O
	
Silent	O
thalamic	B-KP
lesions	I-KP
have	O
also	O
been	O
reported	O
in	O
pediatric	O
patients	O
with	O
neuroborreliosis	O
.	O
[	O
4	O
]	O
In	O
this	O
case	O
,	O
the	O
extent	O
of	O
CN	B-KP
inflammation	I-KP
even	O
without	O
concomitant	O
clinical	O
manifestations	O
is	O
unique	O
within	O
cases	O
of	O
North	B-KP
American	I-KP
neuroborreliosis	I-KP
,	O
particularly	O
for	O
our	O
patient's	O
age	O
group	O
.	O
	
﻿Bell’s	B-KP
palsy	I-KP
represents	O
an	O
idiopathic	O
,	O
unilateral	B-KP
facial	I-KP
paralysis	I-KP
with	O
an	O
annual	O
incidence	O
of	O
approximately	O
15	O
per	O
100,000.	O
	
[	O
1	O
]	O
It	O
remains	O
the	O
most	O
common	O
cause	O
of	O
unilateral	B-KP
facial	I-KP
paralysis	I-KP
,	O
affecting	O
men	O
and	O
women	O
equally	O
,	O
and	O
although	O
the	O
median	O
age	O
at	O
onset	O
is	O
40	O
years	O
,	O
it	O
can	O
occur	O
at	O
any	O
age	O
.	O
[	O
2	O
]	O
Patients	O
with	O
Bell’s	B-KP
palsy	I-KP
commonly	O
present	O
with	O
partial	B-KP
or	I-KP
complete	I-KP
weakness	I-KP
of	I-KP
the	I-KP
muscles	I-KP
of	I-KP
half	I-KP
of	I-KP
the	I-KP
face	I-KP
,	O
resulting	O
in	O
an	O
inability	O
to	O
raise	O
eyebrows	O
,	O
wrinkle	O
the	O
forehead	O
,	O
or	O
close	O
the	O
eyelid	O
;	O
loss	O
of	O
the	O
nasolabial	O
fold	O
;	O
and	O
drooping	O
of	O
the	O
angle	O
of	O
the	O
mouth	O
.	O
	
Other	O
associated	O
symptoms	O
include	O
alterations	O
in	O
taste	O
,	O
hyperacusis	B-KP
,	O
inability	O
to	O
produce	O
tears	O
,	O
and	O
a	O
subjective	O
feeling	O
of	O
facial	B-KP
numbness	I-KP
,	O
though	O
objective	B-KP
sensation	I-KP
is	O
preserved	O
.	O
	
The	O
pathophysiology	B-KP
of	O
Bell’s	B-KP
palsy	I-KP
involves	O
inflammation	B-KP
of	O
the	O
facial	B-KP
nerve	I-KP
at	O
the	O
geniculate	B-KP
ganglion	I-KP
,	O
causing	O
compression	O
and	O
associated	O
ischemia	B-KP
or	O
demyelination	B-KP
.	O
[	O
3	O
]	O
Symptoms	O
are	O
often	O
acute	O
and	O
progressive	O
,	O
evolving	O
during	O
1	O
day	O
to	O
1	O
week	O
.	O
	
It	O
has	O
been	O
postulated	O
that	O
the	O
herpes	B-KP
simplex	I-KP
virus	I-KP
type	I-KP
1	I-KP
may	O
play	O
a	O
causative	O
role	O
,	O
though	O
this	O
theory	O
is	O
still	O
in	O
question	O
.	O
[	O
4	O
]	O
If	O
left	O
untreated	O
,	O
approximately	O
85	O
%	O
of	O
patients	O
with	O
Bell’s	B-KP
palsy	I-KP
will	O
experience	O
some	O
recovery	O
,	O
[	O
5	O
]	O
and	O
treatment	O
with	O
corticosteroids	B-KP
,	O
with	O
or	O
without	O
antiviral	B-KP
medications	I-KP
,	O
has	O
been	O
shown	O
to	O
improve	O
outcomes	O
.	O
[6,7]	O
﻿The	O
unique	O
linkage	O
number	O
was	O
used	O
to	O
link	O
subjects	O
from	O
the	O
index	O
ED	I-KP
visit	O
to	O
subsequent	O
ED	B-KP
encounters	I-KP
or	O
hospitalizations	O
within	O
90	O
days	O
.	O
	
Our	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
the	O
following	O
serious	O
ED	B-KP
or	O
inpatient	O
discharge	O
diagnoses	O
(	O
by	O
ICD-9	O
code	O
)	O
within	O
90	O
days	O
of	O
the	O
index	O
ED	I-KP
Bell’s	I-KP
palsy	I-KP
diagnosis	I-KP
:	I-KP
ischemic	O
stroke	I-KP
(433.01,	O
433.11,	O
433.21,	O
433.31,	O
433.81,	O
433.91,	O
434.01,	O
434.11,	O
434.91,	O
and	O
436	O
)	O
,	O
combined	O
with	O
an	O
algorithm	O
previously	O
validated	O
for	O
identifying	O
acute	O
ischemic	O
stroke	O
(	O
11	O
)	O
,	O
intracranial	O
hemorrhage	I-KP
(	O
431	O
)	O
,	O
or	O
subarachnoid	O
hemorrhage	I-KP
(	O
430	O
)	O
;	O
brain	O
tumor	I-KP
(	O
191	O
)	O
;	O
central	O
nervous	O
system	O
infection	O
,	O
including	O
meningitis	O
,	I-KP
encephalitis	O
,	I-KP
and	O
brain	O
abscess	I-KP
(	O
320-326	O
)	O
;	O
HIV	O
(	O
042	O
)	O
;	O
Guillain-Barré	O
syndrome	I-KP
(357.0);	O
Lyme	O
disease	I-KP
(088.81);	O
otitis	O
media	I-KP
or	O
mastoiditis	O
(	O
381-383	O
)	O
;	O
or	O
herpes	O
zoster	I-KP
(	O
053	O
)	O
.	O
	
These	O
diagnoses	O
were	O
chosen	O
a	O
priori	O
to	O
represent	O
distinct	O
and	O
clinically	O
important	O
disease	O
entities	O
that	O
may	O
present	O
in	O
a	O
similar	O
fashion	O
to	O
Bell’s	O
palsy	I-KP
.	I-KP
	
We	O
excluded	O
some	O
common	O
mimics	O
from	O
our	O
outcomes	O
(	O
eg	O
,	O
diabetic	O
neuropathy	I-KP
,	I-KP
sarcoidosis	O
)	I-KP
because	O
,	O
although	O
they	O
may	O
initially	O
be	O
confused	O
with	O
Bell’s	O
palsy	I-KP
,	I-KP
the	O
clinical	O
significance	O
of	O
misdiagnosis	O
is	O
unclear	O
and	O
patient	O
outcomes	O
would	O
generally	O
not	O
be	O
expected	O
to	O
worsen	O
from	O
delayed	O
diagnosis	O
.	O
	
Additionally	O
,	O
we	O
excluded	O
mortality	O
as	O
a	O
separate	O
outcome	O
because	O
any	O
death	O
related	O
to	O
one	O
of	O
the	O
outcome	O
diagnoses	O
would	O
already	O
be	O
captured	O
.	O
	
﻿Table	O
2	O
shows	O
the	O
results	O
of	O
our	O
multivariate	O
model	O
,	O
which	O
identified	O
multiple	O
factors	O
associated	O
with	O
the	O
likelihood	O
of	O
receiving	O
an	O
alternative	O
diagnosis	O
.	O
	
Demographic	O
factors	O
or	O
comorbid	O
conditions	O
positively	O
associated	O
included	O
increasing	O
age	O
(	O
HR	O
1.11,	O
95	O
%	O
CI	O
1.01	O
to	O
1.21,	O
for	O
every	O
10	O
years	O
)	O
,	O
black	O
compared	O
with	O
white	O
race	O
(	O
HR	O
1.68;	O
95	O
%	O
CI	O
1.13	O
to	O
2.48),	O
and	O
diabetes	B-KP
mellitus	I-KP
(	O
HR	O
1.46;	O
95	O
%	O
CI	O
1.10	O
to	O
1.95).	O
	
The	O
use	O
of	O
CT	B-KP
or	O
MRI	B-KP
imaging	I-KP
on	O
the	O
index	O
visit	O
was	O
also	O
associated	O
with	O
an	O
increase	O
in	O
the	O
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
(	O
HR	O
1.43;	O
95	O
%	O
CI	O
1.10	O
to	O
1.85).	O
	
Private	O
insurance	O
compared	O
with	O
Medicare	O
was	O
negatively	O
associated	O
with	O
an	O
alternative	O
diagnosis	O
(	O
HR	O
0.65;	O
95	O
%	O
CI	O
0.46	O
to	O
0.93).	O
	
The	O
alternative	O
diagnoses	O
made	O
on	O
follow-up	O
are	O
listed	O
in	O
Table	O
3	O
,	O
stratified	O
by	O
7-	O
,	O
14-	O
,	O
30-	O
,	O
and	O
90-day	O
follow-up	O
.	O
	
Of	O
the	O
356	O
individuals	O
with	O
an	O
alternative	O
diagnosis	O
within	O
90	O
days	O
,	O
142	O
(39.9%)	O
were	O
within	O
7	O
days	O
.	O
	
Most	O
common	O
at	O
all	O
4	O
intervals	O
were	O
ischemic	B-KP
stroke	I-KP
,	O
herpes	B-KP
zoster	I-KP
,	O
Guillain-Barré	B-KP
syndrome	I-KP
,	O
and	O
otitis	B-KP
media	I-KP
,	O
accounting	O
for	O
85.4%	O
of	O
all	O
alternative	O
diagnoses	O
.	O
	
﻿ee	O
found	O
that	O
10.9%	O
of	O
patients	O
who	O
received	O
a	O
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
went	O
on	O
to	O
receive	O
a	O
diagnosis	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
on	O
90-day	O
follow-up	O
.	O
	
Guillain-Barré	B-KP
syndrome	I-KP
encompasses	O
multiple	O
heterogeneous	B-KP
immune-mediated	I-KP
neuropathies	I-KP
,	O
generally	O
presenting	O
with	O
progressive	B-KP
and	I-KP
symmetric	I-KP
motor	I-KP
weakness	I-KP
and	O
loss	O
of	O
deep	B-KP
tendon	I-KP
reflexes	I-KP
.	O
	
Multiple	O
variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
exist	O
,	O
with	O
acute	B-KP
inflammatory	I-KP
demyelinating	I-KP
polyneuropathy	I-KP
,	O
the	O
classic	O
form	O
with	O
ascending	B-KP
paralysis	I-KP
,	O
accounting	O
for	O
the	O
majority	O
of	O
cases	O
.	O
[	O
27	O
]	O
Variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
may	O
involve	O
the	O
cranial	B-KP
nerves	I-KP
,	O
including	O
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
,	O
typically	O
presenting	O
with	O
ophthalmoplegia	B-KP
,	O
ataxia	B-KP
,	O
and	O
areflexia	B-KP
with	O
subsequent	O
descending	O
paralysis	O
.	O
	
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
accounts	O
for	O
approximately	O
5	O
%	O
of	O
all	O
cases	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
and	O
may	O
progress	O
in	O
half	O
of	O
cases	O
to	O
cause	O
various	O
other	O
cranial	B-KP
nerve	I-KP
abnormalities	I-KP
.	O
[28,29]	O
Additional	O
variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
that	O
may	O
overlap	O
with	O
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
and	O
initially	O
present	O
with	O
facial	O
symptoms	O
include	O
Bickerstaff	B-KP
encephalitis	I-KP
and	O
pharyngeal-cervical-brachial	B-KP
weakness	I-KP
,	O
though	O
both	O
of	O
these	O
entities	O
may	O
have	O
multiple	O
associated	O
symptoms	O
that	O
would	O
generally	O
preclude	O
a	O
diagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
.	O
[30,31]	O
More	O
detailed	O
research	O
may	O
be	O
warranted	O
to	O
investigate	O
the	O
association	O
between	O
ED	B-KP
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
and	O
subsequent	O
diagnosis	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
.	O
	
﻿Between	O
January	O
2000	O
and	O
April	O
2004	O
,	O
healthy	O
volunteers	O
(	O
controls	O
)	O
and	O
individuals	O
with	O
a	O
history	O
of	O
Lyme	B-KP
disease	I-KP
(	O
patients	O
)	O
between	O
the	O
ages	O
of	O
18	O
and	O
65	O
years	O
were	O
recruited	O
;	O
follow-up	O
evaluations	O
were	O
completed	O
by	O
April	O
2005	O
.	O
	
The	O
institutional	O
review	O
boards	O
at	O
Columbia	O
University	O
and	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
approved	O
the	O
study	O
,	O
and	O
all	O
participants	O
provided	O
written	O
informed	O
consent	O
.	O
	
Evaluations	O
were	O
conducted	O
at	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
and	O
Columbia	O
University	O
Medical	O
Center	O
.	O
	
Treatments	O
were	O
conducted	O
at	O
each	O
patient’s	O
home	O
.	O
	
Patients	O
met	O
the	O
following	O
criteria	O
:	O
(	O
1	O
)	O
history	O
of	O
physician-documented	O
erythema	B-KP
migrans	I-KP
or	O
U.S.	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)-defined	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
,	O
and	O
a	O
positive	O
or	O
equivocal	O
ELISA	B-KP
confirmed	O
by	O
positive	B-KP
Western	I-KP
blot	I-KP
serology	I-KP
[6,7];	O
(	O
2	O
)	O
current	O
positive	B-KP
IgG	I-KP
Western	I-KP
blot	I-KP
using	O
CDC	O
surveillance	O
criteria	O
,	O
assessed	O
using	O
a	O
single	O
reference	O
laboratory	O
(	O
University	O
Hospital	O
of	O
Stony	O
Brook	O
)	O
;	O
(	O
3	O
)	O
treatment	O
for	O
Lyme	B-KP
disease	I-KP
with	O
at	O
least	O
3	O
weeks	O
of	O
IV	B-KP
ceftriaxone	I-KP
,	O
completed	O
at	O
least	O
4	O
months	O
before	O
study	O
entry	O
;	O
(	O
4	O
)	O
subjective	O
memory	O
impairment	O
that	O
,	O
by	O
participant	O
report	O
,	O
started	O
after	O
the	O
onset	O
of	O
Lyme	B-KP
disease	I-KP
;	O
and	O
(	O
5	O
)	O
objective	O
evidence	O
of	O
memory	O
impairment	O
as	O
documented	O
by	O
the	O
Wechsler	B-KP
Memory	I-KP
Scale–III	I-KP
[	O
8	O
]	O
compared	O
with	O
age-	O
,	O
sex-	O
,	O
and	O
education-adjusted	O
population	O
norms	O
.	O
	
These	O
study	O
criteria	O
were	O
conservative	O
and	O
narrow	O
to	O
enhance	O
diagnostic	O
confidence	O
.	O
	
Prior	O
IV	B-KP
antibiotic	I-KP
therapy	I-KP
was	O
required	O
to	O
ensure	O
that	O
all	O
patients	O
had	O
received	O
treatment	O
considered	O
adequate	O
for	O
neurologic	B-KP
Lyme	I-KP
disease	I-KP
by	O
published	O
guidelines	O
.	O
[9,10]	O
﻿Efficacy	O
analyses	O
were	O
performed	O
using	O
all	O
randomized	O
participants	O
,	O
the	O
intent-to-treat	B-KP
(	O
ITT	B-KP
)	O
sample	O
.	O
	
Lyme	B-KP
patient	I-KP
and	O
healthy	O
controls	O
were	O
compared	O
with	O
respect	O
to	O
demographic	O
and	O
baseline	O
clinical	O
characteristics	O
,	O
using	O
t	O
tests	O
for	O
continuous	O
measures	O
and	O
χ^2	O
tests	O
for	O
categorical	O
measures	O
.	O
	
Tests	O
and	O
estimates	O
of	O
differences	O
between	O
groups	O
(	O
IV	B-KP
antibiotic	I-KP
,	O
IV	B-KP
placebo	I-KP
,	O
and	O
healthy	O
controls	O
)	O
with	O
respect	O
to	O
the	O
multivariate	O
measure	O
of	O
cognition	O
(	O
six	O
domains	O
:	O
motor	O
,	O
psychomotor	O
,	O
working	O
memory	O
,	O
attention	O
,	O
verbal	O
fluency	O
,	O
and	O
memory	O
)	O
over	O
time	O
(	O
baseline	O
,	O
week	O
12	O
,	O
and	O
week	O
24	O
)	O
were	O
based	O
on	O
longitudinal	O
mixed-effects	O
models	I-KP
(	O
LMM	O
)	I-KP
,	O
[	O
23	O
]	O
which	O
account	O
for	O
the	O
correlation	O
between	O
the	O
domains	O
and	O
between	O
the	O
repeated	O
observations	O
over	O
time	O
.	O
[	O
24	O
]	O
The	O
LMM	O
included	O
main	O
effects	O
and	O
all	O
interaction	O
terms	O
.	O
	
Time	O
was	O
modeled	O
as	O
a	O
nominal	O
factor	O
rather	O
than	O
a	O
continuous	O
variable	O
.	O
	
Including	O
all	O
two-	O
and	O
three-way	O
interactions	O
,	O
the	O
model	O
for	O
the	O
covariance	O
structure	O
was	O
selected	O
based	O
on	O
maximizing	O
Bayesian	O
information	O
criteria	O
.	O
[25,26]	O
Keeping	O
the	O
model	O
for	O
the	O
covariance	O
as	O
selected	O
,	O
stepwise	O
backward	O
elimination	O
was	O
used	O
to	O
select	O
the	O
“	O
best	O
”	O
model	O
for	O
the	O
mean	O
structure	O
.	O
	
Inference	O
regarding	O
the	O
comparison	O
between	O
the	O
groups	O
was	O
based	O
on	O
the	O
best	O
model	O
.	O
	
Significant	O
omnibus	O
tests	O
for	O
ITT	O
differences	O
among	O
the	O
three	O
groups	O
over	O
time	O
(	O
two-sided	O
α=0.05)	O
were	O
followed	O
by	O
pairwise	O
comparisons	O
;	O
the	O
p	O
values	O
for	O
these	O
post	O
hoc	O
tests	O
are	O
reported	O
unadjusted	O
.	O
	
﻿Baseline	O
lumbar	B-KP
puncture	I-KP
,	O
conducted	O
in	O
33	O
of	O
the	O
37	O
patients	O
,	O
revealed	O
few	O
abnormalities	O
:	O
mildly	O
elevated	O
WBC	B-KP
(	O
two	O
samples	O
)	O
,	O
mildly	O
elevated	O
protein	O
(	O
four	O
samples	O
)	O
,	O
and	O
elevated	O
gammaglobulin	B-KP
(	O
one	O
sample	O
)	O
.	O
	
Positive	O
results	O
werenoted	O
for	O
22	O
on	O
Lyme	B-KP
ELISA	I-KP
,	I-KP
28	O
on	O
IgG	B-KP
WB	I-KP
,	O
and	O
none	O
on	O
IgM	B-KP
WB	I-KP
.	O
For	O
intrathecal	B-KP
Ab	I-KP
production	I-KP
,	O
samples	O
tested	O
positive	O
for	O
4	O
of	O
31	O
(12.9%)	O
patients	O
;	O
each	O
positive	B-KP
intrathecal	I-KP
sample	I-KP
was	O
also	O
seropositive	O
.	O
	
No	O
patient	O
had	O
a	O
positive	O
CSF	B-KP
PCR	B-KP
.	O
When	O
cultured	O
,	O
one	O
sample	O
was	O
positive	O
for	O
growth	O
and	O
revealed	O
spirochetes	B-KP
by	O
both	O
phase	B-KP
contrast	I-KP
and	O
dark-field	B-KP
microscopy	I-KP
.	O
	
To	O
exclude	O
contamination	O
as	O
an	O
explanation	O
,	O
the	O
cells’s	O
DNA	B-KP
was	O
extracted	O
and	O
was	O
used	O
as	O
a	O
template	O
for	O
PCR	B-KP
amplification	I-KP
of	O
the	O
spoT	B-KP
gene	I-KP
.	O
	
Examination	O
of	O
the	O
PCR	B-KP
amplicon	I-KP
by	O
agarose	B-KP
gel	I-KP
electrophoresis	I-KP
revealed	O
an	O
approximately	O
3-kbp	O
band	O
,	O
whereas	O
a	O
PCR	B-KP
amplicon	I-KP
from	I-KP
wild-type	I-KP
strains	I-KP
was	O
approximately	O
2	O
kbp	O
.	O
	
Additionally	O
,	O
the	O
B	B-KP
burgdorferi	I-KP
isolated	O
from	O
the	O
CSF	B-KP
culture	I-KP
was	O
able	O
to	O
grow	O
when	O
transferred	O
into	O
BSKII	B-KP
containing	O
kanamycin	B-KP
(	O
5	O
g	O
/	O
mL)	O
plus	O
streptomycin	B-KP
(	O
100	O
g	O
/	O
mL).	O
	
These	O
results	O
strongly	O
suggest	O
that	O
the	O
B	B-KP
burgdorferi	I-KP
strain	I-KP
found	O
in	O
the	O
CSF	B-KP
culture	I-KP
was	O
the	O
result	O
of	O
contamination	O
by	O
a	O
spoT	B-KP
mutant	I-KP
strain	I-KP
(	O
WC07	B-KP
)	O
of	O
B	B-KP
burgdorferi	I-KP
containing	O
a	O
deletion	O
of	O
part	O
of	O
the	O
spoT	B-KP
gene	I-KP
plus	O
the	O
insertion	O
of	O
a	O
streptomycin	B-KP
resistance	I-KP
gene	I-KP
;	O
spoT	B-KP
mutant	I-KP
strains	I-KP
were	O
under	O
investigation	O
in	O
the	O
lab	O
at	O
the	O
time	O
of	O
the	O
culture	O
.	O
	
﻿Five	O
patients	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
adverse	O
events	O
:	O
two	O
because	O
of	O
thrombus	B-KP
(	O
both	O
on	O
drug	O
)	O
,	O
one	O
because	O
of	O
staphylococcal	B-KP
infection	I-KP
(	O
on	O
placebo	B-KP
)	O
,	O
one	O
because	O
of	O
an	O
allergic	O
reaction	O
(	O
on	O
drug	O
)	O
,	O
and	O
one	O
because	O
of	O
worsening	O
joint	O
pain	O
(	O
on	O
placebo	O
)	O
that	O
required	O
narcotic	O
pain	I-KP
medication	I-KP
.	I-KP
	
Four	O
patients	O
remained	O
in	O
the	O
study	O
despite	O
adverse	O
events	O
that	O
required	O
either	O
early	O
termination	O
of	O
study	O
medication	O
(	O
three	O
on	O
drug	O
;	O
two	O
with	O
allergic	O
reactions	O
,	O
and	O
one	O
with	O
abdominal	O
pain	O
)	O
or	O
hospitalization	O
(	O
one	O
on	O
drug	O
;	O
cholecystectomy	O
at	O
week	O
16	O
)	O
;	O
for	O
these	O
patients	O
,	O
ratings	O
at	O
weeks	O
12	O
and	O
24	O
continued	O
to	O
be	O
conducted	O
without	O
revealing	O
treatment	O
randomization	O
.	O
	
The	O
adverse	O
reactions	O
of	O
seven	O
of	O
these	O
nine	O
patients	O
were	O
thought	O
likely	O
to	O
have	O
been	O
directly	O
related	O
to	O
the	O
study	O
treatment	O
(	O
presence	O
of	O
a	O
PICC	O
line	I-KP
or	I-KP
medication	I-KP
)	I-KP
,	O
for	O
a	O
rate	O
of	O
treatment-related	O
adverse	O
events	O
of	O
6	O
of	O
23	O
(26.1%)	O
among	O
patients	O
given	O
IV	O
ceftriaxone	I-KP
and	O
1	O
of	O
14	O
(7.1%)	O
among	O
patients	O
given	O
IV	O
placebo	I-KP
;	I-KP
all	O
patients	O
recovered	O
fully	O
.	O
	
﻿Conclusions	O
from	O
this	O
study	O
are	O
mixed	O
.	O
	
At	O
the	O
primary	O
efficacy	O
end	O
point	O
of	O
week	O
12	O
,	O
IV	B-KP
ceftriaxone	I-KP
treatment	O
resulted	O
in	O
greater	O
improvement	O
in	O
cognition	O
and	O
,	O
among	O
the	O
more	O
impaired	O
,	O
in	O
physical	O
functioning	O
,	O
pain	O
,	O
and	O
fatigue	O
.	O
	
Clinical	O
significance	O
,	O
however	O
,	O
depends	O
on	O
long-term	O
effects	O
.	O
	
Notable	O
were	O
the	O
long-term	O
benefits	O
for	O
the	O
ceftriaxone	B-KP
group	I-KP
on	O
physical	O
functioning	O
and	O
pain	O
among	O
the	O
more	O
severely	O
affected	O
patients	O
at	O
baseline	O
,	O
because	O
these	O
are	O
among	O
the	O
most	O
troubling	O
aspects	O
of	O
posttreatment	B-KP
Lyme	I-KP
disease	I-KP
.	O
[	O
28	O
]	O
However	O
,	O
our	O
primary	O
interest	O
in	O
this	O
study	O
was	O
on	O
cognition	O
,	O
for	O
which	O
the	O
improvement	O
was	O
not	O
sustained	O
to	O
week	O
24	O
.	O
	
Further	O
,	O
adverse	O
effects	O
attributed	O
to	O
IV	B-KP
ceftriaxone	I-KP
occurred	O
in	O
26	O
%	O
of	O
patients	O
.	O
	
Therefore	O
,	O
considering	O
both	O
the	O
limited	O
duration	O
of	O
cognitive	O
improvement	O
and	O
the	O
risks	O
,	O
10	O
weeks	O
of	O
IV	B-KP
ceftriaxone	I-KP
and	O
then	O
14	O
weeks	O
of	O
no	O
antibiotic	B-KP
is	O
not	O
an	O
effective	O
strategy	O
for	O
sustained	O
cognitive	O
improvement	O
.	O
	
Although	O
certain	O
subgroups	O
(	O
patients	O
with	O
more	O
joint	O
or	O
neurologic	B-KP
abnormalities	I-KP
)	O
may	O
experience	O
long-term	O
benefit	O
from	O
ceftriaxone	B-KP
,	O
the	O
predictor	O
analyses	O
were	O
exploratory	O
rather	O
than	O
hypothesis	O
driven	O
,	O
and	O
they	O
require	O
independent	O
confirmation	O
.	O
	
Pending	O
such	O
confirmation	O
,	O
treatment	O
strategies	O
that	O
are	O
safer	O
and	O
more	O
durable	O
are	O
needed	O
.	O
	
﻿B	B-KP
.	I-KP
burgdorferi	I-KP
(	O
ATCC	O
B31	O
)	O
,	O
grown	O
to	O
late	O
log	O
phase	O
at	O
338C	O
in	O
BSK-H	O
medium	O
(	O
Sigma	O
,	O
St	O
.	O
	
Louis	O
,	O
Mo	O
.	O
)	O
,	O
was	O
used	O
as	O
a	O
Lyme	B-KP
antigen	I-KP
source	I-KP
.	O
	
Spirochetes	B-KP
were	O
electrophoresed	O
on	O
10	O
%	O
polyacrylamide	B-KP
gels	I-KP
by	O
using	O
the	O
discontinuous	O
buffer	O
system	O
of	O
Laemmli	O
and	O
Fayre	O
(	O
12	O
)	O
.	O
	
Separated	O
proteins	B-KP
were	O
transferred	O
to	O
nitrocellulose	B-KP
by	O
means	O
of	O
a	O
Nova	B-KP
blot	I-KP
semidry	I-KP
transfer	I-KP
system	I-KP
(	O
Pharmacia	O
,	O
Piscataway	O
,	O
N.J.).	O
	
Following	O
transfer	O
,	O
the	O
nitrocellulose	B-KP
membranes	I-KP
were	O
blocked	O
by	O
overnight	O
incubation	O
at	O
48C	O
with	O
0.5%	O
bovine	B-KP
serum	I-KP
albumin	I-KP
in	O
PBS	B-KP
.	O
Membranes	B-KP
were	O
next	O
cut	O
into	O
strips	O
,	O
dried	O
,	O
and	O
stored	O
desiccated	O
until	O
needed	O
.	O
	
Sera	O
were	O
tested	O
for	O
IgG	B-KP
and	I-KP
IgM	I-KP
antibodies	I-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
antigens	I-KP
by	O
incubating	O
rehydrated	O
strips	O
with	O
a	O
1:100	O
dilution	O
of	O
test	O
serum	O
in	O
1	O
%	O
nonfat	O
milk	O
containing	O
PBS	B-KP
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
	
The	O
strips	O
were	O
then	O
washed	O
three	O
times	O
and	O
a	O
1:1,000	O
dilution	O
of	O
biotinylated	B-KP
antiserum	I-KP
(	O
goat	O
anti-human	O
IgG	B-KP
γ	I-KP
chain	I-KP
specific	I-KP
or	O
IgM	B-KP
m	I-KP
chain	I-KP
specific	I-KP
)	O
was	O
added	O
for	O
a	O
1-h	O
incubation	O
;	O
incubation	O
was	O
followed	O
by	O
three	O
washes	O
.	O
	
Peroxidase-conjugated	B-KP
streptavidin	I-KP
(	O
diluted	O
1:1,000)	O
was	O
then	O
added	O
,	O
and	O
the	O
mixture	O
was	O
allowed	O
to	O
incubate	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
	
The	O
strips	O
were	O
then	O
washed	O
as	O
before	O
and	O
2	O
ml	O
of	O
substrate	O
solution	O
(	O
4-chloro-1-naphthol	O
)	O
was	O
added	O
.	O
	
After	O
a	O
final	O
wash	O
in	O
distilled	O
water	O
,	O
the	O
strips	O
were	O
dried	O
and	O
evaluated	O
for	O
reactivity	O
by	O
comparison	O
with	O
controls	O
.	O
	
﻿A	O
definitive	O
diagnosis	O
of	O
LNB	B-KP
requires	O
evidence	O
of	O
possible	O
exposure	O
,	O
signs	O
and	O
symptoms	O
of	O
nervous	B-KP
system	I-KP
disease	I-KP
,	O
and	O
supportive	O
laboratory	B-KP
data	I-KP
.	O
	
Because	O
LNB	B-KP
frequently	O
has	O
clinical	B-KP
overlap	I-KP
with	O
other	O
medical	O
illnesses	O
,	O
there	O
are	O
many	O
obstacles	O
and	O
pitfalls	O
to	O
securing	O
the	O
diagnosis	O
with	O
laboratory	B-KP
confirmation	I-KP
.	O
	
B	B-KP
burgdorferi	I-KP
can	O
be	O
identified	O
by	O
direct	B-KP
microscopy	I-KP
in	O
tissue	B-KP
biopsies	I-KP
,	O
electron	B-KP
microscopy	I-KP
,	O
and	O
by	O
culture	B-KP
,	O
but	O
these	O
methodologies	O
are	O
not	O
readily	O
available	O
.	O
[	O
25	O
]	O
Polymerase	B-KP
chain	I-KP
reaction	I-KP
(	O
PCR	B-KP
)	O
for	O
clinical	B-KP
samples	I-KP
has	O
had	O
a	O
low	O
sensitivity	O
for	O
blood	O
and	O
CSF	B-KP
in	O
Lyme	B-KP
disease	I-KP
but	O
has	O
been	O
useful	O
on	O
synovial	B-KP
fluid	I-KP
specimens	I-KP
in	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
.	O
[	O
8	O
,	O
25	O
]	O
﻿The	O
causative	B-KP
agent	I-KP
,	O
the	O
spirochete	B-KP
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
is	O
maintained	O
in	O
an	O
enzootic	B-KP
cycle	I-KP
with	O
vector	B-KP
ticks	I-KP
of	O
the	O
Ixodes	B-KP
ricinus	I-KP
complex	I-KP
,	O
which	O
transmit	O
the	O
spirochete	B-KP
to	O
small	O
mammals	O
.	O
	
The	O
ticks	O
occur	O
in	O
three	O
stages—larval,	O
nymphal	O
,	O
and	O
adult	O
forms—that	O
are	O
interspaced	O
by	O
metamorphosis	O
after	O
a	O
blood	O
meal	O
.	O
	
Saliva	O
,	O
through	O
which	O
B	B-KP
.	I-KP
burgdorferi	I-KP
is	O
transmitted	O
,	O
is	O
an	O
important	O
facilitator	O
for	O
ticks	O
:	O
It	O
contains	O
substances	O
with	O
a	O
locally	O
anesthetizing	O
effect	O
and	O
may	O
prevent	O
the	O
clotting	O
of	O
human	O
blood	O
,	O
which	O
enables	O
the	O
tick	O
to	O
suck	O
blood	O
from	O
superficial	O
capillaries	O
for	O
3	O
to	O
5	O
days	O
.	O
	
Although	O
tick	O
saliva	O
contains	O
antiallergic	B-KP
and	O
anti-inflammatory	B-KP
mediators	O
,	O
it	O
is	O
antigenic	B-KP
to	O
humans	O
.	O
	
Antiarthropod	B-KP
saliva	I-KP
antibodies	I-KP
can	O
be	O
measured	O
in	O
the	O
serum	O
of	O
humans	O
exposed	O
to	O
ticks	O
.	O
	
Ixodes	B-KP
scapularis	I-KP
is	O
the	O
main	O
vector	B-KP
in	O
Europe	O
and	O
the	O
eastern	O
United	O
States	O
.	O
	
In	O
a	O
recent	O
study	O
from	O
northern	O
California	O
,	O
where	O
the	O
infestation	O
of	O
ticks	O
is	O
infrequent	O
but	O
probably	O
increasing	O
,	O
measurement	O
of	O
antiarthropod	B-KP
saliva	I-KP
antibodies	I-KP
revealed	O
the	O
coexistence	O
of	O
seropositivity	B-KP
for	O
Ixodes	B-KP
pacificus	I-KP
and	O
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
confirming	O
that	O
I	B-KP
.	I-KP
pacificus	I-KP
is	O
the	O
primary	O
vector	B-KP
of	O
Lyme	B-KP
disease	I-KP
in	O
that	O
area	O
[	O
1	O
]	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
can	O
be	O
difficult	O
to	O
diagnose	O
,	O
but	O
because	O
of	O
the	O
rising	O
incidence	O
in	O
Canada	O
it	O
is	O
important	O
to	O
maintain	O
a	O
high	O
index	O
of	O
suspicion	O
.	O
	
Laboratory	O
diagnosis	O
is	O
a	O
2-step	O
process	O
.	O
[	O
5	O
]	O
In	O
this	O
case	O
,	O
the	O
emergency	O
physician	O
ordered	O
the	O
screening	O
ELISA	B-KP
(	O
enzyme-linked	B-KP
immunosorbent	I-KP
assay	I-KP
)	O
for	O
your	O
patient	O
.	O
	
If	O
the	O
ELISA	B-KP
result	O
is	O
equivocal	O
or	O
positive	O
,	O
order	O
a	O
Western	B-KP
blot	I-KP
.	O
	
A	O
positive	O
Western	O
blot	O
result	O
confirms	O
the	O
diagnosis	O
.	O
[	O
5	O
]	O
Lyme	B-KP
disease	I-KP
should	O
be	O
considered	O
in	O
any	O
patient	O
with	O
a	O
new	O
onset	O
of	O
Bell	B-KP
palsy	I-KP
.	O
	
Current	O
treatment	O
recommendations	O
for	O
early	O
disseminated	O
Lyme	B-KP
disease	I-KP
with	O
central	B-KP
nervous	I-KP
system	I-KP
involvement	O
include	O
ceftriaxone	B-KP
and	O
oxycycline	B-KP
.	O
[	O
6	O
]	O
For	O
this	O
patient	O
,	O
you	O
order	O
a	O
Western	B-KP
blot	I-KP
,	O
extend	O
his	O
prescription	O
of	O
doxycycline	B-KP
to	O
complete	O
a	O
full	O
21-day	O
course	O
,	O
arrange	O
follow-up	O
,	O
and	O
reassure	O
him	O
that	O
most	O
Lyme	B-KP
disease	I-KP
facial	B-KP
palsies	I-KP
resolve	O
.	O
	
﻿VZV	B-KP
accounted	O
for	O
33	O
%	O
of	O
cases	O
in	O
children	O
and	O
21	O
%	O
in	O
adults	O
(	O
Table	O
1	O
)	O
.	O
	
In	O
one	O
patient	O
,	O
in	O
both	O
of	O
these	O
age	O
groups	O
,	O
the	O
infection	O
was	O
complicated	O
by	O
a	O
concomitant	B-KP
HSV	B-KP
infection	I-KP
.	O
	
The	O
respective	O
numbers	O
in	O
the	O
control	O
group	O
were	O
11	O
%	O
in	O
children	O
and	O
13	O
%	O
in	O
adults	O
.	O
	
The	O
second	O
most	O
common	O
associated	O
agent	O
was	O
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
O	323,323
which	O
was	O
found	O
in	O
22	O
%	O
of	O
children	O
and	O
8	O
%	O
of	O
adults	O
(	O
6	O
%	O
and	O
none	O
in	O
controls	O
)	O
.	O
	
Together	O
,	O
VZV	B-KP
and	O
B	B-KP
.	I-KP
burgdorferi	I-KP
accounted	O
for	O
56	O
%	O
of	O
all	O
associated	O
agents	O
in	O
children	O
with	O
FP	B-KP
compared	O
with	O
11	O
%	O
in	O
controls	O
(P=0.01)	O
and	O
for	O
29	O
%	O
in	O
adults	O
with	O
FP	B-KP
compared	O
with	O
13	O
%	O
in	O
controls	O
(	O
NS	B-KP
)	O
.	O
	
In	O
all	O
,	O
VZV	B-KP
or	O
B	B-KP
.	I-KP
burgdorferi	I-KP
was	O
detected	O
in	O
41	O
%	O
of	O
patients	O
with	O
FP	B-KP
and	O
in	O
12	O
%	O
of	O
controls	O
(P=0.03).	O
	
Other	O
microbes	O
were	O
detected	O
only	O
occasionally	O
.	O
	
Treatable	O
etiologic	B-KP
agents	I-KP
accounted	O
for	O
52	O
%	O
of	O
all	O
FP	B-KP
cases	O
compared	O
with	O
26	O
%	O
of	O
controls	O
(P=0.04).	O
	
﻿VZV	B-KP
and	O
B	B-KP
.	I-KP
burgdorferi	I-KP
were	O
the	O
most	O
common	O
agents	O
associated	O
with	O
FP	B-KP
and	O
accounted	O
for	O
more	O
than	O
a	O
half	O
of	O
the	O
cases	O
in	O
children	O
and	O
for	O
one	O
third	O
in	O
adults	O
,	O
significantly	O
more	O
frequent	O
than	O
in	O
patients	O
with	O
other	O
neurological	B-KP
diseases	I-KP
.	O
	
﻿Currently	O
,	O
the	O
accuracy	O
of	O
serodiagnosis	B-KP
of	O
Lyme	B-KP
borreliosis	I-KP
is	O
limited	O
by	O
the	O
high	O
rate	O
of	O
false-positive	B-KP
enzyme	B-KP
immunoassay	I-KP
(	O
EIA	B-KP
)	O
and	O
immunofluorescence	B-KP
assay	I-KP
results	O
,	O
which	O
can	O
lead	O
to	O
overdiagnosis	B-KP
[	O
7	O
,	O
15	O
]	O
.	O
	
A	O
positive	O
or	O
equivocal	O
result	O
should	O
be	O
confirmed	O
by	O
immunoblotting	B-KP
[	O
6	O
,	O
14	O
]	O
.	O
	
Although	O
neurologic	B-KP
involvement	O
in	O
Lyme	B-KP
borreliosis	I-KP
is	O
classically	O
seen	O
after	O
several	O
weeks	O
to	O
months	O
of	O
infection	O
with	O
B	B-KP
.	I-KP
burgdorferi	I-KP
[	O
11	O
]	O
,	O
isolated	O
facial	B-KP
palsy	I-KP
has	O
been	O
reported	O
to	O
occur	O
earlier	O
,	O
at	O
times	O
concomitant	B-KP
with	O
or	O
preceding	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
)	O
[	O
5	O
,	O
10	O
]	O
.	O
	
An	O
immunoglobulin	B-KP
G	I-KP
(	O
IgG	B-KP
)	O
immunoblot	B-KP
may	O
be	O
negative	O
in	O
early	O
Lyme	B-KP
borreliosis	I-KP
[	O
6	O
]	O
.	O
	
We	O
hypothesized	O
that	O
as	O
facial	B-KP
palsy	I-KP
is	O
usually	O
an	O
early	O
manifestation	O
of	O
Lyme	B-KP
borreliosis	I-KP
,	O
a	O
diagnostic	O
IgM	B-KP
immunoblot	B-KP
will	O
be	O
observed	O
.	O
	
Recently	O
,	O
an	O
effort	O
to	O
improve	O
the	O
accuracy	O
of	O
serodiagnosis	B-KP
of	O
Lyme	B-KP
borreliosis	I-KP
was	O
undertaken	O
[	O
3	O
]	O
.	O
	
We	O
used	O
the	O
proposed	O
IgM	B-KP
immunoblot	B-KP
criteria	O
to	O
confirm	O
B	B-KP
.	I-KP
burgdorferi	I-KP
infection	O
in	O
patients	O
with	O
acute	B-KP
facial	I-KP
palsy	I-KP
.	O
	
﻿The	O
true	O
proportion	O
of	O
cases	O
of	O
facial	B-KP
palsy	I-KP
that	O
are	O
attributable	O
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
infection	O
in	O
areas	O
where	O
the	O
disease	O
is	O
endemic	B-KP
has	O
been	O
estimated	O
at	O
between	O
6	O
and	O
33	O
%	O
,	O
although	O
no	O
study	O
included	O
immunoblot	B-KP
confirmation	O
of	O
the	O
infection	O
[	O
1	O
,	O
4	O
,	O
8	O
,	O
9	O
,	O
13	O
]	O
.	O
	
Thus	O
,	O
empirical	O
antibiotic	B-KP
treatment	O
for	O
all	O
cases	O
of	O
acute	B-KP
facial	I-KP
palsy	I-KP
is	O
not	O
justifiable	O
.	O
	
Corticosteroids	B-KP
,	O
which	O
are	O
often	O
prescribed	O
for	O
idiopathic	B-KP
Bell’s	B-KP
palsy	I-KP
,	O
are	O
unwarranted	O
and	O
perhaps	O
deleterious	B-KP
in	O
cases	O
of	O
infection	O
[	O
8	O
]	O
.	O
	
There	O
are	O
often	O
no	O
clinical	O
clues	O
to	O
suggest	O
Lyme	B-KP
borreliosis	I-KP
at	O
presentation	O
,	O
and	O
the	O
palsy	B-KP
may	O
even	O
precede	O
EM	B-KP
.	O
False-positive	B-KP
EIA	B-KP
and	O
immunofluorescence	B-KP
assay	I-KP
results	O
are	O
common	O
.	O
	
﻿Neuroborreliosis	B-KP
in	O
our	O
patient	O
was	O
diagnosed	O
by	O
clinical	B-KP
symptoms	I-KP
,	O
CSF	B-KP
and	O
serum	B-KP
analysis	I-KP
.	O
	
In	O
serum	B-KP
and	O
CSF	B-KP
,	O
IgM	B-KP
was	O
positive	O
and	O
IgG	B-KP
intermediates	B-KP
for	O
B	B-KP
.	I-KP
burgdorferi	I-KP
using	O
the	O
ELISA	B-KP
and	O
immunoblot	B-KP
.	O
	
The	O
antibody	B-KP
specificity	I-KP
index	I-KP
was	O
significantly	O
positive	O
for	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
In	O
addition	O
,	O
Borrelia-IgM-CSF	B-KP
/	O
serum	B-KP
ratio	O
was	O
elevated	O
and	O
showed	O
intrathecal	B-KP
synthesis	I-KP
of	O
specific	O
antibodies	B-KP
as	O
well	O
as	O
oligoclonal-IgG	B-KP
bands	I-KP
in	O
isoelectric	B-KP
focusing	I-KP
electrophoresis	I-KP
.	O
	
These	O
results	O
strongly	O
argue	O
for	O
neuroborreliosis	B-KP
.	O
[	O
9	O
,	O
10	O
]	O
﻿Lyme	B-KP
disease	I-KP
has	O
spread	O
across	O
the	O
US	O
Pacific	O
coast	O
via	O
the	O
western	O
black-legged	B-KP
tick	I-KP
.	O
[	O
5	O
]	O
Other	O
species	O
of	O
ticks	O
found	O
in	O
the	O
United	O
States	O
have	O
not	O
been	O
shown	O
to	O
transmit	O
B	B-KP
burgdorferi	I-KP
.	O
[	O
5	O
,	O
8	O
]	O
Black-legged	B-KP
ticks	I-KP
live	O
for	O
2	O
years	O
and	O
have	O
3	O
feeding	O
stages	O
:	O
larvae	B-KP
,	O
nymph	B-KP
,	O
and	O
adult	B-KP
.	O
[	O
8	O
]	O
﻿Laboratory	O
findings	O
from	O
affected	O
patient	O
serum	B-KP
includes	O
:	O
elevated	O
erythrocyte	B-KP
sedimentation	I-KP
rate	I-KP
(	O
ESR	B-KP
)	O
,	O
cryoprecipitates	B-KP
,	O
an	O
initially	O
elevated	O
serum	B-KP
IgM	B-KP
antibody	I-KP
titer	B-KP
with	O
a	O
later	O
occurring	O
elevation	O
of	O
serum	B-KP
IgG	B-KP
antibody	I-KP
titer	B-KP
,	O
normal	O
complement	B-KP
C3	B-KP
levels	O
,	O
and	O
an	O
absence	O
of	O
rheumatoid	B-KP
factor	I-KP
or	O
antinuclear	B-KP
antibodies	B-KP
.	O
	
During	O
phases	O
of	O
remission	B-KP
,	O
the	O
ESR	B-KP
shows	O
significant	O
reduction	O
,	O
but	O
not	O
always	O
to	O
normal	O
levels	O
.	O
[	O
22	O
]	O
The	O
western	B-KP
blot	I-KP
is	O
one	O
testing	O
method	O
where	O
the	O
patient's	O
blood	O
is	O
cross-reacted	O
with	O
a	O
series	O
of	O
antigens	B-KP
that	O
are	O
derivatives	B-KP
of	O
B	B-KP
burgdorferi's	I-KP
proteins	B-KP
.	O
[	O
13	O
,	O
19	O
]	O
Other	O
effective	O
tests	O
are	O
an	O
immunoflorescent	B-KP
assay	I-KP
(	O
IFA	B-KP
titer	B-KP
)	O
or	O
an	O
enzyme	B-KP
linked	I-KP
immunoassay	I-KP
(	O
ELISA	B-KP
)	O
method	O
.	O
[	O
13	O
,	O
19	O
]	O
﻿Although	O
tick-borne	B-KP
encephalitis	I-KP
(	O
TBE	B-KP
)	O
has	O
been	O
recognized	O
in	O
Europe	O
for	O
more	O
than	O
70	O
years	O
and	O
has	O
been	O
the	O
topic	O
of	O
numerous	O
reports	O
,	O
information	O
on	O
the	O
involvement	O
of	O
facial	B-KP
nerves	I-KP
in	O
the	O
course	O
of	O
the	O
disease	O
is	O
limited	O
.	O
	
Our	O
study	O
conducted	O
at	O
a	O
single	O
medical	O
centre	O
revealed	O
that	O
facial	B-KP
nerve	I-KP
involvement	O
in	O
the	O
course	O
of	O
TBE	B-KP
in	O
Central	O
Europe	O
is	O
(	O
i	O
)	O
infrequent	O
—	O
O	369,369
it	O
was	O
found	O
in	O
only	O
11	O
of	O
12	O
[	O
18	O
]	O
(0.9%)	O
consecutive	O
adult	O
patients	O
diagnosed	O
with	O
TBE	B-KP
;	O
(	O
ii	O
)	O
manifests	O
with	O
unilateral	O
or	O
rarely	O
bilateral	O
peripheral	B-KP
facial	I-KP
palsy	I-KP
(	O
PFP	B-KP
)	O
(	O
nine	O
and	O
two	O
patients	O
,	O
respectively	O
)	O
.	O
	
﻿Serum	B-KP
samples	O
from	O
18	O
persons	O
who	O
had	O
gingivitis	B-KP
or	O
periodontitis	B-KP
but	O
no	O
history	O
of	O
Lyme	B-KP
borreliosis	I-KP
were	O
tested	O
by	O
enzyme-linked	B-KP
immunosorbent	I-KP
assay	I-KP
for	O
antibodies	B-KP
to	O
Borrelia	B-KP
burgdorferi	I-KP
.	O
	
Of	O
these	O
,	O
five	O
(	O
28	O
%	O
)	O
had	O
immunoglobulin	B-KP
M	I-KP
antibody	B-KP
and	O
four	O
(	O
22	O
%	O
)	O
contained	O
immunoglobulin	B-KP
G	I-KP
antibodies	B-KP
to	O
this	O
spirochete	B-KP
.	O
	
﻿Indirect	B-KP
fluorescent-antibody	I-KP
staining	B-KP
methods	I-KP
and	O
enzyme-linked	B-KP
immunosorbent	I-KP
assay	I-KP
(	O
ELISA	B-KP
)	O
are	O
frequently	O
relied	O
upon	O
to	O
confirm	O
Lyme	B-KP
borreliosis	I-KP
infections	O
.	O
	
These	O
antibody	B-KP
tests	O
are	O
particularly	O
useful	O
when	O
the	O
clinical	O
presentation	O
is	O
unclear	O
.	O
	
In	O
an	O
effort	O
to	O
improve	O
the	O
sensitivity	O
of	O
the	O
ELISA	B-KP
,	O
investigators	O
have	O
fractionated	O
Borrelia	B-KP
burgdorferi	I-KP
,	O
the	O
etiologic	B-KP
agent	I-KP
of	O
Lyme	B-KP
borreliosis	I-KP
,	O
and	O
have	O
coated	O
purified	O
flagellin	B-KP
or	O
flagellin-enriched	B-KP
subunits	B-KP
of	O
this	O
spirochete	B-KP
to	O
the	O
solid	O
phase	O
[	O
6	O
,	O
9	O
]	O
.	O
	
Flagellin	B-KP
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
has	O
an	O
approximate	O
molecular	O
mass	O
of	O
41,000	O
daltons	B-KP
and	O
shares	B-KP
epitopes	I-KP
with	O
similar	O
polypeptides	B-KP
extracted	O
from	O
other	O
Borrelia	B-KP
spp	I-KP
.	I-KP
and	O
from	O
Treponema	B-KP
spp	I-KP
.	I-KP
[	O
14	O
]	O
.	O
	
Antigenic	B-KP
interrelationships	O
among	O
the	O
endoflagella	B-KP
of	O
treponemes	B-KP
are	O
well	O
documented	O
[	O
5	O
]	O
.	O
	
Although	O
sera	B-KP
from	O
patients	O
with	O
Lyme	B-KP
borreliosis	I-KP
sometimes	O
show	O
reactivity	O
in	O
fluorescent	B-KP
treponemal	I-KP
antibody-absorption	O
tests	O
for	O
syphilis	B-KP
[	O
3	O
,	O
10	O
,	O
16	O
,	O
20	O
]	O
,	O
Treponema	B-KP
pallidum	I-KP
infections	O
can	O
be	O
excluded	O
serologically	B-KP
with	O
the	O
Veneral	B-KP
Disease	I-KP
Research	I-KP
Laboratory	I-KP
(	O
VDRL	B-KP
)	O
or	O
rapid	B-KP
plasma	I-KP
reagin	I-KP
card	I-KP
tests	I-KP
[	O
20	O
]	O
.	O
	
﻿Serum	B-KP
samples	I-KP
obtained	O
from	O
patients	O
who	O
had	O
gingivitis	B-KP
or	O
periodontitis	B-KP
but	O
no	O
history	O
of	O
Lyme	B-KP
borreliosis	I-KP
were	O
or	O
periodontitis	B-KP
but	O
no	O
history	O
of	O
Lyme	B-KP
borreliosis	I-KP
were	O
tested	O
for	O
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
by	O
ELISA	B-KP
.	O
Of	O
the	O
18	O
tested	O
for	O
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
by	O
ELISA	B-KP
.	O
Of	O
the	O
18	O
specimens	O
analyzed	O
,	O
5	O
(	O
28	O
%	O
)	O
had	O
detectable	O
amounts	O
of	O
IgM	B-KP
antibody	B-KP
and	O
4	O
(	O
22	O
%	O
)	O
contained	O
IgG	B-KP
antibodies	B-KP
to	O
this	O
antibody	B-KP
and	O
4	O
(	O
22	O
%	O
)	O
contained	O
IgG	B-KP
antibodies	B-KP
to	O
this	O
spirochete	B-KP
.	O
	
Titers	O
of	O
IgM	B-KP
antibody	B-KP
were	O
elevated	O
(1:2,560)	O
Titers	B-KP
of	O
IgM	B-KP
antibody	B-KP
were	O
elevated	O
(1:2,560)	O
﻿Two	O
days	O
later	O
,	O
the	O
rash	B-KP
in	O
the	O
right	O
leg	O
increased	O
in	O
size	O
.	O
	
It	O
was	O
described	O
as	O
a	O
4	O
cm	O
rash	B-KP
circular	B-KP
with	O
erythematous	B-KP
edges	I-KP
,	O
clearing	O
and	O
central	B-KP
erythema	I-KP
consistent	O
with	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
)	O
(bull’s	O
eye	I-KP
)	O
.	O
	
﻿In	O
the	O
late	O
1970s	O
,	O
Lyme	B-KP
disease	I-KP
was	O
virtually	O
unknown	O
.	O
	
Originally	O
termed	O
Lyme	B-KP
arthritis	I-KP
,	O
Lyme	B-KP
disease	I-KP
was	O
first	O
documented	O
when	O
a	O
group	O
of	O
children	O
living	O
near	O
Lyme	O
,	O
Connecticut	O
,	O
became	O
ill	O
with	O
arthritis-type	B-KP
symptoms	O
.	O
	
In	O
the	O
early	O
1980s	O
,	O
the	O
bacterial	B-KP
pathogen	I-KP
,	O
Borrelia	B-KP
burgdorferi	I-KP
sensu	O
stricto	O
species	O
complex	O
,	O
was	O
identified	O
as	O
the	O
causative	B-KP
agent	I-KP
.	O
	
﻿The	O
life	O
span	O
of	O
ticks	O
vary	O
from	O
2	O
years	O
to	O
3	O
years	O
.	O
	
Blacklegged	B-KP
ticks	I-KP
have	O
a	O
four-stage	O
life	O
cycle	O
:	O
egg	B-KP
,	O
larvae	B-KP
,	O
nymph	B-KP
,	O
and	O
adult	B-KP
.	O
	
Ticks	O
feed	O
only	O
once	O
during	O
each	O
stage	O
,	O
and	O
male	O
ticks	O
of	O
some	O
species	O
rarely	O
feed	O
and	O
never	O
engorge	O
.	O
	
Flat	O
,	O
unfed	O
ticks	O
attach	O
to	O
the	O
host	O
and	O
engorge	O
on	O
a	O
blood	O
meal	O
.	O
	
The	O
transmission	O
of	O
bacteria	O
from	O
the	O
tick	O
to	O
the	O
host	O
comes	O
from	O
the	O
saliva	O
of	O
the	O
infected	O
tick	O
and	O
is	O
disseminated	O
through	O
the	O
host’s	O
blood	O
or	O
tissue	O
to	O
other	O
locations	O
.	O
	
During	O
the	O
feeding	O
process	O
,	O
ticks	O
will	O
concentrate	O
ingested	O
blood	O
by	O
returning	O
much	O
of	O
the	O
water	O
and	O
salts	O
to	O
the	O
host	O
;	O
thus	O
,	O
alternating	O
periods	O
of	O
sucking	O
blood	O
and	O
salivation	O
with	O
regurgitation	O
occur	O
.	O
	
Once	O
the	O
infected	O
tick	O
is	O
attached	O
,	O
the	O
chances	O
of	O
transmission	O
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
increase	O
with	O
time	O
:	O
0	O
%	O
at	O
24	O
hours	O
,	O
12	O
%	O
at	O
48	O
hours	O
,	O
79	O
%	O
at	O
72	O
hours	O
,	O
and	O
94	O
%	O
at	O
96	O
hours	O
.	O
[	O
7	O
]	O
Hence	O
,	O
the	O
sooner	O
the	O
infected	O
tick	O
is	O
discovered	O
and	O
removed	O
,	O
the	O
better	O
the	O
outcome	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
is	O
recognized	O
as	O
a	O
multisystem	O
vector-borne	B-KP
disease	O
.	O
	
Changing	O
and	O
intermittent	O
signs	O
and	O
symptoms	O
may	O
make	O
diagnosis	O
difficult	O
.	O
	
Lyme	B-KP
disease	I-KP
is	O
often	O
referred	O
to	O
as	O
the	O
“	O
great	B-KP
imitator	I-KP
”	O
because	O
it	O
mimics	O
diseases	O
such	O
as	O
arthritis	B-KP
and	O
multiple	B-KP
sclerosis	I-KP
.	O
	
﻿In	O
the	O
early	O
stage	O
(	O
3	O
days	O
to	O
30	O
days	O
post	O
tick-bite	O
)	O
,	O
the	O
classic	O
sign	O
of	O
the	O
“bull’s-eye”	O
skin	O
rash	O
,	O
or	O
erythema	B-KP
migrans	I-KP
,	O
appears	O
in	O
approximately	O
70	O
%	O
to	O
80	O
%	O
of	O
patients	O
.	O
	
The	O
rash	O
may	O
be	O
warm	O
,	O
but	O
is	O
rarely	O
painful	O
or	O
itchy	O
and	O
appears	O
near	O
the	O
site	O
of	O
the	O
bite	O
.	O
	
The	O
rash	O
can	O
expand	O
gradually	O
over	O
a	O
period	O
of	O
days	O
and	O
parts	O
of	O
the	O
rash	O
will	O
clear	O
,	O
resulting	O
in	O
the	O
bull’s-eye	B-KP
appearance	O
(	O
Figure	O
1	O
)	O
.	O
	
This	O
rash	O
is	O
extremely	O
difficult	O
to	O
distinguish	O
on	O
nonwhite	O
skin	O
tones	O
;	O
thus	O
,	O
other	O
symptoms	O
should	O
be	O
considered	O
.	O
	
Additional	O
signs	O
of	O
Lyme	B-KP
disease	I-KP
include	O
:	O
fatigue	O
;	O
headache	O
;	O
fever	O
;	O
chills	O
;	O
stiff	O
neck	O
;	O
muscle	O
aches	O
;	O
pain	O
and	O
swelling	O
in	O
large	O
joints	O
,	O
such	O
as	O
knees	O
;	O
paralysis	B-KP
on	O
one	O
or	O
both	O
sides	O
of	O
the	O
face	O
;	O
and	O
enlarged	O
lymph	B-KP
nodes	I-KP
.	O
	
In	O
later	O
stages	O
,	O
the	O
nervous	B-KP
system	I-KP
and	O
heart	O
may	O
be	O
affected	O
.	O
	
﻿The	O
risk	O
of	O
human	O
infection	O
with	O
B	B-KP
burgdorferi	I-KP
is	O
determined	O
by	O
the	O
geographic	O
distribution	O
of	O
vector	B-KP
tick	I-KP
species	I-KP
,	O
local	O
factors	O
that	O
increase	O
or	O
decrease	O
tick	O
abundance	O
and	O
rates	O
of	O
infection	O
,	O
and	O
human	O
behaviors	O
that	O
affect	O
the	O
likelihood	O
of	O
being	O
bitten	O
.	O
	
In	O
the	O
Northeast	O
where	O
homes	O
are	O
often	O
situated	O
in	O
heavily	O
tick-infested	O
areas	O
,	O
exposure	O
is	O
thought	O
to	O
occur	O
primarily	O
in	O
the	O
peridomestic	O
environment	O
immediately	O
around	O
the	O
home	O
.	O
[44–47]	O
In	O
the	O
North	O
Central	O
states	O
,	O
areas	O
of	O
highest	O
risk	O
are	O
often	O
lightly	O
populated	O
[	O
48	O
]	O
;	O
infection	O
in	O
these	O
areas	O
is	O
more	O
often	O
related	O
to	O
weekend	O
travel	O
and	O
recreation	O
.	O
	
Specific	O
peridomestic	B-KP
risk	I-KP
factors	I-KP
include	O
the	O
presence	O
of	O
a	O
suitable	O
tick	O
habitat	O
,	O
landscaping	O
practices	O
that	O
enhance	O
tick	O
survival	O
(	O
eg	O
,	O
failure	O
to	O
clear	O
leaf	O
litter	O
)	O
,	O
deer	O
density	O
,	O
and	O
outdoor	O
activities	O
,	O
such	O
as	O
gardening	O
.	O
[49–53]	O
Certain	O
occupations	O
and	O
hobbies	O
also	O
increase	O
the	O
risk	O
of	O
infection	O
.	O
	
Forestry	O
workers	O
,	O
farmers	O
,	O
soldiers	O
,	O
hunters	O
,	O
hikers	O
,	O
and	O
orienteers	O
have	O
higher	O
rates	O
of	O
infection	O
in	O
studies	O
from	O
the	O
United	O
States	O
,	O
[	O
54	O
]	O
Asia	O
,	O
[55,56]	O
and	O
throughout	O
Europe	O
.	O
[57–61]	O
Animal	O
studies	O
and	O
clinical	O
observations	O
indicate	O
that	O
I	B-KP
scapularis	I-KP
ticks	I-KP
require	O
at	O
least	O
36	O
hours	O
of	O
attachment	O
in	O
order	O
to	O
transmit	O
B	B-KP
burgdorferi	I-KP
,	O
[	O
62	O
]	O
supporting	O
a	O
possible	O
preventive	O
role	O
for	O
daily	O
tick	O
checks	O
and	O
showering	O
after	O
potential	O
exposure	O
.	O
[53,63]	O
Unfortunately	O
,	O
similar	O
studies	O
have	O
demonstrated	O
that	O
I	O
ricinus	O
ticks	O
,	O
especially	O
when	O
infected	O
with	O
B	B-KP
afzelii	I-KP
,	O
can	O
transmit	O
infection	O
efficiently	O
after	O
much	O
shorter	O
periods	O
of	O
attachment	O
.	O
[	O
2	O
]	O
﻿As	O
shown	O
for	O
the	O
years	O
2010	O
to	O
2013	O
,	O
Lyme	B-KP
disease	I-KP
incidence	O
is	O
bimodal	O
with	O
respect	O
to	O
age	O
,	O
with	O
highest	O
rates	O
among	O
children	O
aged	O
5	O
to	O
15	O
years	O
and	O
adults	O
older	O
than	O
50	O
years	O
(	O
Fig	O
.	O
	
5	O
)	O
.	O
	
In	O
the	O
United	O
States	O
,	O
the	O
incidence	O
is	O
higher	O
among	O
males	O
in	O
all	O
age	O
groups	O
.	O
	
In	O
contrast	O
,	O
females	O
account	O
for	O
51	O
%	O
to	O
60	O
%	O
of	O
identified	O
cases	O
in	O
many	O
European	O
series	O
,	O
yielding	O
an	O
incidence	O
higher	O
than	O
males	O
in	O
at	O
least	O
some	O
series	O
.	O
[28,61,86,87]	O
Although	O
these	O
patterns	O
likely	O
reflect	O
behavior-related	O
differences	O
in	O
exposure	O
across	O
populations	O
,	O
age	O
and	O
sex-specific	O
differences	O
in	O
susceptibility	O
and	O
care-seeking	O
behavior	O
may	O
also	O
contribute	O
.	O
	
Over	O
time	O
,	O
the	O
US	O
incidence	O
has	O
increased	O
disproportionately	O
among	O
males	O
,	O
shifting	O
the	O
overall	O
sex	O
ratio	O
from	O
51	O
%	O
male	O
in	O
1992	O
to	O
53	O
%	O
male	O
in	O
2006	O
.	O
[	O
28	O
]	O
This	O
sex-specific	O
increase	O
has	O
been	O
most	O
pronounced	O
among	O
children	O
.	O
	
In	O
a	O
separate	O
analysis	O
of	O
US	O
data	O
for	O
2001	O
to	O
2002	O
,	O
age	O
and	O
sex	O
distribution	O
were	O
found	O
to	O
vary	O
among	O
cases	O
reported	O
in	O
endemic	B-KP
and	I-KP
nonendemic	I-KP
areas	I-KP
.	O
[	O
88	O
]	O
In	O
12	O
high-incidence	O
states	O
,	O
the	O
modal	O
age	O
for	O
cases	O
was	O
6	O
years	O
,	O
and	O
54	O
%	O
were	O
among	O
males	O
.	O
	
In	O
contrast	O
,	O
in	O
nonendemic	B-KP
states	I-KP
,	O
the	O
modal	O
age	O
was	O
44	O
years	O
,	O
and	O
47	O
%	O
were	O
among	O
males	O
.	O
	
Barring	O
fundamental	O
differences	O
in	O
risk	O
factors	O
for	O
infection	O
,	O
this	O
discrepancy	O
suggests	O
misclassification	O
(	O
ie	O
,	O
that	O
a	O
substantial	O
proportion	O
of	O
illnesses	O
reported	O
in	O
nonendemic	B-KP
areas	I-KP
are	O
actually	O
caused	O
by	O
other	O
conditions	O
)	O
.	O
	
This	O
finding	O
is	O
consistent	O
with	O
a	O
higher	O
risk	O
of	O
misdiagnosis	O
in	O
nonendemic	B-KP
areas	I-KP
,	O
a	O
consequence	O
of	O
the	O
effect	O
of	O
prior	O
probability	O
on	O
the	O
predictive	O
value	O
of	O
clinical	O
and	O
laboratory	O
findings	O
.	O
[	O
89	O
]	O
﻿Patients	O
may	O
seek	O
treatment	O
from	O
a	O
doctor	O
of	O
chiropractic	O
for	O
the	O
joint	O
pain	O
,	O
myalgias	B-KP
,	O
and	O
neurologic	B-KP
symptoms	I-KP
that	O
often	O
accompany	O
Lyme	B-KP
disease	I-KP
.	O
	
﻿Burgdorfer	O
et	O
al	O
identified	O
the	O
etiologic	B-KP
agent	I-KP
in	O
1981	O
.	O
[	O
4	O
]	O
He	O
and	O
his	O
research	O
team	O
were	O
able	O
to	O
isolate	O
spirochetal	B-KP
bacteria	I-KP
from	O
Ixodes	B-KP
dammini	I-KP
(	O
scapularis	B-KP
)	O
ticks	O
gathered	O
from	O
an	O
endemic	O
area	O
.	O
	
These	O
spirochetes	B-KP
reacted	O
with	O
immunoglobulins	B-KP
from	O
patients	O
recovering	O
from	O
Lyme	B-KP
disease	I-KP
.	O
	
﻿Lyme	B-KP
disease	I-KP
,	O
also	O
known	O
as	O
Lyme	B-KP
borreliosis	I-KP
,	O
is	O
the	O
most	O
common	O
tick-borne	B-KP
infection	I-KP
in	O
North	O
America	O
.	O
[	O
5	O
]	O
It	O
is	O
caused	O
by	O
the	O
bacterium	B-KP
Borrelia	B-KP
burgdorferi	I-KP
.	O
	
The	O
disease	O
is	O
endemic	O
in	O
the	O
Northeast	O
,	O
mid-Atlantic	O
,	O
upper	O
Midwest	O
,	O
and	O
the	O
West	O
Coast	O
in	O
northern	O
California	O
and	O
Oregon	O
.	O
	
The	O
arthropod	B-KP
vector	I-KP
in	O
the	O
Northeast	O
,	O
mid-Atlantic	O
,	O
and	O
upper	O
Midwest	O
is	O
Ixodes	B-KP
scapularis	I-KP
(	O
blacklegged	B-KP
or	O
deer	B-KP
tick	I-KP
)	O
,	O
and	O
on	O
the	O
West	O
Coast	O
,	O
Ixodes	B-KP
pacificus	I-KP
.	O
[	O
6	O
]	O
Lyme	B-KP
borreliosis	I-KP
is	O
also	O
endemic	O
in	O
Europe	O
and	O
Asia	O
,	O
although	O
the	O
arthropod	B-KP
vector	I-KP
and	O
etiologic	B-KP
agents	I-KP
differ	O
(	O
Table	O
1	O
)	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
,	O
caused	O
by	O
Borrrelia	B-KP
burgdorferi	I-KP
and	O
transmitted	O
by	O
the	O
blacklegged	B-KP
tick	I-KP
,	O
is	O
the	O
most	O
common	O
vector-borne	B-KP
disease	O
in	O
the	O
United	O
States	O
(	O
US	O
)	O
[	O
Adams	O
et	O
al	O
.	O
,	O
2016	O
]	O
.	O
	
For	O
persons	O
who	O
live	O
in	O
or	O
have	O
recently	O
travelled	O
to	O
an	O
endemic	O
area	O
,	O
diagnosis	O
can	O
be	O
made	O
based	O
on	O
erythema	B-KP
migrans	I-KP
,	O
the	O
hallmark	O
rash	O
of	O
early	O
Lyme	B-KP
disease	I-KP
[	O
Wormser	O
et	O
al	O
.	O
,	O
2006	O
]	O
.	O
	
﻿LD	B-KP
in	O
the	O
US	O
is	O
transmitted	O
by	O
the	O
Ixodes	B-KP
scapularis	I-KP
or	O
Ixodes	B-KP
Pacificus	I-KP
tick	B-KP
species	I-KP
,	O
commonly	O
known	O
as	O
the	O
black-legged	B-KP
or	O
deer	B-KP
tick	I-KP
.	O
	
﻿The	O
EM	B-KP
rash	B-KP
begins	O
anywhere	O
from	O
3	O
to	O
30	O
days	O
after	O
the	O
bite	O
occurs	O
,	O
but	O
,	O
on	O
average	O
,	O
at	O
7	O
days	O
,	O
and	O
then	O
gradually	O
expands	O
.	O
	
EM	B-KP
initially	O
appears	O
at	O
the	O
site	O
of	O
tick	O
attachment	O
but	O
may	O
appear	O
anywhere	O
on	O
the	O
body	O
as	O
the	O
disease	O
progresses	O
.	O
	
EM	B-KP
is	O
distinguishable	O
from	O
an	O
urticarial	B-KP
hypersensitivity	I-KP
response	O
to	O
the	O
tick	O
bite	O
by	O
observing	O
for	O
size	O
of	O
the	O
lesion	O
and	O
expansion	O
versus	O
regression	O
of	O
the	O
initial	O
area	O
.	O
	
﻿Ixodes	B-KP
ticks	I-KP
may	O
also	O
be	O
infected	O
with	O
human	B-KP
granulocytic	I-KP
anaplasmosis	I-KP
(	O
HGA	B-KP
)	O
and	O
babesiosis	B-KP
and	O
are	O
able	O
to	O
transmit	O
these	O
infections	O
as	O
a	O
single	O
infection	O
or	O
coinfection	O
.	O
[	O
5	O
]	O
NPs	B-KP
treating	O
patients	O
who	O
live	O
in	O
or	O
have	O
traveled	O
through	O
regions	O
with	O
a	O
high	O
LD	B-KP
incidence	O
should	O
maintain	O
a	O
high	O
degree	O
of	O
suspicion	O
and	O
undergo	O
testing	O
for	O
LD	B-KP
if	O
warranted	O
by	O
symptoms	O
.	O
	
﻿Bell’s	B-KP
palsy	I-KP
may	O
occur	O
either	O
unilaterally	O
or	O
bilaterally	O
.	O
	
Meningitis	B-KP
,	O
joint	B-KP
inflammation	I-KP
of	O
knees	O
and	O
other	O
large	O
joints	O
,	O
as	O
well	O
as	O
cardiac	B-KP
irregularities	I-KP
may	O
occur	O
.	O
	
﻿Acquired	O
unilateral	O
facial	B-KP
weakness	I-KP
is	O
most	O
commonly	O
because	O
of	O
paralysis	O
of	O
the	O
peripheral	B-KP
facial	I-KP
nerve	I-KP
.	O
	
Central	O
causes	O
,	O
although	O
rare	O
in	O
children	O
,	O
must	O
be	O
considered	O
when	O
a	O
patient	O
presents	O
with	O
sparing	O
of	O
the	O
forehead	O
musculature	O
.	O
[	O
1	O
]	O
Historically	O
,	O
the	O
most	O
commonly	O
identified	O
cause	O
of	O
an	O
acquired	O
peripheral	B-KP
facial	I-KP
palsy	I-KP
in	O
children	O
has	O
been	O
otitis	B-KP
media	I-KP
(	O
often	O
without	O
mastoiditis	B-KP
)	O
.	O
	
[	O
2	O
]	O
However	O
,	O
over	O
the	O
past	O
several	O
decades	O
the	O
prevalence	O
of	O
Borrelia	B-KP
burgdorferi	I-KP
infections	O
has	O
increased	O
significantly	O
.	O
[	O
3	O
]	O
In	O
endemic	O
areas	O
,	O
such	O
as	O
the	O
Northeastern	O
United	O
States	O
,	O
Lyme	B-KP
disease	I-KP
has	O
become	O
the	O
most	O
commonly	O
identified	O
cause	O
of	O
acquired	O
facial	B-KP
palsy	I-KP
,	O
[	O
2	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
]	O
especially	O
among	O
children	O
.	O
[	O
8	O
]	O
﻿If	O
children	O
with	O
Lyme	B-KP
disease	I-KP
facial	B-KP
palsy	I-KP
could	O
be	O
identified	O
at	O
the	O
time	O
of	O
initial	O
evaluation	O
,	O
diagnostic	O
testing	O
and	O
therapeutic	O
management	O
could	O
be	O
optimized	O
.	O
	
﻿Case	O
identification	O
was	O
conducted	O
in	O
2	O
phases	O
.	O
	
First	O
,	O
for	O
the	O
initial	O
screening	O
,	O
we	O
created	O
a	O
computer-assisted	O
key	O
word	O
screening	O
tool	O
called	O
regular-expression	O
matching	O
.	O
	
﻿In	O
Lyme	B-KP
disease–endemic	O
areas	O
,	O
children	O
frequently	O
develop	O
Borrelia	B-KP
infections	I-KP
after	O
an	O
unrecognized	O
Ixodes	B-KP
scapularis	I-KP
tick	I-KP
bite	O
.	O
‍	O
[	O
1	O
]	O
Common	O
clinical	O
manifestations	O
include	O
an	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
)	O
lesion	B-KP
,	O
facial	B-KP
palsy	I-KP
,	O
meningitis	B-KP
,	O
and	O
arthritis	B-KP
.	O
[	O
‍	O
2	O
]	O
However	O
,	O
Lyme	B-KP
“	O
mimics	O
”	O
(	O
ie	O
,	O
patients	O
with	O
clinical	O
symptoms	O
compatible	O
with	O
possible	O
Lyme	B-KP
disease	I-KP
but	O
who	O
ultimately	O
were	O
found	O
to	O
have	O
alternate	O
diagnoses	O
)	O
cause	O
initial	O
diagnostic	O
and	O
therapeutic	O
uncertainty	O
.	O
	
﻿Clinicians	O
use	O
clinical	O
prediction	O
rules	O
to	O
combine	O
available	O
demographic	O
,	O
clinical	O
,	O
and	O
laboratory	O
factors	O
to	O
estimate	O
the	O
probability	O
of	O
an	O
outcome	O
and	O
assist	O
clinical	O
decision-making	O
.	O
‍	O
[	O
3	O
]	O
Clinicians	O
also	O
use	O
prediction	O
rules	O
to	O
estimate	O
the	O
probability	O
of	O
Lyme	B-KP
disease	I-KP
for	O
children	O
presenting	O
with	O
facial	B-KP
palsy	I-KP
,	O
[	O
4	O
,	O
5	O
]	O
meningitis	B-KP
,	O
[	O
6	O
,	O
7	O
,	O
8	O
]	O
and	O
arthritis	B-KP
.	O
‍	O
[	O
9	O
]	O
﻿We	O
defined	O
a	O
case	O
of	O
Lyme	B-KP
disease	I-KP
as	O
a	O
patient	O
with	O
potential	O
exposure	O
to	O
the	O
causative	B-KP
organism	I-KP
who	O
had	O
either	O
a	O
physician-diagnosed	O
EM	B-KP
lesion	I-KP
or	O
positive	O
2-tiered	B-KP
serology	B-KP
results	O
as	O
well	O
as	O
manifestations	O
compatible	O
with	O
Lyme	B-KP
disease	I-KP
.	O
‍	O
﻿Patterns	O
of	O
spirochete	B-KP
enzootic	O
transmission	O
are	O
geographically	O
influenced	O
and	O
involve	O
both	O
smallmammal	O
reservoir	O
hosts	O
,	O
such	O
as	O
white-footed	O
mice	O
,	O
and	O
larger	O
animals	O
,	O
such	O
as	O
white-tailed	O
deer	O
,	O
which	O
are	O
critical	O
for	O
adult	O
tick	O
feeding	O
.	O
	
The	O
rising	O
incidence	O
and	O
expanding	O
distribution	O
of	O
Lyme	B-KP
disease	I-KP
in	O
the	O
United	O
States	O
are	O
probably	O
multifactorial	O
,	O
but	O
increased	O
density	O
and	O
range	O
of	O
the	O
tick	B-KP
vectors	I-KP
play	O
a	O
key	O
role	O
.	O
	
The	O
geographic	O
range	O
of	O
I	B-KP
.	I-KP
scapularis	I-KP
is	O
apparently	O
increasing	O
:	O
by	O
2015	O
,	O
it	O
had	O
been	O
detected	O
in	O
nearly	O
50	O
%	O
more	O
U.S	O
counties	O
than	O
in	O
1996	O
.	O
	
﻿Meanwhile	O
,	O
tickborne	B-KP
viral	I-KP
infections	I-KP
are	O
also	O
on	O
the	O
rise	O
and	O
could	O
cause	O
serious	O
illness	O
and	O
death	O
.	O
[	O
1	O
]	O
One	O
example	O
is	O
Powassan	B-KP
virus	I-KP
(	O
POWV	B-KP
)	O
,	O
the	O
only	O
known	O
North	O
American	O
tickborne	B-KP
encephalitis-	I-KP
causing	I-KP
flavivirus	I-KP
.	O
[	O
3	O
]	O
POWV	B-KP
was	O
recognized	O
as	O
a	O
human	B-KP
pathogen	I-KP
in	O
1958	O
after	O
being	O
isolated	O
from	O
the	O
brain	O
of	O
a	O
child	O
who	O
died	O
of	O
encephalitis	B-KP
in	O
Powassan	O
,	O
Ontario	O
.	O
	
People	O
infected	O
with	O
POWV	B-KP
often	O
have	O
a	O
febrile	B-KP
illness	I-KP
that	O
can	O
be	O
followed	O
by	O
progressive	O
and	O
severe	O
neurologic	B-KP
manifestations	I-KP
,	O
resulting	O
in	O
death	O
in	O
10	O
to	O
15	O
%	O
of	O
cases	O
and	O
long-term	O
sequelae	B-KP
in	O
50	O
to	O
70	O
%	O
of	O
survivors	O
.	O
[	O
3	O
]	O
An	O
antigenically	B-KP
similar	I-KP
virus	I-KP
,	O
POWV	B-KP
lineage	I-KP
II	I-KP
,	O
or	O
deer	B-KP
tick	I-KP
virus	I-KP
,	O
was	O
discovered	O
in	O
New	O
England	O
in	O
1997	O
.	O
	
Both	O
POWV	B-KP
subtypes	O
are	O
linked	O
to	O
human	O
disease	O
,	O
but	O
their	O
distinct	O
enzootic	B-KP
cycles	I-KP
may	O
affect	O
their	O
likelihood	O
of	O
causing	O
such	O
disease	O
.	O
	
Lineage	B-KP
II	I-KP
seems	O
to	O
be	O
maintained	O
in	O
an	O
enzootic	B-KP
cycle	I-KP
between	O
I	B-KP
.	I-KP
scapularis	I-KP
and	O
whitefooted	O
mice	O
—	O
O	931,931
which	O
may	O
portend	O
increased	O
human	O
transmission	O
,	O
because	O
I	B-KP
.	I-KP
scapularis	I-KP
is	O
the	O
primary	O
vector	B-KP
of	O
other	O
serious	O
pathogens	O
,	O
including	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
Whereas	O
only	O
20	O
U.S.	O
cases	O
of	O
POWV	B-KP
infection	O
were	O
reported	O
before	O
2006	O
,	O
[	O
3	O
]	O
99	O
were	O
reported	O
between	O
2006	O
and	O
2016	O
.	O
	
Other	O
tickborne	B-KP
encephalitis	I-KP
flaviviruses	I-KP
cause	O
thousands	O
of	O
cases	O
of	O
neuroinvasive	B-KP
illness	I-KP
in	O
Europe	O
and	O
Asia	O
each	O
year	O
,	O
despite	O
the	O
availability	O
of	O
effective	O
vaccines	O
in	O
those	O
regions	O
.	O
	
The	O
increase	O
in	O
POWV	B-KP
cases	O
coupled	O
with	O
the	O
apparent	O
expansion	O
of	O
the	O
I	B-KP
.	I-KP
scapularis	I-KP
range	O
highlight	O
the	O
need	O
for	O
increased	O
attention	O
to	O
this	O
emerging	O
virus	O
.	O
	
﻿The	O
biggest	O
gap	O
,	O
however	O
,	O
is	O
in	O
vaccines	O
:	O
there	O
are	O
no	O
licensed	O
vaccines	O
for	O
humans	O
targeting	O
any	O
U.S.	O
tickborne	B-KP
pathogen	I-KP
.	O
	
One	O
vaccine	O
that	O
was	O
previously	O
marketed	O
to	O
prevent	O
Lyme	B-KP
disease	I-KP
,	O
LYMErix	B-KP
,	O
generated	O
an	O
immune	B-KP
response	I-KP
against	O
the	O
OspA	B-KP
lipoprotein	I-KP
of	O
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
and	O
antibodies	B-KP
consumed	O
by	O
the	O
tick	O
during	O
a	O
blood	O
meal	O
targeted	O
the	O
spirochete	B-KP
in	O
the	O
vector	B-KP
.	O
[	O
5	O
]	O
Nonetheless	O
,	O
the	O
manufacturer	O
withdrew	O
LYMErix	B-KP
from	O
the	O
market	O
for	O
a	O
combination	O
of	O
reasons	O
,	O
including	O
falling	O
sales	O
,	O
liability	O
concerns	O
,	O
and	O
reports	O
suggesting	O
it	O
might	O
be	O
linked	O
to	O
autoimmune	B-KP
arthritis	I-KP
,	O
although	O
studies	O
supported	O
the	O
vaccine’s	O
safety	O
.	O
	
Similar	O
concerns	O
will	O
probably	O
affect	O
development	O
of	O
other	O
Lyme	B-KP
disease	I-KP
vaccines	I-KP
.	O
[	O
5	O
]	O
﻿Nonserologic	O
platform	O
technologies	O
may	O
also	O
improve	O
diagnostic	O
capabilities	O
,	O
particularly	O
in	O
identifying	O
emerging	O
pathogens	B-KP
.	O
	
Two	O
previously	O
unknown	O
tickborne	B-KP
RNA	I-KP
viruses	I-KP
,	O
Heartland	B-KP
virus	I-KP
and	O
Bourbon	B-KP
virus	I-KP
,	O
were	O
discovered	O
by	O
researchers	O
using	O
next-generation	O
sequencing	O
to	O
help	O
link	O
organisms	O
with	O
sets	O
of	O
unexplained	O
clinical	O
symptoms	O
.	O
	
The	O
development	O
and	O
widespread	O
implementation	O
of	O
next-generation	O
diagnostics	O
will	O
be	O
critical	O
to	O
understanding	O
the	O
driving	O
factors	O
behind	O
epidemiologic	O
trends	O
and	O
the	O
full	O
clinical	O
scope	O
of	O
tickborne	B-KP
disease	I-KP
.	O
	
In	O
addition	O
,	O
sensitive	O
,	O
specific	O
and	O
,	O
where	O
possible	O
,	O
point-of-care	O
assays	O
will	O
facilitate	O
appropriate	O
clinical	O
care	O
for	O
infected	O
persons	O
,	O
guide	O
long-term	O
preventive	O
efforts	O
,	O
and	O
aid	O
in	O
testing	O
of	O
new	O
therapeutics	O
and	O
vaccines	B-KP
.	O
	
﻿Cranial	B-KP
neuropathies	I-KP
appear	O
in	O
early	O
neuroborreliosis	B-KP
in	O
about	O
60	O
%	O
of	O
patients	O
and	O
develop	O
in	O
45	O
%	O
of	O
patients	O
in	O
late	O
neuroborreliosis	B-KP
.	O
[	O
6	O
]	O
In	O
addition	O
,	O
up	O
to	O
55	O
%	O
of	O
pediatric	O
patients	O
with	O
neuroborreliosis	B-KP
can	O
have	O
FP	B-KP
.	O
[	O
7	O
]	O
FP	B-KP
accounts	O
for	O
70	O
%	O
to	O
80	O
%	O
of	O
all	O
cranial	B-KP
nerve	I-KP
neuropathies	I-KP
in	O
early	O
LB	B-KP
[	O
6	O
]	O
and	O
for	O
about	O
one	O
third	O
of	O
the	O
cases	O
in	O
late	O
LB	B-KP
.	O
[	O
8	O
]	O
﻿Lyme	B-KP
borreliosis	I-KP
or	O
serological	B-KP
evidence	I-KP
of	O
it	O
has	O
been	O
found	O
in	O
6	O
%	O
to	O
20	O
%	O
of	O
adult	O
patients	O
with	O
FP	B-KP
.	O
[	O
9	O
,	O
10	O
,	O
11	O
]	O
The	O
incidence	O
of	O
LB	B-KP
is	O
higher	O
in	O
children	O
with	O
FP	B-KP
than	O
in	O
adults	O
with	O
FP	B-KP
.	O
In	O
studies	O
on	O
pediatric	O
FP	B-KP
,	O
as	O
many	O
as	O
two	O
thirds	O
of	O
the	O
patients	O
have	O
had	O
LB	B-KP
.	O
[	O
12	O
]	O
In	O
a	O
German	O
multicenter	O
study	O
,	O
LB	B-KP
was	O
diagnosed	O
in	O
every	O
third	O
child	O
with	O
FP	B-KP
all	O
year	O
around	O
and	O
in	O
every	O
second	O
child	O
during	O
the	O
warm	O
season	O
.	O
[	O
7	O
]	O
Thus	O
,	O
LB	B-KP
was	O
the	O
most	O
frequently	O
verifiable	O
cause	O
of	O
FP	B-KP
in	O
that	O
study	O
.	O
	
﻿Bilateral	O
occurrence	O
is	O
a	O
special	O
feature	O
of	O
the	O
FP	B-KP
caused	O
by	O
LB	B-KP
.	O
Paralysis	O
is	O
bilateral	O
in	O
18	O
%	O
to	O
25	O
%	O
of	O
the	O
FP	B-KP
patients	O
with	O
LB	O
,	O
[	O
5	O
,	O
11	O
]	O
whereas	O
the	O
prevalence	O
of	O
bilateral	O
paralysis	O
is	O
only	O
0.3%	O
to	O
2	O
%	O
in	O
Bell’s	B-KP
palsy	I-KP
.	O
[	O
13	O
]	O
In	O
the	O
current	O
prospective	O
study	O
we	O
screened	O
consecutive	O
patients	O
with	O
FP	B-KP
for	O
antibodies	B-KP
to	O
Borrelia	B-KP
burgdorferi	I-KP
and	O
for	O
symptoms	O
or	O
signs	O
related	O
to	O
LB	B-KP
.	O
We	O
analyzed	O
the	O
risk	O
factors	O
for	O
the	O
occurrence	O
of	O
LB	B-KP
among	O
the	O
FP	B-KP
patients	O
and	O
for	O
a	O
poor	O
outcome	O
of	O
FP	B-KP
.	O
Strict	O
criteria	O
were	O
applied	O
for	O
the	O
diagnosis	O
of	O
LB	B-KP
.	O
	
﻿An	O
enzyme-linked	B-KP
immunosorbent	I-KP
assay	I-KP
(	O
ELISA	B-KP
)	O
kit	O
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
that	O
uses	O
B	B-KP
.	I-KP
burgdorferi	I-KP
flagellin	B-KP
as	O
the	O
antigen	B-KP
was	O
used	O
for	O
the	O
titration	O
of	O
antibodies	B-KP
in	O
serum	B-KP
,	O
as	O
has	O
been	O
described	O
previously	O
.	O
[	O
14	O
]	O
The	O
cutoff	B-KP
titers	I-KP
for	O
serum	B-KP
immunoglobulin	B-KP
IgG	B-KP
and	O
IgM	B-KP
antibodies	B-KP
were	O
500	O
and	O
2,500,	O
respectively	O
.	O
	
These	O
cutoff	B-KP
titers	I-KP
conform	O
with	O
the	O
antibody	B-KP
level	O
3	O
standard	O
deviations	O
above	O
the	O
mean	O
of	O
a	O
reference	O
population	O
living	O
in	O
an	O
area	O
in	O
central	O
Finland	O
with	O
a	O
low	O
LB	B-KP
prevalence	O
.	O
[	O
14	O
]	O
The	O
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
in	O
the	O
CSF	B-KP
were	O
tested	O
by	O
the	O
same	O
method	O
used	O
for	O
serum	B-KP
.	O
	
The	O
cutoff	O
limits	O
for	O
both	O
the	O
IgM	B-KP
and	O
IgG	B-KP
antibodies	B-KP
in	O
CSF	B-KP
were	O
3.0	O
in	O
the	O
same	O
scale	O
as	O
applied	O
to	O
serum	B-KP
analysis	O
.	O
	
The	O
IgG	B-KP
antibody	B-KP
titer	B-KP
of	O
the	O
CSF	B-KP
was	O
divided	O
by	O
the	O
total	O
IgG	B-KP
concentration	O
in	O
the	O
CSF	B-KP
.	O
A	O
corresponding	O
ratio	O
between	O
the	O
IgG	B-KP
antibodies	B-KP
and	O
the	O
total	O
IgG	B-KP
concentration	O
in	O
the	O
serum	B-KP
was	O
also	O
calculated	O
.	O
	
If	O
the	O
calculated	O
ratio	O
of	O
the	O
CSF	B-KP
was	O
more	O
than	O
2-fold	O
higher	O
than	O
that	O
of	O
the	O
serum	B-KP
,	O
the	O
IgG	B-KP
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
in	O
the	O
CSF	B-KP
were	O
considered	O
to	O
be	O
intrathecally	O
synthesized	O
.	O
	
Routine	O
chemical	O
and	O
cytological	O
analyses	O
were	O
performed	O
on	O
the	O
CSF	B-KP
.	O
Syphilis	B-KP
was	O
ruled	O
out	O
as	O
a	O
source	O
of	O
false-positive	O
serological	O
results	O
by	O
an	O
examination	O
for	O
Treponema	B-KP
pallidum	I-KP
antibodies	B-KP
(	O
hemagglutination	B-KP
assay	I-KP
;	O
Porton	O
Cambridge	O
,	O
Newmarket	O
,	O
Great	O
Britain	O
)	O
.	O
	
﻿The	O
median	O
interval	O
between	O
the	O
onset	O
of	O
FP	B-KP
and	O
the	O
assessment	O
of	O
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
was	O
4	O
days	O
(	O
range	O
,	O
0-20	O
days	O
)	O
.	O
	
In	O
the	O
LB	B-KP
group	O
the	O
geometric	O
mean	O
levels	O
of	O
the	O
serum	O
IgM	O
and	O
IgG	O
antibodies	O
to	O
B	O
.	O
burgdorferi	O
were	O
2.3-fold	O
and	O
3.2-fold	O
higher	O
than	O
the	O
cutoff	O
limits	O
,	O
respectively	O
.	O
	
Three	O
patients	O
had	O
IgG	B-KP
antibodies	B-KP
only	O
,	O
and	O
7	O
patients	O
had	O
both	O
IgG	B-KP
and	O
IgM	B-KP
antibodies	B-KP
.	O
	
None	O
of	O
the	O
patients	O
had	O
IgM	B-KP
antibodies	B-KP
only	O
.	O
	
The	O
T	B-KP
.	I-KP
pallidum	I-KP
hemagglutination	I-KP
assay	I-KP
was	O
done	O
for	O
8	O
of	O
the	O
11	O
cases	O
,	O
and	O
it	O
was	O
negative	O
in	O
all	O
of	O
them	O
.	O
	
CSF	B-KP
specimens	O
from	O
the	O
11	O
patients	O
with	O
LB	B-KP
were	O
analyzed	O
on	O
admission	O
,	O
and	O
9	O
of	O
them	O
showed	O
abnormalities	O
.	O
	
Eight	O
(	O
73	O
%	O
)	O
were	O
positive	O
for	O
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
Five	O
patients	O
had	O
both	O
IgM	B-KP
and	O
IgG	B-KP
antibodies	B-KP
,	O
1	O
had	O
IgM	B-KP
antibodies	B-KP
only	O
(	O
IgG	B-KP
antibodies	B-KP
not	O
done	O
)	O
,	O
and	O
2	O
had	O
IgG	B-KP
antibodies	B-KP
only	O
.	O
	
The	O
geometric	O
mean	O
levels	O
of	O
the	O
IgM	B-KP
and	O
IgG	B-KP
antibodies	B-KP
were	O
46-fold	O
(	O
range	O
,	O
3.3-530)	O
and	O
24-fold	O
(	O
range	O
,	O
2.3-330)	O
higher	O
than	O
the	O
cutoff	O
limits	O
,	O
respectively	O
.	O
	
The	O
Borrelia	B-KP
PCR	B-KP
test	I-KP
was	O
carried	O
out	O
on	O
CSF	B-KP
samples	O
of	O
10	O
of	O
the	O
11	O
patients	O
and	O
the	O
sera	O
of	O
9	O
of	O
the	O
11	O
patients	O
;	O
the	O
test	O
was	O
positive	O
for	O
one	O
CSF	B-KP
sample	O
only	O
.	O
	
Five	O
(	O
45	O
%	O
)	O
of	O
the	O
patients	O
had	O
pleocytosis	B-KP
in	O
the	O
CSF	B-KP
(	O
geometric	O
mean	O
of	O
the	O
leukocyte	O
count	O
,	O
148	O
106	O
/	O
L;	O
range	O
,	O
26-560	O
106	O
/	O
L).	O
	
An	O
elevated	O
protein	O
concentration	O
(	O
mean	O
,	O
2,780	O
mg	O
/	O
L;	O
range	O
,	O
1,420-4,370	O
mg	O
/	O
L)	O
was	O
found	O
in	O
three	O
patients	O
.	O
	
﻿Two	B-KP
recent	O
systematic	O
reviews	I-KP
focused	I-KP
on	I-KP
LD	B-KP
vaccines	I-KP
that	I-KP
are	I-KP
no	O
longer	O
available	O
on	O
the	O
market	O
.	O
	
Zhao	O
et	O
al	O
.	O
(	O
2017	O
)	O
concluded	O
that	O
whilst	O
side-effects	O
were	O
rare	O
,	B-KP
further	O
research	O
on	O
efficacy	O
and	O
safety	O
was	O
needed	O
.	O
	
Badawi	O
et	O
al	O
.	O
(	O
2017	O
)	O
compared	O
monovalent	O
vaccines	O
(	O
LYMErix	O
,	I-KP
ImmuLyme	I-KP
)	I-KP
(	O
neither	O
currently	O
available	B-KP
)	O
with	O
preliminary	O
data	O
for	O
next-generation	O
multivalent	O
vaccines	O
and	B-KP
concluded	I-KP
that	O
the	O
multivalent	O
vaccine	O
was	O
slightly	O
more	O
tolerable	O
than	O
the	O
monovalent	O
one	O
,	O
which	O
in	O
turn	O
was	O
not	O
worse	O
than	O
other	B-KP
vaccines	O
in	O
the	O
USA-based	O
Vaccine	O
Adverse	O
Event	O
Reporting	O
System	O
(	O
VAERS	O
)	O
.	O
	
Despite	O
approval	O
for	O
the	O
LYMErix	O
vaccine	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
,	O
the	O
LYMErix	O
vaccine	O
was	O
voluntarily	O
withdrawn	O
from	O
the	O
market	O
,	O
in	O
2002	O
,	O
due	O
to	O
poor	O
sales	O
.	O
	
The	O
replacement	O
of	O
monovalent	O
vaccines	O
with	O
vaccines	O
that	O
have	O
a	O
similar	O
approach	O
may	O
,	O
therefore	O
,	O
not	O
be	O
the	O
best	O
method	O
for	O
new	O
vaccine	O
development	O
(	O
Badawi	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
	
Only	O
one	O
review	O
examined	O
the	O
effect	O
of	O
antibiotic	O
prophylaxis	O
(	O
after	O
a	O
bite	O
)	O
.	O
	
In	O
this	O
review	O
,	O
Warshafsky	O
et	O
al	O
.	O
(	O
2010	O
)	O
concluded	O
that	O
pooled	O
data	O
from	O
four	O
placebo-controlled	O
trials	O
supported	O
the	O
use	O
of	O
antibiotic	O
prophylaxis	O
in	O
endemic	O
areas	O
.	O
	
﻿Two	O
matched	O
case-control	O
studies	O
sampled	O
participants	O
with	O
and	O
without	O
LD	B-KP
(	O
Connally	O
et	O
al	O
.	O
,	O
2009	O
;	O
Vazquez	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
	
Findings	O
showed	O
that	O
the	O
use	O
of	O
tick	O
repellents	O
on	O
skin	O
or	O
clothing	O
was	O
associated	O
with	O
lower	O
rates	O
of	O
LD	B-KP
(	O
adjusted9	O
OR	O
0.8,	O
95	O
%	O
CI	O
0.6	O
to	O
0.9	O
for	O
Vazquez	O
et	O
al	O
.	O
,	O
2008	O
;	O
OR	O
0.71,	O
95	O
%	O
CI	O
0.49	O
to	O
1.02,	O
p	O
<	O
0.1	O
for	O
Connally	O
et	O
al	O
.	O
(	O
2009	O
)	O
.	O
	
Similarly	O
,	O
Vazquez	O
et	O
al	O
.	O
(	O
2008	O
)	O
showed	O
that	O
wearing	O
protective	O
clothes	O
was	O
effective	O
(	O
adjusted	O
OR	O
0.6,	O
95	O
%	O
CI	O
0.5	O
to	O
0.7).	O
	
Connally	O
et	O
al	O
.	O
(	O
2009	O
)	O
(	O
p	O
>	O
0.20)	O
reported	O
that	O
wearing	O
light-coloured	O
clothes	O
(	O
cases	O
88	O
%	O
v	O
controls	O
90	O
%	O
)	O
and	O
long	O
trousers	O
(	O
cases	O
65	O
%	O
v	O
controls	O
70	O
%	O
)	O
were	O
less	O
common	O
among	O
people	O
diagnosed	O
with	O
LD	B-KP
,	O
compared	O
with	O
controls	O
,	O
but	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
	
The	O
evidence	O
was	O
mixed	O
for	O
tick	O
checking	O
;	O
being	O
identified	O
as	O
preventative	O
in	O
Connally	O
et	O
al	O
.	O
(	O
2009	O
)	O
(	O
OR	O
0.64,	O
95	O
%	O
CI	O
0.43	O
to	O
0.94),	O
but	O
not	O
in	O
Vazquez	O
et	O
al	O
.	O
(	O
2008	O
)	O
(	O
OR	O
1.1,	O
95	O
%	O
CI	O
0.8	O
to	O
1.4,	O
NS	O
)	O
.	O
	
Connally	O
et	O
al	O
.	O
(	O
2009	O
)	O
additionally	O
showed	O
that	O
bathing	O
within	O
2	O
h	O
of	O
being	O
outside	O
in	O
the	O
garden	O
may	O
prevent	O
LD	B-KP
(	O
OR	O
0.60,	O
95	O
%	O
CI	O
0.38	O
to	O
0.96,	O
p	O
<	O
0.05).	O
	
﻿Low-quality	O
evidence	O
suggested	O
that	O
permethrin-treated	B-KP
(	O
vs	O
.	O
	
untreated	O
)	O
battle	O
uniform	O
[	O
Faulde	O
et	O
al	O
.	O
,	O
2015	O
]	O
and	O
Citriodiol	B-KP
insect	B-KP
repellent	I-KP
[	O
Gardulf	O
et	O
al	O
.	O
,	O
2004	O
]	O
may	O
reduce	O
the	O
frequency	O
of	O
tick	O
bites	O
.	O
[	O
Faulde	O
et	O
al	O
.	O
(2015)'s]	O
historical	O
controlled	O
study	O
showed	O
that	O
in	O
2009	O
,	O
tick	O
bite	O
incidence	O
was	O
39.3	O
with	O
262	O
bites	O
in	O
66,679	O
exposure	O
days	O
,	O
whilst	O
in	O
2010	O
(	O
when	O
the	O
treated	O
uniform	O
was	O
worn	O
)	O
the	O
incidence	O
was	O
0.16	O
with	O
53	O
bites	O
in	O
63,571	O
exposure	O
days	O
(	O
representing	O
a	O
99.6%	O
reduction	O
)	O
.	O
	
The	O
same	O
pattern	O
of	O
findings	O
was	O
reported	O
in	O
2011	O
(	O
representing	O
a	O
98.6%	O
reduction	O
)	O
.	O
	
In	O
[	O
Gardulf	O
et	O
al	O
.	O
(2004)'s]	O
crossover	O
RCT	B-KP
,	O
lemon	B-KP
eucalyptus	I-KP
extract	I-KP
(	O
Citriodiol10	B-KP
)	O
was	O
self-applied	O
to	O
participants	O
'	O
legs	O
.	O
	
Overall	O
,	O
there	O
were	O
fewer	O
tick	O
bites	O
per	O
person	O
with	O
the	O
spray	O
compared	O
with	O
no	O
spray	O
,	O
(	O
median	O
0.5,	O
range	O
0	O
to	O
2	O
with	O
;	O
median	O
1.5,	O
range	O
0	O
to	O
9	O
without	O
;	O
z−2.02,	O
p	O
<	O
0.05)	O
and	O
fewer	O
ticks	O
,	O
that	O
were	O
crawling	O
(	O
not	O
attached	O
)	O
(	O
median	O
3.5,	O
range	O
1	O
to	O
13	O
with	O
;	O
median	O
4.0,	O
range	O
1	O
to	O
20	O
without	O
;	O
NS	O
)	O
.	O
	
﻿Two	O
RCTs	B-KP
[	O
Wressnigg	O
et	O
al	O
.	O
,	O
2014	O
;	O
Wressnigg	O
et	O
al	O
.	O
,	O
2013	O
]	O
assessed	O
the	O
immunogenicity	O
of	O
a	O
new	O
multivalent	B-KP
vaccine	I-KP
for	O
preventing	O
LD	B-KP
.	O
[	O
Wressnigg	O
et	O
al	O
.	O
(	O
2013	O
)	O
]	O
found	O
that	O
whilst	O
all	O
doses	O
(	O
30	O
,	O
60	O
or	O
90	O
μg	O
)	O
,	O
given	O
on	O
three	O
occasions	O
28	O
days	O
apart	O
,	O
and	O
formulations	O
(	O
with	O
or	O
without	O
an	O
adjuvant	O
to	O
enhance	O
the	O
effect13	O
)	O
produced	O
a	O
positive	O
response	O
,	O
the	O
90	O
μg	O
non-adjuvanted	O
formulation	O
produced	O
the	O
highest	O
response	O
after	O
the	O
first	O
three	O
vaccinations	O
.	O
	
However	O
,	O
after	O
a	O
booster	O
(	O
9	O
to	O
12	O
months	O
later	O
)	O
,	O
the	O
30	O
μg	O
adjuvanted	B-KP
dose	I-KP
was	O
most	O
effective	O
.	O
[	O
Wressnigg	O
et	O
al	O
.	O
(	O
2014	O
)	O
]	O
compared	O
healthy	O
people	O
who	O
were	O
either	O
seropositive	O
[	O
14	O
]	O
or	O
seronegative	O
[	O
15	O
]	O
for	O
LD	O
.	O
Participants	O
received	O
three	O
doses	O
(	O
30	O
or	O
60	O
μg	O
of	O
vaccine	O
with	O
aluminium	B-KP
hydroxide	I-KP
adjuvant	I-KP
)	O
28	O
days	O
apart	O
,	O
with	O
a	O
booster	O
at	O
6	O
months	O
or	O
9	O
to	O
12	O
months	O
.	O
	
In	O
seronegative	B-KP
people	I-KP
,	O
the	O
antibody	O
responses	O
induced	O
by	O
the	O
dose	O
formulations	O
were	O
similar	O
(p=0.062;	O
range	O
for	O
30	O
μg	O
,	O
3799	O
to	O
6937	O
,	O
for	O
60	O
μg	O
,	O
4575	O
to	O
8543	O
)	O
.	O
	
In	O
seropositive	B-KP
people	I-KP
,	O
the	O
60	O
μg	O
dose	O
(	O
range	O
,	O
4895	O
to	O
9435	O
)	O
resulted	O
in	O
significantly	O
higher	O
antibody	O
response	O
than	O
the	O
30	O
μg	O
dose	O
(	O
range	O
,	O
2413	O
to	O
4371	O
;	O
p=0.0001).	O
	
The	O
booster	O
response	O
was	O
effective	O
at	O
both	O
time	O
points	O
,	O
but	O
more	O
so	O
when	O
administered	O
at	O
9	O
to	O
12	O
months	O
.	O
	
However	O
,	O
there	O
was	O
a	O
dose	O
effect	O
among	O
seropositive	B-KP
participants	I-KP
favouring	O
the	O
higher	O
(	O
60	O
μg	O
)	O
dose	O
(p=0.0359;	O
for	O
five	O
[	O
16	O
]	O
of	O
the	O
six	O
serotypes	O
,	O
(	O
range	O
28,735	O
to	O
42,381),	O
over	O
the	O
30	O
μg	O
dose	O
(	O
range	O
12,653	O
to	O
17,485).	O
	
[	O
17	O
]	O
﻿Over	O
the	O
study	O
period	O
,	O
932	O
LB	B-KP
cases	O
were	O
reported	O
by	O
SGPs	B-KP
of	O
which	O
,	O
265	O
were	O
excluded	O
by	O
the	O
expert	O
group	O
for	O
the	O
following	O
reasons	O
:	O
did	O
not	O
meet	O
the	O
case	O
definition	O
(	O
n	O
=	O
61	O
)	O
,	O
clinical	O
manifestation	O
not	O
described	O
(	O
n	O
=	O
146	O
)	O
,	O
absence	O
of	O
serology	O
confirmation	O
for	O
disseminated	O
LB	O
(	O
n	O
=	O
44	O
)	O
,	O
no	O
lumbar	O
puncture	O
for	O
neurological	O
manifestations	O
,	O
except	O
for	O
meningoradiculitis	B-KP
or	O
unilateral	B-KP
facial	I-KP
paralysis	I-KP
(	O
n	O
=	O
14	O
)	O
.	O
	
A	O
total	O
of	O
667	O
LB	B-KP
cases	O
were	O
included	O
(	O
94	O
in	O
2011	O
,	O
85	O
in	O
2012	O
,	O
113	O
in	O
2013	O
,	O
76	O
in	O
2014	O
,	O
105	O
in	O
2015	O
and	O
194	O
in	O
2016	O
)	O
.	O
	
﻿Of	O
667	O
diagnoses	O
,	O
633	O
were	O
EM	B-KP
diagnoses	O
(	O
95	O
%	O
)	O
,	O
591	O
(	O
96	O
%	O
)	O
were	O
solitary	B-KP
lesions	I-KP
,	O
465	O
(	O
75	O
%	O
)	O
were	O
equal	O
or	O
greater	O
than	O
5	O
cm	O
,	O
537	O
(	O
94	O
%	O
)	O
had	O
a	O
centrifugal	O
extension	O
and	O
393	O
(	O
68	O
%	O
)	O
had	O
a	O
central	O
clearing	O
(	O
Table	O
2	O
)	O
.	O
	
A	O
total	O
of	O
34	O
cases	O
presented	O
with	O
disseminated	O
LB	B-KP
(	O
5	O
%	O
)	O
,	O
corresponding	O
to	O
arthritis	B-KP
(	O
n	O
=	O
17	O
)	O
,	O
acrodermatitis	B-KP
(	O
n	O
=	O
6	O
)	O
,	O
lymphocytoma	B-KP
(	O
n	O
=	O
4	O
)	O
,	O
radiculitis	B-KP
(	O
n	O
=	O
4	O
)	O
,	O
facial	B-KP
paralysis	I-KP
(	O
n	O
=	O
2	O
)	O
and	O
both	O
meningoradiculitis	B-KP
and	O
radiculitis	B-KP
(	O
n	O
=	O
1	O
)	O
.	O
	
﻿Among	O
LNB	B-KP
hospitalised	O
cases	O
,	O
37	O
%	O
presented	O
facial	B-KP
nerve	I-KP
disorders	I-KP
(	O
including	O
27	O
%	O
with	O
unilateral	B-KP
facial	I-KP
nerve	I-KP
paralysis	I-KP
)	O
,	O
35	O
%	O
had	O
meningitis	B-KP
,	O
9	O
%	O
polyneuropathy	B-KP
and	O
9	O
%	O
encephalitis	B-KP
,	O
myelitis	B-KP
or	O
encephalomyelitis	B-KP
.	O
	
HIR	B-KP
of	O
LNB	B-KP
show	O
a	O
bimodal	O
distribution	O
of	O
age	O
with	O
a	O
first	O
peak	O
occurring	O
in	O
children	O
aged	O
5–9	O
years	O
old	O
(1.3	O
/	O
100,000	O
of	O
the	O
age	O
group	O
)	O
and	O
a	O
second	O
peak	O
in	O
adults	O
70–79	O
years	O
old	O
(1.3	O
cases	O
/	O
100,000	O
of	O
the	O
age	O
group	O
)	O
.	O
	
The	O
proportion	O
of	O
hospitalised	O
cases	O
with	O
LNB	O
differed	O
significantly	O
by	O
age	O
(	O
Figure	O
5	O
)	O
.	O
	
Among	O
hospitalised	O
cases	O
,	O
those	O
age	O
5–9	O
and	O
70–79	O
years	O
old	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
had	O
LNB	B-KP
compared	O
with	O
other	O
age	O
groups	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
:	O
3.02;	O
95	O
%	O
CI	O
:	O
2.41–	O
3.78	O
and	O
OR	O
:	O
1.94;	O
95	O
%	O
CI	O
:	O
1.58–2.39,	O
respectively	O
)	O
.	O
	
﻿The	O
vector	B-KP
,	O
the	O
tick	O
Ixodes	B-KP
ricinus	I-KP
is	O
present	O
in	O
most	O
parts	O
of	O
mainland	O
France	O
,	O
except	O
above	O
1,200	O
m	O
and	O
in	O
the	O
dry	O
Mediterranean	O
areas	O
[	O
36	O
]	O
.	O
	
Ixodes	B-KP
ricinus	I-KP
ticks	O
,	O
the	O
primary	O
vector	O
in	O
Europe	O
,	O
are	O
usually	O
found	O
in	O
vegetation	O
types	O
with	O
deciduous	O
or	O
mixed	O
woodland	O
that	O
maintain	O
high	O
humidity	O
(	O
requiring	O
a	O
relative	O
humidity	O
of	O
at	O
least	O
80	O
%	O
)	O
and	O
in	O
areas	O
of	O
moderate	O
to	O
high	O
rainfall	O
,	O
such	O
as	O
in	O
eastern	O
and	O
central	O
regions	O
of	O
mainland	O
France	O
[4,36-38]	O
.	O
	
Since	O
infection	O
is	O
correlated	O
with	O
tick	O
abundance	O
and	O
human	O
to	O
tick	O
exposure	O
,	O
this	O
variability	O
in	O
incidence	O
rates	O
could	O
be	O
explained	O
by	O
differences	O
in	O
geographical	O
and	O
climate	O
characteristics	O
,	O
in	O
types	O
of	O
exposure	O
(	O
recreational	O
and	O
occupational	O
exposure	O
to	O
ticks	O
and	O
outdoor	O
activities	O
)	O
and	O
presence	O
of	O
competent	O
reservoir	O
hosts	O
.	O
	
Tick	O
nymphs	B-KP
are	O
mainly	O
responsible	O
for	O
transmitting	O
Borrelia	B-KP
to	O
humans	O
and	O
quest	O
most	O
actively	O
from	O
spring	O
to	O
autumn	O
[4,36,37]	O
.	O
	
Diagnoses	O
of	O
acute	O
LB	B-KP
peak	O
in	O
summer	O
in	O
many	O
northern	O
and	O
central	O
countries	O
of	O
Europe	O
[	O
4	O
]	O
.	O
	
These	O
findings	O
were	O
also	O
confirmed	O
in	O
our	O
study	O
with	O
higher	O
incidences	O
of	O
LB	B-KP
from	O
July	O
to	O
September	O
.	O
	
﻿Lichen	B-KP
sclerosus	I-KP
(	O
LS	B-KP
)	O
is	O
a	O
chronic	O
mucocutaneous	B-KP
inflammatory	I-KP
disorder	I-KP
that	O
most	O
commonly	O
affects	O
the	O
anogenital	B-KP
skin	I-KP
and	O
occurs	O
more	O
frequently	O
in	O
females	O
than	O
in	O
males	O
.	O
[	O
1	O
]	O
Clinically	O
,	O
it	O
presents	O
as	O
white	O
,	O
sometimes	O
painful	O
,	O
pruritic	B-KP
papules	I-KP
or	O
plaques	B-KP
.	O
	
Despite	O
its	O
predilection	O
for	O
the	O
anogenital	B-KP
regions	I-KP
the	O
condition	O
can	O
occur	O
throughout	O
the	O
body	O
,	O
although	O
lesions	O
of	O
the	O
oral	O
mucosa	O
are	O
exceedingly	O
rare	O
and	O
those	O
involving	O
the	O
gingiva	O
are	O
even	O
more	O
so	O
.	O
[2,3]	O
In	O
the	O
oral	B-KP
mucosa	I-KP
LS	I-KP
is	O
seen	O
typically	O
in	O
middle-aged	O
females	O
,	O
the	O
most	O
common	O
sites	O
being	O
the	O
lower	O
lip	O
,	O
buccal	O
mucosa	O
and	O
upper	O
lip	O
.	O
[	O
2	O
]	O
An	O
increased	O
risk	O
of	O
genital	B-KP
squamous	I-KP
cell	I-KP
carcinoma	I-KP
(	O
SCC	B-KP
)	O
has	O
been	O
documented	O
in	O
genital	B-KP
LS	I-KP
,	O
thus	O
resulting	O
in	O
an	O
increased	O
need	O
for	O
close	O
follow-up	O
and	O
management	O
of	O
affected	O
patients	O
.	O
[1,2]	O
Malignancy	O
involving	O
oral	O
cases	O
of	O
LS	B-KP
,	O
however	O
,	O
has	O
not	O
been	O
reported	O
.	O
[	O
2	O
]	O
First-line	O
treatment	O
of	O
LS	B-KP
typically	O
involves	O
the	O
use	O
of	O
topical	B-KP
corticosteroids	I-KP
;	O
nevertheless	O
,	O
the	O
condition	O
is	O
not	O
cured	O
and	O
remissions	O
do	O
not	O
usually	O
occur	O
.	O
[	O
1	O
]	O
﻿The	O
underlying	O
aetiology	O
of	O
LS	B-KP
remains	O
unidentified	O
;	O
however	O
,	O
several	O
possible	O
causes	O
have	O
been	O
suggested	O
,	O
ranging	O
from	O
chronic	O
irritation	O
to	O
an	O
autoimmune	O
component	O
,	O
as	O
well	O
as	O
infectious	O
causes	O
.	O
[	O
1	O
]	O
Infection	O
with	O
Borrelia	B-KP
burgdorferi	I-KP
,	O
the	O
causative	B-KP
organism	I-KP
of	O
Lyme	B-KP
disease	I-KP
,	O
has	O
been	O
proposed	O
as	O
a	O
possible	O
aetiology	B-KP
,	O
due	O
to	O
a	O
similarity	O
in	O
their	O
histological	O
features	O
and	O
the	O
identification	O
of	O
Borrelia	B-KP
organisms	I-KP
in	O
some	O
cases	O
of	O
LS	O
.	O
[	O
4	O
]	O
Evidence	O
of	O
this	O
association	O
has	O
remained	O
conflicting	O
over	O
the	O
years	O
,	O
due	O
in	O
part	O
to	O
the	O
overall	O
lack	O
of	O
consistency	O
in	O
identifying	O
Borrelia	B-KP
in	O
many	O
LS	B-KP
cases	O
and	O
in	O
general	O
.	O
[1,5,6]	O
Furthermore	O
,	O
LS	B-KP
does	O
not	O
appear	O
to	O
have	O
predominantly	O
infectious	O
characteristics	O
,	O
as	O
there	O
has	O
been	O
only	O
a	O
single	O
case	O
report	O
of	O
LS	B-KP
occurring	O
in	O
sexual	O
partners	O
.	O
[	O
5	O
]	O
This	O
does	O
not	O
,	O
however	O
,	O
discount	O
the	O
possibility	O
that	O
LS	B-KP
is	O
a	O
reactive	O
process	O
occurring	O
in	O
Borrelia-infected	B-KP
skin	I-KP
or	O
soft	B-KP
tissue	I-KP
.	O
	
It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
various	O
instances	O
of	O
Borrelia	B-KP
involvement	O
of	O
LS	O
have	O
all	O
been	O
reported	O
in	O
European	O
cases	O
,	O
with	O
no	O
previous	O
cases	O
reported	O
in	O
the	O
United	O
States	O
.	O
[	O
1	O
]	O
While	O
spirochaetal	B-KP
forms	I-KP
have	O
been	O
observed	O
histologically	O
in	O
US	O
cases	O
of	O
LS	B-KP
,	O
further	O
identification	O
of	O
these	O
organisms	O
as	O
Borrelia	B-KP
has	O
not	O
been	O
demonstrated	O
by	O
serology	B-KP
,	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
(	O
PCR	B-KP
)	O
,	O
culture	B-KP
or	O
immunohistochemistry	B-KP
.	O
[	O
7	O
]	O
This	O
regional	O
difference	O
may	O
be	O
explained	O
by	O
the	O
variation	O
in	O
the	O
geographical	O
distribution	O
of	O
different	O
genotypic	B-KP
species	I-KP
of	O
Borrelia	B-KP
,	O
with	O
disease	O
in	O
North	O
America	O
associated	O
with	O
a	O
single	O
type	O
and	O
European	O
cases	O
being	O
linked	O
to	O
multiple	O
genetically	O
distinct	O
strains	O
.	O
[	O
7	O
]	O
﻿The	O
typical	O
course	O
of	O
LS	B-KP
is	O
a	O
lifelong	O
chronic	O
condition	O
that	O
may	O
relapse	O
and	O
remit	O
or	O
may	O
lead	O
to	O
scarring	O
and	O
anatomical	O
defects	O
,	O
with	O
SCC	B-KP
being	O
a	O
more	O
ominous	O
but	O
less	O
likely	O
complication	O
of	O
genital	B-KP
LS	I-KP
.	O
[	O
1	O
]	O
Treatment	O
usually	O
involves	O
topical	B-KP
corticosteroids	I-KP
,	O
calcineurin	B-KP
inhibitors	I-KP
,	O
retinoids	B-KP
,	O
moisturizers	B-KP
and	O
long-term	O
surveillance	O
for	O
the	O
development	O
of	O
carcinoma	B-KP
.	O
[	O
1	O
]	O
Antibiotics	O
are	O
used	O
typically	O
to	O
treat	O
associated	O
infections	O
that	O
may	O
develop	O
;	O
however	O
,	O
due	O
to	O
the	O
possible	O
role	O
of	O
Borrelia	B-KP
involvement	O
,	O
the	O
question	O
is	O
raised	O
as	O
to	O
whether	O
antibiotics	O
may	O
be	O
useful	O
as	O
a	O
supplemental	O
modality	O
,	O
as	O
there	O
are	O
reports	O
of	O
LS	B-KP
treated	O
with	O
antibiotics	O
with	O
favourable	O
outcomes	O
.	O
[	O
9	O
]	O
Additional	O
clinical	O
trials	O
to	O
evaluate	O
this	O
further	O
may	O
be	O
warranted	O
.	O
	
There	O
are	O
approximately	O
27	O
reported	O
cases	O
of	O
oral	B-KP
LS	I-KP
with	O
histological	O
confirmation	O
and	O
eight	O
cases	O
involving	O
the	O
gingiva	B-KP
,	O
[	O
2	O
]	O
making	O
this	O
the	O
28th	O
oral	O
case	O
and	O
the	O
ninth	O
with	O
gingival	O
involvement	O
.	O
	
It	O
also	O
appears	O
to	O
be	O
the	O
first	O
case	O
of	O
oral	B-KP
LS	I-KP
with	O
Borrelia	B-KP
involvement	O
identified	O
by	O
FFM	B-KP
reported	O
in	O
the	O
United	O
States	O
.	O
[1,7]	O
﻿These	O
exclusions	O
left	O
373	O
persons	O
the	O
reporting	O
physician	O
thought	O
had	O
Lyme	B-KP
disease	I-KP
.	O
	
Ninety	O
did	O
not	O
meet	O
CDC's	B-KP
case	O
definition	O
(	O
7	O
)	O
and	O
were	O
excluded	O
from	O
analysis	O
.	O
	
The	O
reasons	O
for	O
exclusion	O
were	O
32	O
had	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
)	O
less	O
than	O
5	O
centimeters	O
(	O
cm	O
)	O
in	O
size	O
;	O
23	O
,	O
flu-like	O
symptoms	O
and	O
positive	O
serology	O
;	O
18	O
,	O
incomplete	O
information	O
;	O
9	O
,	O
arthralgia	B-KP
(	O
that	O
is	O
,	O
no	O
reported	O
joint	O
swelling	O
)	O
and	O
positive	O
serology	O
;	O
and	O
8	O
,	O
only	O
tick	O
bite	O
with	O
or	O
without	O
positive	O
serology	O
.	O
	
The	O
90	O
not	O
meeting	O
the	O
case	O
definition	O
were	O
treated	O
,	O
usually	O
with	O
oral	B-KP
doxycycline	I-KP
or	O
tetracycline	B-KP
.	O
	
﻿Of	O
the	O
283	O
patients	O
meeting	O
CDC's	B-KP
criteria	O
for	O
Lyme	B-KP
disease	I-KP
,	O
169	O
(59.7	O
percent	O
)	O
were	O
reported	O
to	O
have	O
EM	B-KP
;	O
65	O
with	O
and	O
104	O
without	O
arthritic	B-KP
,	O
neuro-	B-KP
logic	I-KP
,	O
or	O
cardiac	B-KP
manifestations	I-KP
(	O
see	O
figure	O
)	O
.	O
	
Of	O
the	O
remaining	O
114	O
(40.3	O
percent	O
)	O
,	O
101	O
complained	O
of	O
arthritic	B-KP
,	O
16	O
of	O
neurologic	B-KP
,	O
and	O
4	O
of	O
cardiac	B-KP
symptoms	I-KP
without	O
having	O
the	O
characteristic	B-KP
rash	I-KP
.	O
(	O
Although	O
the	O
physicians	O
were	O
to	O
report	O
only	O
observed	O
rashes	O
,	O
it	O
was	O
obvious	O
that	O
patient	O
descriptions	O
of	O
prior	O
EM	B-KP
influenced	O
diagnostic	O
decisions	O
and	O
were	O
often	O
included	O
in	O
the	O
Lyme	B-KP
disease	I-KP
case	O
report	O
forms	O
.	O
)	O
﻿More	O
than	O
half	O
the	O
subjects	O
(	O
154	O
or	O
54.4	O
percent	O
)	O
had	O
joint	O
complaints	O
.	O
	
Ninety-four	O
(33.2	O
percent	O
)	O
had	O
only	O
arthritis	O
as	O
a	O
complaint	O
,	O
and	O
arthritis	O
occurred	O
more	O
frequently	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.6;	O
confidence	O
interval	O
[	O
CI	O
]	O
0.9-2.7;	O
P=0.09)	O
in	O
females	O
(	O
57	O
of	O
139	O
or	O
41.0	O
percent	O
)	O
than	O
in	O
males	O
(	O
44	O
of	O
144	O
or	O
30.6	O
percent	O
)	O
.	O
	
Neurological	B-KP
abnormalities	I-KP
were	O
present	O
in	O
27	O
subjects	O
and	O
included	O
a	O
combination	O
of	O
the	O
following	O
:	O
17	O
had	O
facial	B-KP
palsy	I-KP
;	O
7	O
,	O
lymphocytic	B-KP
meningitis	I-KP
;	O
6	O
,	O
peripheral	B-KP
radiculitis	I-KP
;	O
and	O
2	O
,	O
en-	B-KP
cephalitis	I-KP
.	O
	
Eleven	O
had	O
neurological	O
findings	O
in	O
either	O
the	O
presence	O
of	O
,	O
or	O
documented	O
history	O
of	O
,	O
EM	B-KP
while	O
16	O
did	O
not	O
.	O
	
Five	O
also	O
had	O
arthritis	O
.	O
	
The	O
most	O
common	O
neurological	O
presentation	O
was	O
facial	B-KP
palsy	I-KP
by	O
itself	O
;	O
this	O
condition	O
was	O
present	O
in	O
16	O
(	O
8	O
with	O
EM	B-KP
and	O
1	O
each	O
with	O
concomitant	B-KP
arthritis	I-KP
or	O
EM	B-KP
and	O
arthritis	O
)	O
.	O
	
Seven	O
patients	O
had	O
heart	O
block	O
with	O
positive	O
serologi-	O
cal	O
tests	O
for	O
Lyme	B-KP
disease	I-KP
.	O
	
Three	O
of	O
these	O
also	O
had	O
EM	B-KP
,	O
or	O
documented	O
EM	B-KP
in	O
the	O
past	O
,	O
while	O
four	O
had	O
concomitant	B-KP
arthritis	I-KP
(	O
see	O
figure	O
)	O
.	O
	
﻿Sixty	O
patients	O
(21.2	O
percent	O
)	O
received	O
intravenous	B-KP
therapy	I-KP
.	O
	
Ceftriaxone	B-KP
,	O
with	O
or	O
without	O
other	O
antibiotics	B-KP
,	O
was	O
most	O
frequently	O
used	O
(	O
57	O
,	O
95	O
percent	O
)	O
.	O
	
As	O
expected	O
,	O
intravenous	B-KP
antibiotics	I-KP
were	O
used	O
more	O
frequently	O
(	O
OR	O
3.7;	O
CI	O
1.9-7.0;	O
P<0.001)	O
in	O
those	O
with	O
arthritic	B-KP
,	I-KP
neurologic	I-KP
,	I-KP
and	I-KP
cardiac	I-KP
manifestations	I-KP
without	O
EM	B-KP
(	O
39	O
,	O
34.2	O
percent	O
)	O
than	O
in	O
those	O
with	O
EM	B-KP
(	O
21	O
,	O
12.4	O
percent	O
)	O
.	O
	
In	O
addition	O
,	O
intravenous	B-KP
therapy	I-KP
was	O
more	O
frequently	O
used	O
(	O
OR	O
3.8;	O
CI	O
1.3-11.2;	O
P=0.009)	O
in	O
those	O
with	O
EM	B-KP
and	O
arthritic	B-KP
,	I-KP
neurologic	I-KP
,	I-KP
and	I-KP
cardiac	I-KP
manifestations	I-KP
(	O
14	O
of	O
65	O
;	O
21.5	O
percent	O
)	O
than	O
in	O
those	O
having	O
EM	B-KP
only	O
(	O
7	O
of	O
104	O
;	O
6.7	O
percent	O
)	O
.	O
	
﻿Whereas	O
10-	O
to	O
30-day	O
courses	O
of	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin	B-KP
are	O
recommended	O
for	O
treating	O
early	O
infections	B-KP
(6,12,13),	O
30-day	O
courses	O
of	O
these	O
antibiotics	B-KP
are	O
the	O
most	O
frequently	O
recommended	O
therapy	O
for	O
Lyme	B-KP
arthritis	I-KP
.	O
	
With	O
the	O
exception	O
of	O
patients	O
with	O
isolated	O
facial	B-KP
palsy	I-KP
,	O
those	O
with	O
neurological	O
involvement	O
are	O
often	O
treated	O
with	O
intravenous	O
ceftriaxone	B-KP
or	O
penicillin	B-KP
for	O
2	O
to	O
4	O
weeks	O
(	O
14	O
)	O
.	O
	
The	O
basis	O
for	O
a	O
longer	O
course	O
of	O
treatment	O
for	O
chronic	O
infections	O
with	O
complications	O
is	O
that	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
a	O
very	O
slow	O
grower	O
with	O
a	O
12-hour	O
or	O
longer	O
generation	O
time	O
(	O
15	O
)	O
,	O
and	O
the	O
bacteria	O
is	O
believed	O
to	O
persist	O
in	O
the	O
tissues	O
,	O
particularly	O
within	O
the	O
central	B-KP
nervous	I-KP
system	I-KP
.	O
	
﻿Lyme	B-KP
disease	I-KP
is	O
a	O
tick-transmitted	B-KP
spirochaetal	I-KP
illness	I-KP
caused	O
by	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
Its	O
worldwide	O
distribution	O
correlated	O
with	O
the	O
geographic	O
ranges	O
of	O
certain	O
ixodid	B-KP
ticks	I-KP
.	O
	
Ixodes	B-KP
damnini	I-KP
and	O
Ixodes	B-KP
pacificus	I-KP
are	O
the	O
principal	O
vectors	O
in	O
the	O
USA	O
,	O
whereas	O
Ixodes	B-KP
ricinus	I-KP
and	O
Ixodes	B-KP
persulcatus	I-KP
are	O
the	O
vectors	O
throughout	O
Europe	O
and	O
Asia	O
,	O
respectively	O
.	O
	
Central	B-KP
nervous	I-KP
system	I-KP
(	O
CNS	B-KP
)	O
presentations	O
occur	O
in	O
10±15%	O
of	O
cases	O
;	O
23	O
%	O
of	O
reported	O
cases	O
were	O
in	O
children	O
and	O
adolescents	O
[	O
1	O
,	O
2	O
]	O
.	O
	
﻿Neurological	O
manifestations	O
include	O
meningitis	B-KP
,	O
encephalitis	B-KP
,	O
cranial	B-KP
neuritis	I-KP
±	O
O	80,80
including	O
unilateral	O
or	O
bilateral	O
facial	B-KP
palsy	I-KP
±	O
O	129,129
motor	O
and	O
sensory	O
radiculoneuritis	B-KP
,	O
mononeuritis	B-KP
multiplex	I-KP
,	O
chorea	B-KP
and	O
myelitis	B-KP
.	O
	
The	O
usual	O
pattern	O
consists	O
of	O
fluctuating	O
symptoms	O
of	O
meningitis	B-KP
accompanied	O
by	O
facial	B-KP
nerve	I-KP
palsy	I-KP
and	O
peripheral	B-KP
radiculoneuropathy	O
[	O
1	O
]	O
.	O
	
In	O
96	O
children	O
reported	O
by	O
Belman	O
et	O
al	O
.	O
[	O
3	O
]	O
the	O
most	O
frequent	O
neurological	O
symptom	O
was	O
headache	B-KP
and	O
the	O
most	O
frequent	O
neurological	O
sign	O
facial	B-KP
palsy	I-KP
.	O
	
Less	O
common	O
manifestations	O
in	O
children	O
were	O
sleep	O
disturbances	O
and	O
papilloedema	O
,	O
with	O
increased	O
intracranial	O
pressure	O
.	O
	
The	O
latter	O
seems	O
to	O
be	O
unique	O
to	O
North	O
American	O
paediatric	O
Lyme	B-KP
disease	I-KP
.	O
	
Peripheral	B-KP
neuropathy	I-KP
and	O
meningoradiculitis	O
,	I-KP
in	O
contrast	O
with	O
adults	O
,	O
were	O
rare	O
[	O
3	O
]	O
.	O
	
﻿The	O
treatment	O
of	O
neurological	O
abnormalities	O
is	O
intravenous	B-KP
antibiotics	I-KP
(	O
ceftriaxone	B-KP
,	O
penicillin	B-KP
G	I-KP
)	O
and	O
steroids	B-KP
.	O
	
Other	O
manifestations	O
can	O
be	O
treated	O
with	O
oral	B-KP
antibiotics	I-KP
(	O
doxycycline	B-KP
,	O
amoxicillin	B-KP
,	O
cefuroxime	B-KP
,	O
erythromycin	B-KP
)	O
.	O
	
About	O
15	O
%	O
of	O
patients	O
experience	O
a	O
Herxheimer-like	O
reaction	O
during	O
the	O
first	O
24	O
h	O
of	O
therapy	O
,	O
presenting	O
as	O
fever	O
,	O
chills	O
,	O
myalgia	O
,	O
headache	O
,	O
tachycardia	O
,	O
tachypnoea	O
and	O
mild	O
vasodilatation	O
with	O
mild	O
hypotension	O
.	O
	
An	O
increased	O
circulating	O
neutrophil	O
count	O
is	O
found	O
[	O
1	O
]	O
.	O
	
The	O
weakness	O
of	O
both	O
hands	O
,	O
arthralgia	B-KP
and	O
erythema	B-KP
in	O
our	O
patient	O
could	O
be	O
side	O
effects	O
of	O
the	O
antibiotics	O
or	O
represent	O
a	O
mild	O
Herxheimer	O
reaction	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
the	O
spirochete	B-KP
Borrelia	B-KP
burgdorferi	I-KP
that	O
is	O
transmitted	O
to	O
humans	O
by	O
Ixodes	B-KP
ticks	I-KP
.	O
	
First	O
described	O
in	O
Connecticut	O
in	O
the	O
late	O
1970s	O
by	O
Steere	O
et	O
al	O
,	O
[	O
1	O
]	O
Lyme	B-KP
disease	I-KP
is	O
a	O
multisystem	O
disorder	O
with	O
3	O
clinical	O
stages	O
that	O
include	O
dermatologic	O
(	O
erythema	B-KP
migrans	I-KP
)	O
,	O
cardiac	O
(	O
heart	B-KP
block	I-KP
,	O
carditis	B-KP
)	O
,	O
neurologic	O
(	O
facial	B-KP
nerve	I-KP
palsy	I-KP
,	O
meningitis	B-KP
,	O
meningoencephalitis	B-KP
)	O
,	O
and	O
rheumatologic	O
(	O
arthritis	B-KP
)	O
symptoms	O
.	O
	
﻿Peripheral	B-KP
craniopathy	I-KP
or	O
facial	B-KP
nerve	I-KP
palsy	I-KP
is	O
the	O
single	O
most	O
common	O
neurologic	B-KP
manifestation	I-KP
of	O
Lyme	B-KP
disease	I-KP
in	O
children	O
.	O
[2,3]	O
In	O
many	O
cases	O
,	O
it	O
may	O
be	O
the	O
only	O
neurologic	O
abnormality	O
present	O
and	O
it	O
can	O
develop	O
without	O
an	O
antecedent	O
erythema	B-KP
migrans	I-KP
rash	B-KP
.	O
	
Lyme	B-KP
disease	I-KP
is	O
identified	O
as	O
the	O
causative	B-KP
agent	I-KP
in	O
up	O
to	O
25	O
%	O
of	O
all	O
cases	O
of	O
facial	B-KP
nerve	I-KP
palsy	I-KP
in	O
children	O
who	O
reside	O
in	O
endemic	O
areas	O
.	O
[	O
4	O
]	O
Although	O
more	O
common	O
in	O
Europe	O
,	O
facial	B-KP
nerve	I-KP
palsy	I-KP
is	O
found	O
in	O
3	O
%	O
to	O
5	O
%	O
of	O
all	O
children	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
United	O
States	O
.	O
[	O
5	O
]	O
We	O
are	O
particularly	O
interested	O
in	O
children	O
with	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
because	O
they	O
are	O
a	O
group	O
that	O
may	O
be	O
at	O
particularly	O
high	O
risk	O
for	O
adverse	B-KP
neuropsychologic	I-KP
sequelae	I-KP
,	O
because	O
a	O
high	O
proportion	O
have	O
pleocytosis	O
of	O
the	O
cerebrospinal	B-KP
fluid	I-KP
.	O
[	O
6	O
]	O
﻿Despite	O
the	O
generally	O
favorable	O
outcomes	O
of	O
children	O
with	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
reported	O
in	O
previous	O
studies	O
,	O
some	O
of	O
which	O
included	O
children	O
who	O
never	O
received	O
treatment	O
for	O
the	O
disease	O
,	O
[8–11]	O
there	O
is	O
widespread	O
concern	O
about	O
possible	O
long-term	O
neurologic	B-KP
sequelae	I-KP
.	O
	
Several	O
reports	O
in	O
adults	O
have	O
suggested	O
that	O
there	O
may	O
be	O
adverse	O
cognitive	O
effects	O
from	O
Lyme	B-KP
disease	I-KP
,	O
[12,13]	O
particularly	O
in	O
memory	O
processes	O
(	O
short-term	O
and	O
longterm	O
memory	O
)	O
,	O
intelligence	O
,	O
information	O
processing	O
speed	O
,	O
fine-motor	O
dexterity	O
,	O
problem	O
solving	O
,	O
and	O
new	O
learning	O
.	O
	
No	O
studies	O
have	O
specifically	O
evaluated	O
the	O
long-term	O
outcomes	O
of	O
children	O
with	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
.	O
	
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
long-term	O
neuropsychologic	O
and	O
health	O
outcomes	O
of	O
children	O
with	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
.	O
	
﻿Children	O
2	O
to	O
18	O
years	O
of	O
age	O
at	O
the	O
time	O
of	O
diagnosis	O
with	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
that	O
was	O
diagnosed	O
at	O
least	O
6	O
months	O
before	O
enrollment	O
were	O
eligible	O
for	O
the	O
study	O
.	O
	
We	O
defined	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
according	O
to	O
the	O
Centers	B-KP
for	I-KP
Disease	I-KP
Control	I-KP
and	I-KP
Prevention	I-KP
national	O
surveillance	O
case	O
definition	O
;	O
[	O
15	O
]	O
thus	O
,	O
all	O
cases	O
had	O
facial	B-KP
nerve	I-KP
palsy	I-KP
and	O
either	O
erythema	B-KP
migrans	O
or	O
positive	B-KP
serology	I-KP
.	O
	
﻿All	O
of	O
the	O
case	O
subjects	O
met	O
the	O
Centers	B-KP
for	I-KP
Disease	I-KP
Control	I-KP
and	I-KP
Prevention	I-KP
surveillance	O
case	O
definition	O
for	O
Lyme	B-KP
disease	I-KP
.	O
	
Thirteen	O
(	O
30	O
%	O
)	O
of	O
the	O
patients	O
were	O
female	O
and	O
40	O
(	O
93	O
%	O
)	O
were	O
white	O
.	O
	
Thirteen	O
(	O
30	O
%	O
)	O
had	O
erythema	B-KP
migrans	I-KP
at	O
the	O
onset	O
of	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
.	O
	
The	O
majority	O
of	O
the	O
interviews	O
were	O
completed	O
by	O
either	O
a	O
parent	O
or	O
a	O
guardian	O
(	O
79	O
%	O
of	O
the	O
cases	O
and	O
80	O
%	O
of	O
the	O
controls	O
)	O
.	O
	
﻿As	O
is	O
the	O
case	O
with	O
most	O
patients	O
with	O
facial	B-KP
nerve	I-KP
palsy	I-KP
attributable	O
to	O
Lyme	B-KP
disease	I-KP
,	O
all	O
case	O
subjectsin	O
the	O
study	O
had	O
peripheral	B-KP
facial	I-KP
nerve	I-KP
palsy	I-KP
with	O
both	O
the	O
forehead	O
and	O
the	O
eye	O
affected	O
,	O
indicating	O
a	O
lesion	B-KP
of	O
the	O
lower	B-KP
motor	I-KP
neuron	I-KP
.	O
	
Most	O
patients	O
had	O
unilateral	O
facial	B-KP
nerve	I-KP
palsy	I-KP
:	O
23	O
(	O
53	O
%	O
)	O
were	O
rightsided	O
and	O
19	O
(	O
44	O
%	O
)	O
were	O
left-sided	O
.	O
	
One	O
patient	O
(	O
2	O
%	O
)	O
had	O
bilateral	O
facial	B-KP
palsy	I-KP
.	O
	
Nine	O
(	O
21	O
%	O
)	O
of	O
the	O
patients	O
underwent	O
a	O
lumbar	O
puncture	O
,	O
7	O
of	O
whom	O
had	O
a	O
pleocytosis	B-KP
of	O
the	O
cerebrospinal	O
fluid	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
(	O
LD	B-KP
)	O
is	O
the	O
most	O
common	O
tick-borne	B-KP
infection	I-KP
in	O
North	O
America	O
[1,2]	O
.	O
	
It	O
was	O
first	O
publically	O
recognized	O
in	O
the	O
United	O
States	O
in	O
1975	O
in	O
the	O
towns	O
of	O
Lyme	O
and	O
Old	O
Lyme	O
Connecticut	O
as	O
a	O
result	O
of	O
an	O
investigation	O
into	O
51	O
cases	O
(	O
39	O
children	O
)	O
with	O
a	O
similar	O
form	O
of	O
arthritis	B-KP
,	O
although	O
the	O
first	O
case	O
was	O
describe	O
five	O
years	O
earlier	O
by	O
a	O
dermatologist	O
in	O
Wisconsin	O
[3,4]	O
.	O
	
In	O
North	O
America	O
early	O
signs	O
of	O
infection	O
may	O
include	O
erythema	B-KP
migrans	I-KP
(	O
EM	B-KP
,	O
a	O
characteristic	O
skin	B-KP
rash	I-KP
that	O
often	O
has	O
a	O
bulls	B-KP
eye	I-KP
appearance	O
)	O
and	O
fever	O
and	O
non-specific	O
symptoms	O
like	O
headache	O
and	O
lethargy	O
[5,6]	O
.	O
	
If	O
untreated	O
,	O
the	O
disease	O
can	O
progress	O
to	O
disseminated	O
LD	B-KP
with	O
neurological	O
,	O
cardiac	O
and	O
arthritic	O
manifestations	O
[	O
7	O
]	O
.	O
	
Lyme	B-KP
disease	I-KP
in	O
North	O
America	O
is	O
caused	O
by	O
Borrelia	B-KP
burgdorferi	I-KP
sensu	I-KP
stricto	I-KP
(	O
hereafter	O
called	O
B	B-KP
.	I-KP
burgdorferi	I-KP
)	O
and	O
recently	O
Borrelia	B-KP
mayonii	I-KP
was	O
identified	O
and	O
may	O
be	O
responsible	O
for	O
a	O
proportion	O
of	O
cases	O
,	O
however	O
the	O
performance	O
of	O
LD	B-KP
diagnostic	O
tests	O
to	O
identify	O
B	B-KP
.	I-KP
mayonii	I-KP
infection	B-KP
is	O
not	O
available	O
[	O
8	O
]	O
.	O
	
In	O
Europe	O
B	B-KP
.	I-KP
afzelii	I-KP
,	O
B	B-KP
.	I-KP
garinii	I-KP
,	O
B	B-KP
.	I-KP
burgdorferi	I-KP
,	O
B	B-KP
.	I-KP
spielmanii	I-KP
,	O
B	B-KP
.	I-KP
bissettii	I-KP
and	O
B	B-KP
.	I-KP
bavariensis	I-KP
cause	O
disease	O
with	O
a	O
wider	O
variety	O
of	O
symptoms	O
than	O
reported	O
in	O
North	O
America	O
;	O
a	O
number	O
of	O
genospecies	B-KP
including	O
B	B-KP
garinii	I-KP
occur	O
in	O
Asia	O
.	O
	
﻿Ticks	B-KP
of	O
the	O
genus	B-KP
Ixodes	B-KP
transmit	O
the	O
spirochete	B-KP
when	O
they	O
feed	O
.	O
	
Ixodes	B-KP
scapularis	I-KP
,	O
the	O
blacklegged	B-KP
tick	I-KP
,	O
is	O
the	O
main	O
vector	O
in	O
northeastern	O
and	O
upper	O
midwestern	O
United	O
States	O
and	O
Canada	O
while	O
I	B-KP
.	I-KP
pacificus	I-KP
is	O
the	O
major	O
vector	O
in	O
western	O
United	O
States	O
and	O
western	O
Canada	O
[9,10]	O
.	O
	
The	O
primary	O
vectors	B-KP
of	O
LD	B-KP
in	O
Europe	O
and	O
Asia	O
are	O
I	B-KP
.	I-KP
ricinus	I-KP
and	O
I	B-KP
.	I-KP
persulcatus	I-KP
respectively	O
[6,11]	O
.	O
	
The	O
principal	O
natural	O
hosts	O
of	O
immature	O
stages	O
of	O
the	O
ticks	B-KP
and	O
B	B-KP
.	I-KP
burgdorferi	I-KP
include	O
rodents	O
,	O
other	O
small	O
and	O
medium	O
sized	O
mammals	O
,	O
reptiles	O
and	O
birds	O
,	O
while	O
adult	O
female	O
ticks	O
feed	O
mainly	O
on	O
deer	O
[	O
12	O
]	O
.	O
	
﻿Currently	O
in	O
Canada	O
and	O
the	O
United	O
States	O
,	O
a	O
two-tiered	B-KP
serology	I-KP
protocol	I-KP
is	O
the	O
only	O
validated	O
diagnostic	O
approach	O
for	O
LD	B-KP
diagnosis	O
recommended	O
by	O
United	O
States	O
CDC	B-KP
and	O
the	O
Public	B-KP
Health	I-KP
Agency	I-KP
of	O
Canada	O
[17,18]	O
.	O
	
This	O
two-tiered	B-KP
test	I-KP
is	O
typically	O
an	O
enzyme	B-KP
immunoassay	I-KP
(	O
EIA	B-KP
)	O
to	O
detect	O
IgM	B-KP
or	O
IgG	B-KP
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdoferi	I-KP
in	O
serum	B-KP
and	O
if	O
the	O
sample	O
is	O
positive	O
or	O
equivocal	O
on	O
the	O
screening	O
assay	B-KP
,	O
then	O
a	O
western	B-KP
blot	I-KP
is	O
used	O
to	O
detect	O
serum	B-KP
IgM	B-KP
or	O
IgG	B-KP
antibodies	B-KP
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
﻿Whole	B-KP
cell	I-KP
sonicate	I-KP
(	O
WCS	B-KP
)	O
ELISAs	B-KP
for	O
early	O
LD	B-KP
included	O
10	O
lines	O
from	O
6	O
studies	O
Table	O
3	O
.	O
	
Three	O
commercial	O
est	O
kits	O
were	O
included	O
;	O
Lyme	B-KP
Stat	I-KP
Test	I-KP
Kit	I-KP
,	O
VIDAS	B-KP
Lyme	I-KP
Screen	I-KP
II	I-KP
and	O
Wampole	B-KP
Bb	I-KP
ELISA	I-KP
test	I-KP
system	I-KP
(	O
see	O
S2	O
Text	O
)	O
across	O
six	O
lines	O
and	O
three	O
studies	O
.	O
	
These	O
performed	O
differently	O
than	O
the	O
four	O
in	O
house	O
WCS	B-KP
ELISAs	B-KP
and	O
the	O
authors	O
did	O
not	O
offer	O
an	O
explanation	O
for	O
the	O
divergent	O
results	O
.	O
	
﻿Testing	O
for	O
LD	B-KP
in	O
patients	O
exhibiting	O
signs	O
and	O
symptoms	O
of	O
LD	B-KP
for	O
less	O
than	O
30	O
days	O
is	O
challenging	O
as	O
the	O
performance	O
of	O
available	O
test	O
protocols	O
is	O
not	O
optimal	O
for	O
making	O
clinical	O
decisions	O
.	O
	
This	O
is	O
largely	O
due	O
to	O
the	O
time	O
required	O
for	O
the	O
infected	O
individual’s	O
immune	O
system	O
to	O
mount	O
a	O
reaction	O
.	O
	
This	O
is	O
why	O
researchers	O
have	O
explored	O
the	O
use	O
of	O
a	O
variety	O
of	O
targets	O
including	O
VlsE	B-KP
and	O
C6	B-KP
expressed	O
after	O
infection	O
,	O
Osp	B-KP
C	I-KP
and	O
Fla	B-KP
B	I-KP
expressed	O
by	O
the	O
feeding	O
tick	O
to	O
detect	O
infection	O
sooner	O
[71,72]	O
.	O
	
However	O
,	O
cross-reactivity	O
and	O
genetic	O
variability	O
within	O
the	O
targets	O
has	O
limited	O
the	O
diagnostic	O
performance	O
of	O
any	O
single	O
target	O
[73,74]	O
.	O
	
Thus	O
the	O
results	O
of	O
expected	O
sensitivities	O
and	O
specificities	O
in	O
Table	O
8	O
emphasize	O
the	O
importance	O
of	O
physician	O
evaluation	O
and	O
informed	O
judgement	O
when	O
deciding	O
to	O
treat	O
rather	O
than	O
rely	O
entirely	O
on	O
imperfect	O
serological	B-KP
test	I-KP
protocols	I-KP
.	O
	
Notable	O
findings	O
in	O
the	O
table	O
include	O
the	O
higher	O
specificity	O
associated	O
with	O
the	O
two-tier	B-KP
testing	I-KP
method	I-KP
and	O
the	O
poor	O
and	O
highly	O
variable	O
sensitivity	O
of	O
serological	B-KP
tests	I-KP
in	O
the	O
initial	O
stages	O
of	O
disease	O
when	O
an	O
individual	O
is	O
mounting	O
an	O
immune	O
response	O
to	O
B	B-KP
.	I-KP
burgdorferi	I-KP
.	O
	
﻿Lyme	B-KP
neuroborreliosis	I-KP
is	O
diagnostically	O
challenging	O
because	O
of	O
its	O
diverse	O
manifestations	O
.	O
	
The	O
well-documented	O
neurologic	O
spectrum	O
includes	O
lymphocytic	B-KP
meningitis	I-KP
,	O
cranial	B-KP
neuropathy	I-KP
,	O
and	O
radiculoneuritis	B-KP
in	O
the	O
early	O
disseminated	O
stage	O
;	O
and	O
peripheral	B-KP
neuropathy	I-KP
,	O
chronic	O
encephalomyelitis	B-KP
,	O
and	O
mild	O
encephalopathy	B-KP
in	O
the	O
late	O
persistent	O
stage	O
.	O
	
This	O
case	O
report	O
describes	O
a	O
74-year-old	O
man	O
who	O
developed	O
progressive	O
left	O
hemiparesis	B-KP
and	O
facial	B-KP
palsy	I-KP
.	O
	
The	O
patient	O
was	O
hospitalized	O
to	O
rule	O
out	O
a	O
cerebral	O
vascular	O
accident	O
.	O
	
The	O
diagnosis	O
of	O
Lyme	B-KP
borreliosis	I-KP
was	O
established	O
with	O
serologic	O
studies	O
.	O
	
The	O
patient	O
was	O
treated	O
with	O
intravenous	O
ceftriaxone	B-KP
and	O
responded	O
with	O
rapid	O
clinical	O
and	O
functional	O
recovery	O
.	O
	
Lyme	B-KP
neuroborreliosis	I-KP
presenting	O
as	O
hemiparesis	B-KP
has	O
rarely	O
been	O
reported	O
.	O
	
Prompt	O
diagnosis	O
and	O
treatment	O
appear	O
to	O
facilitate	O
symptomatic	O
relief	O
and	O
prevent	O
persistent	O
neurologic	O
deficits	O
.	O
	
﻿Lyme	B-KP
disease	I-KP
is	O
a	O
multisystem	O
infectious	O
syndrome	O
of	O
considerable	O
public	O
concern	O
,	O
both	O
because	O
of	O
its	O
prevalence	O
and	O
because	O
of	O
the	O
availability	O
of	O
diagnostic	O
and	O
therapeutic	O
measures	O
to	O
combat	O
it	O
.	O
	
It	O
is	O
now	O
the	O
most	O
common	O
arthropodborne	B-KP
infection	I-KP
in	O
the	O
United	O
States	O
,	O
occurring	O
in	O
48	O
of	O
the	O
50	O
states	O
at	O
rates	O
of	O
up	O
to	O
12,000	O
cases	O
annually	O
.	O
[	O
1	O
]	O
The	O
causative	B-KP
organism	I-KP
,	O
Borrelia	B-KP
burgdorferi	I-KP
,	O
is	O
a	O
flagellated	O
spirochete	B-KP
transmitted	O
from	O
small-mammal	O
reservoirs	O
to	O
human	O
beings	O
through	O
bites	O
from	O
infected	O
ticks	O
of	O
the	O
Ixodes	B-KP
species	I-KP
(	O
commonly	O
known	O
as	O
deer	O
ticks	O
)	O
.	O
	
﻿It	O
has	O
been	O
estimated	O
that	O
10	O
%	O
to	O
40	O
%	O
of	O
persons	O
afflicted	O
will	O
develop	O
neurologic	O
abnormalities	O
.	O
[	O
2-4	O
]	O
The	O
clinical	O
manifestations	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
are	O
markedly	O
diverse	O
and	O
include	O
lymphocytic	B-KP
meningitis	I-KP
,	O
cranial	B-KP
neuropathy	I-KP
,	O
and	O
radiculoneuritis	B-KP
in	O
the	O
early	O
disseminated	O
stage	O
,	O
and	O
peripheral	B-KP
neuropathy	I-KP
(	O
mainly	O
sensory	O
)	O
,	O
chronic	O
encephalopalomyelitis	B-KP
,	O
and	O
mild	O
encephalopathy	B-KP
in	O
the	O
late	O
persistent	O
stage	O
.	O
[2,4-8]	O
Only	O
rarely	O
do	O
the	O
neurologic	O
abnormalities	O
of	O
Lyme	B-KP
disease	I-KP
simulate	O
progressive	O
stroke	O
.	O
[4,9,10]	O
The	O
case	O
described	O
here	O
is	O
one	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
presenting	O
as	O
hemiparesis	B-KP
.	O
	
